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Abstract 
 
The management of head and neck cancer (HNC) using radiotherapy +/- chemotherapy (C)RT is 
associated with significant morbidity, due to key structures required for speech, swallowing, 
respiration, and voice falling within the treatment field. Common sequelae of non-surgical 
treatment include a wide range of toxicities, though dysphagia (swallowing difficulty) is 
particularly prominent. Dysphagia may be a short-term acute toxicity, or persist long-term, and 
can have a significant negative impact on quality of life. With recent advancements in 
technology, new conformal radiotherapy techniques such as helical intensity modulated 
radiotherapy (H-IMRT) have been introduced into clinical practice. Such techniques offer 
potential to limit the radiation exposure to non-cancerous normal tissues, and potentially reduce 
associated treatment toxicities - whilst maintaining cure rates. However as yet, there is limited 
literature documenting the incidence, severity, and pattern of treatment related toxicities, 
including dysphagia, associated with H-IMRT +/- chemotherapy, to support if such 
improvements for the patient are realised. Understanding how patients are impacted by new 
treatment approaches is crucial information for speech pathology services, that manage the 
dysphagia and related toxicities of patients. Therefore, the overall objective of this thesis was to 
evaluate the incidence and severity of dysphagia and related toxicities of patients undergoing H-
IMRT +/- chemotherapy to inform speech pathology management practices. A secondary 
objective was to use this information to develop, and then evaluate a new clinical pathway of 
care. These objectives were addressed in a series of 4 studies. 
Study 1 (Chapter 2) prospectively examined the range of dysphagia and related toxicities 
from baseline to 12 weeks post H-IMRT +/- chemotherapy for a heterogeneous cohort of patients 
with mixed tumour sites and stages. A high proportion of patients were found to continue to 
experience grade 2-3 toxicity that peaked in the final week of treatment. Symptoms consistently 
improved thereafter, with the majority better than baseline by 12 weeks post-treatment. 
Concurrent chemotherapy at least doubled the odds of experiencing most symptoms. The 
findings of Chapter 2 confirmed that despite advancements in radiotherapy technique, patients 
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continue to require speech pathology supportive care, particularly in the final weeks of treatment 
and the acute period post-treatment.  
In contrast to the heterogeneous cohort examined in Chapter 2, Chapter 3 examined the 
clinical outcomes of a “high-risk” subgroup, including patients with oropharyngeal squamous 
cell carcinoma (OPSCC) receiving H-IMRT with concurrent chemotherapy. A high proportion of 
patients experienced grade 3 dysphagia with comparable or lower incidence of most other 
toxicities compared with traditional IMRT. Symptoms peaked in the final week of treatment and 
improved thereafter. However, most symptoms had not returned to baseline by 12 weeks post-
treatment. Grade 3 dysphagia was twice as common for patients with T3-4 tumours compared to 
T2 tumours. The findings of Chapter 3 confirm the OPSCC patient group continue to be at “high 
risk” for dysphagia despite advances in conformal radiotherapy and should be prioritised for 
intensive speech pathology support. 
In Chapter 4, further tumour subsite analysis sought to address the gap in the literature by 
prospectively documenting the toxicity outcomes of a subgroup of patients anecdotally 
considered “low risk” for dysphagia - those patients with parotid tumours and cutaneous HNC 
receiving H-IMRT or 3D conformal radiation therapy (3DCRT). Findings confirmed that a very 
low proportion of patients experienced dysphagia or related toxicity requiring speech pathology 
support. If present, symptoms peaked in week 5 of treatment and resolved rapidly. The findings 
of Chapter 4 confirm this patient group is indeed at “low risk” for dysphagia and related 
toxicities during radiation treatment and represent a subgroup likely amenable to an alternative 
service delivery model. 
Utilising the results from studies reported in Chapters 2-4, Chapter 5 examined an 
alternative service delivery model for patients at low dysphagia risk. That study prospectively 
evaluated the implementation, clinical safety, cost analysis, and service efficiency of a new 
interdisciplinary service delivery model (The Pathway) of primary dietetic management using 
dysphagia screening with rapid access to speech pathology when required. Results suggest The 
Pathway is a safe and effective method of managing this subgroup of “low risk” patients during 
radiotherapy treatment. Patients experienced a reduction in hospital appointments, creating direct 
benefit for the health service through resource recovery - facilitating reallocation of speech 
pathology services to the “high risk” patients identified in Chapter 3.  
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The findings, clinical implications, limitations, and future areas of research are discussed 
in Chapter 6 of this thesis. In conclusion, this thesis provides information detailing the incidence, 
severity, and temporal pattern of dysphagia and related toxicities experienced by patients with 
HNC undergoing H-IMRT +/- chemotherapy to optimise supportive care and enhance patient 
education. These findings can be used to inform the timing and intensity of patient centred 
speech pathology service delivery models that meet the specific needs of patient subgroups and 
can form the basis of future guidelines for speech pathology support.  
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CHAPTER 1: An overview of head and neck cancer and 
current management practice  
 
1.0 Chapter Overview 
The overall objectives of this thesis are to (a) further the understanding of the toxicities 
including swallowing difficulty resulting from helical Intensity Modulated Radiation Therapy 
(H-IMRT) with or without chemotherapy in the treatment of head and neck cancer (HNC) in the 
acute phase, and (b) explore speech pathology supportive care and service delivery for patients 
with HNC during and immediately post-treatment with a particular focus on patients identified as 
“low-risk” for swallowing difficulties. To provide context for this thesis Chapter 1 aims to 
present the reader with a background to HNC, including its epidemiology, the sites of HNC, how 
it is classified, previous and current treatment options and the subsequent swallow related 
toxicities resulting from treatment in the acute phase based on a review of the current literature. 
Gaps in the existing literature documenting toxicity outcomes will be discussed in detail. The 
reader will also be introduced to the role of the speech pathologist in the assessment and 
management of HNC patients in the acute phase of treatment, with particular emphasis on the 
service delivery models used nationally and internationally and the evidence guiding these 
models. Chapter 1 will then conclude with a statement of the overall objective and aims of the 
thesis including an outline that orients the reader to the thesis content.  
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1.1 Introduction to Head and Neck Cancer 
Cancer is a major global health burden and is the second leading cause of death 
worldwide (Bernicker, 2019). The cost to health care associated with cancer care is significant 
and has been shown to exceed costs for other common diseases such as cardiovascular disease, 
diabetes, mental health, and trauma (Brown, Riley, Schussler, & Etzioni, 2002; Sam & Cheung, 
2019). The focus of this thesis is on one form of cancer, HNC which is the fifth most common 
non-skin cancer worldwide (Siegel, Miller, & Jemal, 2015). HNC is a particularly complex 
disease due to its location in proximity to key structures associated with speech, swallowing, 
respiration, and the brain and spinal cord, necessitating complex treatment from a large 
multidisciplinary team (MDT). Thus, the economic burden of HNC is high with medical costs in 
the United States estimated at $3.64 billion in 2010 and projected to rise to $4.34 billion in 2020 
(Mariotto, Robin Yabroff, Shao, Feuer, & Brown, 2011). The following sections will further 
introduce the reader to HNC and discuss its epidemiology, tumour sites, diagnosis, treatment, 
and management. 
1.1.1 Head and Neck Cancer Epidemiology 
Whilst globally HNC is the fifth most common non-skin cancer worldwide, in Australia 
where this research was conducted HNC has remained the seventh most commonly diagnosed 
cancer with an estimated 5,212 new cases diagnosed in 2019 (Australian Institute of Health and 
Welfare, 2015; Australian Institute of Health and Welfare [AIHW], 2019). HNC continues to 
have a higher incidence in males than females (72% versus 28%) with a 70.7% overall chance of 
5-year survival in Australia (Australian Institute of Health and Welfare [AIHW], 2018).  
Squamous cell carcinoma (SCC) is the most common malignancy to develop in the head 
and neck region (Hj Wu, 2009). Traditionally the diagnosis of head and neck SCC has been seen 
in older males with a history of significant alcohol and tobacco use (Hj Wu, 2009; Marur & 
Forastiere, 2016). However, despite declining tobacco use, rates of HNC remain high, largely 
due to a shift in the profile and epidemiology of HNC due to the human papilloma virus (HPV) 
(Hj Wu, 2009; Marur & Forastiere, 2016; Vokes, Agrawal, & Seiwert, 2015). The risk factors for 
HPV associated HNC are unique. Patients are typically younger, have a higher socio-economic 
status and education level, have more life-time sexual partners, are from a white racial 
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background, and have less history of tobacco and alcohol use (Marur & Forastiere, 2016; 
McDermott & Bowles, 2019).  
Recent years have seen a rise in the number of HPV associated HNC cases and a decline 
in non-HPV associated HNC (Pytynia, Dahlstrom, & Sturgis, 2014; Vokes et al., 2015). HPV 
associated HNC is predominantly found in oropharyngeal tumour sites with the vast majority 
caused by the HPV16 strain (Pytynia et al., 2014; Vokes et al., 2015). In North America 56% of 
oropharyngeal SCC (OPSCC) cases are HPV positive, 52% in Japan, 45% in Australia, 39% in 
northern and western Europe, and 13% in the rest of the world (Marur & Forastiere, 2016). In 
comparison, tumours of the oral cavity, hypopharynx, larynx, and paranasal sinus/nasal cavity 
continue to be largely HPV negative and associated with the traditional risk factors of tobacco 
and alcohol use (Li et al., 2018; Stepnick & Gilpin, 2010). Tumours of the nasopharynx are a 
unique entity and are frequently associated with the Epstein-Barr Virus, with a genetic 
susceptibility in people from southeast Asia and northern Africa (Shield et al., 2017). 
The incidence of each subsite of HNC is influenced by race, geography, sex, and age with 
variations found globally (McDermott & Bowles, 2019; Shield et al., 2017). However, 
particularly in western countries oropharyngeal cancer is now the most prevalent site of HNC 
due to the impact of HPV (Li et al., 2018; Mourad et al., 2017; Shield et al., 2017). This is a 
trend also observed in Australia where this research was undertaken (Ariyawardana & Johnson, 
2013; Hocking et al., 2011). Tumours of the oral cavity including the lip are the next most 
common tumour site globally, followed by the larynx and then hypopharynx. Comparatively, 
tumours of the nasopharynx, paranasal sinus/nasal cavity, and salivary glands experience a much 
lower incidence globally (Li et al., 2018; McDermott & Bowles, 2019). Tumours of the thyroid 
have experienced an exponential increase in incidence globally, particularly in women (Kwon et 
al., 2018), which is likely due to increased screening programs resulting in detection of greater 
numbers of subclinical thyroid cancer (Vecchia et al., 2015). Other sites of HNC such as 
cutaneous (skin) HNC have variable incidence dependent on factors such as solar exposure. In 
Australia, the incidence of cutaneous HNC is relatively high due to increased sun exposure 
related to climate and lifestyle (Gurudutt & Genden, 2011; Perera, Gnaneswaran, Staines, Win, 
& Sinclair, 2015).  
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In light of the epidemiological changes in HNC extensive research into this area is 
changing the way HNC is now diagnosed and treated, with data demonstrating biological and 
prognostic differences between HPV related and unrelated HNSCC (Vokes et al., 2015). Seminal 
work by Fakhry et al. (2008) reported the improved survival of patients with HPV-positive HNC 
in response to chemoradiotherapy (CRT). This results in greater numbers of younger patients 
undertaking non-surgical HNC treatment with improved survival rates, however commonly 
experienced treatment related toxicities have led to increased survivorship morbidity post-
treatment requiring support from an extensive MDT (Cohen et al., 2016). Survivorship is defined 
as commencing at the time of diagnosis and lasts through the lifespan, including the patient, their 
family members, friends, and caregivers (Shapiro, 2018). Survivorship care has become an 
increasingly important part of the cancer care continuum (Shapiro, 2018), with many studies 
dedicated to reducing survivorship morbidity post HNC treatment (Cohen et al., 2016). 
1.1.2 Head and Neck Cancer Tumour Sites 
Head and neck cancer includes tumours arising from the mucosal layers of the upper 
aero-digestive tract. Beginning where the skin meets the mucosa at the nasal vestibule and the 
vermillion borders of the lips and continues through the mouth, pharynx, and larynx to the 
junction of the cricoid cartilage and the cervical trachea, and where the hypopharynx meets the 
cervical oesophagus. HNC also includes the salivary glands, thyroid and parathyroid glands, and 
skin of the head and neck (American Academy of Otolaryngology-Head and Neck Surgery 
Foundation, 2014; Hj Wu, 2009; National Comprehensive Cancer Network, 2016). Tumours of 
the upper aero-digestive tract are organised into major sites that may be subdivided to anatomic 
subsites. The major sites include the (1) oral cavity, (2) the oropharynx, (3) the hypopharynx, (4) 
the larynx, (5) the nasopharynx, and (6) the nose and paranasal sinuses (American Academy of 
Otolaryngology-Head and Neck Surgery Foundation, 2014). The major sites are represented in 
Figure 1.1 (Vokes, Weichselbaum, Lippman, & Hong, 1993). Each tumour site has an increased 
or decreased proximity to key structures involved in speech, swallowing, and respiration which 
results in varied morbidity and mortality associated with both the tumour itself and treatment due 
to the impact on surrounding normal tissues. This then results in differing supportive care needs 
from the MDT for patients with different HNC tumour sites which will be discussed in more 
detail in the following sections. 
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Figure 1.1 Sagittal section of the upper aerodigestive tract1 
 
 
 
 
 
 
 
1 Head and Neck Cancer. Reproduced with permission from (Vokes, Weichselbaum, Lippman, & Hong, 
(1993). Head and Neck Cancer. New England Journal of Medicine, 328(3), 184-194. 
Doi:10.1056/nejm199301213280306/) Copyright Massachusetts Medical Society. 
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 As described by the American Academy of Otolaryngology-Head and Neck Surgery 
Foundation (2014) the oral cavity is defined anteriorly as the contact point of the skin with the 
vermillion of the lips extending posteriorly to the junction of the hard and soft palate, the anterior 
tonsillar pillars, and the circumvallate papillae on the tongue. The anatomical subsites include the 
lips, anterior tongue, floor of mouth, buccal mucosa, upper and lower alveolar ridges, hard 
palate, and retromolar trigone. The oropharynx begins where the oral cavity ends and extends 
from the soft palate superiorly to the level of the hyoid bone inferiorly. The tonsil, base of 
tongue, soft palate, and pharyngeal walls comprise the anatomic subsites of the oropharynx. The 
nasopharynx is bound anteriorly by the choanae at the back of the nose, superiorly by the 
sphenoid and upper cervical vertebrae, and inferiorly by the soft palate. The paranasal sinuses 
consist of the paired maxillary sinuses, the frontal sinuses, the ethmoid sinuses and the central 
sphenoid sinus. The nasal cavity includes the lining of the nasal cavity and the nasal septum. 
Sinonasal carcinomas can include the anterior skull base. The hypopharynx begins superiorly at 
the level of the hyoid bone and extends inferiorly to the cricopharyngeus muscle. The anatomic 
subsites of the hypopharynx are the pyriform sinuses, the posterior cricoid region, and the 
pharyngeal wall. The larynx is bordered superiorly by the oropharynx, inferiorly by the trachea 
and laterally, and posteriorly by the hypopharynx. The larynx is comprised of a cartilaginous 
framework and is divided vertically by the vocal folds with the following subsites, supraglottic 
(epiglottis, false cords, arytenoids cartilages and aryepiglottic folds), glottic (true vocal folds to 1 
centimeter below), and subglottic (1 centimeter below the true vocal folds to the inferior aspect 
of the cricoid cartilage) larynx.  
Each of these regions of the head and neck in particular are of great functional 
importance for chewing, normal swallowing, speech, voice production, and airway maintenance 
or are managed with treatment fields that impact the functioning of multiple structures of the 
head and neck (e.g. nasopharynx tumours). For this reason, patients with cancer of the oral 
cavity, oropharynx, nasopharynx, hypopharynx, and larynx often present with changes to 
function at the point of diagnosis, and frequently experience further treatment related morbidity 
necessitating significant MDT support in the short and long term (Li et al., 2018; Stepnick & 
Gilpin, 2010). In addition, as discussed previously, many of these HNC sites have the highest 
incidence rates within Australian clinical services. Hence, patients with cancers in these head and 
 7 
neck tumour sites tend to comprise a majority of the HNC MDT workload within Australian 
HNC centres. 
Tumours of the thyroid, skin, and salivary glands constitute a slightly different subgroup 
of HNC’s from a management perspective. Salivary gland tumours include those arising from the 
parotid, submandibular, sublingual, and minor salivary glands. Tumours of the thyroid include 
those arising from the left or right lobes and the parathyroid glands (American Academy of 
Otolaryngology-Head and Neck Surgery Foundation, 2014). Head and neck cancer of the skin is 
described as cutaneous cancers (non-mucosal) arising from the skin of the face (including the 
temple), ears, neck, and hair-bearing lip (Riffat, Palme, & Veness, 2015). Whilst these tumours 
are located adjacent to key functional structures involved in speech and swallowing, they are 
often spared and can be kept out of the treatment field. Hence, patients with salivary gland and 
cutaneous HNC may experience a different pattern of treatment related effects which impacts 
their supportive care needs. 
1.1.3 Head and Neck Cancer Diagnosis 
Diagnosis of HNC requires clinical information from multiple sources and a range of 
medical investigations including a physical exam, flexible nasendoscopy, radiographic, 
intraoperative, and pathologic findings. Head and neck cancers are classified using the American 
Joint Committee on Cancer (AJCC) tumour, node, metastasis (TNM) staging system which uses 
a 1-4 numerical stage with subdivision denoted by a, b, or c. This classification system can assist 
clinicians with the assessment of disease status, prognosis and management planning. T (X, 0, is, 
1-4) refers to the characteristics of the tumour at the primary site, which may be based on size, 
location, or both and the criteria differs depending on tumour site. N (X, 0-3) refers to the degree 
of regional lymph node involvement with N1-2b and N3 indicating ipsilateral nodes of 
increasing size and N2c indicating bilateral or contralateral nodes. M (X, 0-1) denotes the 
presence or absence of distant metastases. The TNM classification is then tabulated to give a 
numerical stage of disease, I, II, III or IV with subdivisions denoted with an a, b or c status (see 
Table 1.1 for example of TNM classification) (American Academy of Otolaryngology-Head and 
Neck Surgery Foundation, 2014; American Joint Committee on Cancer, 2010).  
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Table 1.1 
AJCC Anatomic Staging Prognostic Group Table for the Larynx, Oropharynx, Hypopharynx, 
Oral Cavity, Salivary Glands and Paranasal Sinuses2 
Stage Grouping T N M 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
 T1 N1 M0 
 T2 N1 M0 
 T3 N1 M0 
Stage IVa T4a N0 M0 
 T4a N1 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N2 M0 
 T4a N2 M0 
Stage IVb Any T N3 M0 
 T4b Any N M0 
Stage IVc Any T Any N M1 
  
 
2 Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The 
original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) 
published by Springer Science+Business Media. 
 9 
1.1.4 Head and Neck Cancer Treatment 
Decisions regarding the management of head and neck malignancy are complex and 
multifactorial. International guidelines dictate that they are best made through a multidisciplinary 
meeting consisting of a variety of health professionals including otorhinolarygologists (ear nose 
and throat surgeons), plastic surgeons, maxillofacial surgeons, radiation oncologists, medical 
oncologists, dentists, palliative care specialists, speech pathologists, and dietitians (Cohen et al., 
2016; Hj Wu, 2009; National Comprehensive Cancer Network, 2016; National Institute for 
Health and Care Excellence, 2016). At these meetings, consensus decisions regarding diagnosis 
and appropriate treatment plans are presented to the patient for consent in discussion with their 
family/carer (Hall, 2015). Non-surgical treatment often referred to as organ preserving treatment, 
aims to preserve structural integrity and includes radiotherapy treatment (RT) and chemotherapy. 
Whilst surgical treatment alone is a mainstay of HNC management it is not within the scope of 
this thesis topic and will only be discussed in the context of non-surgical management following 
surgery for HNC. Treatment plans are either curative or palliative in nature and may include one, 
two, or in some circumstances three modalities (surgery, radiotherapy, and chemotherapy) 
depending on stage, site, and patient variables. Palliative treatment may involve a smaller dose of 
radiotherapy or chemotherapy for symptom management. As palliative treatment also falls 
outside the scope of this thesis topic, the following sections will only discuss treatment regimens 
that are of curative intent.  
1.1.4.1 Non-surgical treatment: radiotherapy overview.  Therapeutic radiation or 
photon therapy is generally produced by a linear accelerator (LA) and is measured in Gray (Gy). 
Radiotherapy to the head and neck region is a complex treatment. It is critical that structures 
infiltrated by cancer receive an adequate radiation dose whilst nearby structures that are 
important to the functions of saliva production, mastication, swallowing, voice, and hearing are 
spared a radiation dose that would cause permanent damage. In light of this, the treating 
radiation oncologist and radiation therapist work together to create each individual patient’s 
treatment plan, including their treatment fields and dose to each field. The treatment fields are 
planned following a computed tomography (CT) scan that the radiation oncologist uses to 
contour the gross tumour volume (GTV) and the clinical tumour volume (CTV) which includes 
the microscopic tumour around the GTV. A 3 or 5mm margin is added around the CTV to allow 
for patient movement or machine variability called the planning treatment volume (PTV). To 
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minimise any movement during RT, patients are immobilised with a custom-made thermoplastic 
shell contouring the patients face, neck and shoulders (Kelly, 2014; Tejpal et al., 2010).  
Normal structures in the head and neck region frequently called organs at risk (OARs), 
including the spinal cord, brainstem, inner ear, eyes, salivary glands, oral cavity, pharyngeal 
constrictors, and glottis are outlined on the CT to minimise the dose to these key structures. Work 
by the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) Group over the 
last 10 years has sought to identify optimal dose constraints for these structures (Bentzen et al., 
2010; Bhandare et al., 2010; Deasy et al., 2010; Kirkpatrick, van der Kogel, & Schultheiss, 2010; 
Lawrence et al., 2010; Marks et al., 2010; Mayo, Martel, et al., 2010; Mayo, Yorke, & Merchant, 
2010; Rancati et al., 2010). Studies within the last 5 years have also begun to highlight the 
potential of considered dose restrictions to additional structures. In particular, within the field of 
SP, focused interest on protecting key swallowing related structures often referred to as the 
Dysphagia/Aspiration Related Structures (DARS) (Eisbruch et al., 2004) or the Swallowing 
Organs at Risk (SWORs) (Christianen et al., 2012), has received much attention. Early work has 
sought to identify which structures are most important to protect swallowing function and at 
what dose potential damage is caused (Hawkins, Kadam, Jackson, & Eisbruch, 2018; Hutchison, 
Cartmill, Wall, & Ward, 2019; Roe et al., 2010). Although the work in this field is ongoing, the 
emerging evidence base for the potential of DARS protection is promising (Barnhart, Cartmill, et 
al., 2019; Hutchison et al., 2019). Over the last 30 years radiation therapy techniques have 
evolved with increasing potential to achieve such dose constraints. The different radiation 
techniques, their implications for the patient, and the impact of dose constraints will be discussed 
further in section 1.3.  
1.1.4.1.1 Definitive radiotherapy treatment.  Definitive treatment infers no prior surgical 
treatment has been conducted and the RT may be given in isolation or in combination with 
chemotherapy (Argiris, Karamouzis, Raben, & Ferris, 2008a; Hj Wu, 2009). Primary RT is 
generally prescribed for smaller tumours and given in combination with chemotherapy for larger 
tumours. The conventional radiotherapy dosage for curative intent definitive RT for HNC is daily 
fractions of 1.8-2.0 Gy, up to a total dose of 66-70Gy over 6-7 weeks of treatment (Argiris et al., 
2008a).  
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1.1.4.1.2 Adjuvant radiotherapy treatment.  Adjuvant RT infers the RT is given in 
conjunction with surgery, usually following surgery which is referred to as post-operative 
radiotherapy (PORT) and in some cases prior. The conventional dosage for adjuvant RT for HNC 
is daily fractions of 1.8-2.0 Gy, up to a total dose of 60-66Gy over 6 weeks. Patients generally 
require a period of 6 weeks between surgery and commencing PORT to ensure healing of the 
surgical wound. Following surgery many patients experience negative changes to speech and 
swallowing function. PORT can then result in additional treatment related side effects further 
affecting speech and swallowing function, further influencing patients supportive care needs 
(Kulasinghe, Lim, Perry, & Punyadeera, 2015).  
1.1.4.2 Non-surgical treatment: chemotherapy overview.  The addition of 
chemotherapy is now a central component of curative treatment of locally advanced HNC (stage 
III and IV), with synchronous CRT found to be more effective than induction chemotherapy 
(chemotherapy prior to radiation), particularly for the oral and oropharyngeal tumour sites 
(Argiris et al., 2008a; Kelly, 2014). The platinum compound cisplatin is the standard agent used 
in combination with radiation with carboplatin used in some circumstances (Argiris et al., 
2008a). Chemotherapy regimes can vary between institutions, though the most commonly 
accepted regimes currently are high dose cisplatin, 100mg/m2 given at the beginning of weeks 1, 
4, and 7 of RT and weekly cisplatin, 40mg/m2 given weekly during RT (Kelly, 2014). Studies 
into which regime provides the best balance of cure with associated treatment related toxicity are 
ongoing. The exact manner in which cisplatin and carboplatin in combination with radiation 
achieves cell kill is not completely understood. Radiosensitisation, inhibition of sublethal 
damage repair, or inhibition of lethal damage repair are all possible theories (Kelly, 2014).  
The utilisation of CRT is standard care in the treatment of HPV positive tumours with 
seminal work by Fakhry et al. (2008) reporting an improved therapeutic response and overall 
survival of patients with HPV positive tumours receiving concurrent chemotherapy compared to 
patients with HPV negative disease. More recently, epidermal growth factor (EGFR) inhibition 
using the biological agent cetuximab has become a common alternative to cisplatin based 
chemotherapy if patients are unable to tolerate a platinum based treatment or have a history of 
renal failure (Argiris et al., 2008a; Kelly, 2014). In the last decade, several studies have been 
investigating the use of cetuximab as a form of treatment de-escalation in an effort to reduce 
treatment related toxicity (Mirghani & Blanchard, 2018). However, recent results from two large 
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randomised multicentre control trials have found inferior overall survival with similar toxicity 
rates when comparing cetuximab with cisplatin in HPV positive oropharyngeal cancers (Gillison 
et al., 2019; Mehanna et al., 2019). These landmark studies confirm cetuximab is not an 
appropriate de-escalation strategy and that cisplatin with radiotherapy should remain the standard 
of care for HPV positive patients. This places greater importance on finding alternative suitable 
de-escalation strategies, such as conformal RT techniques to maximise quality of life (QOL) for 
patients with HNC. 
1.1.5 Head and Neck Cancer Management 
Whilst treatment for HNC is delivered by the medical team, a wide range of health 
professionals are involved in assisting the patient to maximise their treatment outcomes. 
Research has established patients with HNC managed through integrated MDTs with a range of 
health professionals have improved outcomes and survival rates (De Felice, Tombolini, et al., 
2018; Friedland et al., 2011). This is due to the complexity of HNC and the morbidity of 
treatment, particularly the toxicities associated with non-surgical treatment. The extensive 
toxicities experienced by patients will be discussed in greater detail in Section 1.2 and are 
influenced by the nature of RT received (discussed in detail in Section 1.3) and the addition of 
chemotherapy. As recommended by the National Comprehensive Cancer Network Clinical 
Practice Guidelines in Oncology (National Comprehensive Cancer Network, 2016) and the 
Australian Optimal Care Pathway for People with Head and Neck Cancers (Cancer Council 
Victoria and Department of Health and Human Services Victoria, 2015) - in order to sufficiently 
address the wide range of needs patients with HNC experience, management from the MDT is 
required from pre-treatment long into survivorship.  
Speech pathologists are internationally recognised as core members of this integrated 
head and neck MDT, bringing specialist knowledge and clinical skills in the assessment and 
management of oropharyngeal dysphagia and communication disorders to the team (Cancer 
Council Victoria and Department of Health and Human Services Victoria, 2015; Cohen et al., 
2016; De Felice, Tombolini, et al., 2018; National Comprehensive Cancer Network, 2013; 
Schindler et al., 2015). There is a large evidence base supporting the benefit of SP involvement 
before, during and after (C)RT to optimise swallowing outcomes (Messing et al., 2019; Murphy 
& Gilbert, 2009; Russi et al., 2012; Servagi-Vernat et al., 2015; Wall, Cartmill, Ward, Hill, 
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Isenring, & Porceddu, 2016). Speech pathology in HNC will be discussed in greater detail in 
section 1.4. However, for health services to deliver the best care to patients with HNC we must 
understand what the biggest issues are for patients in order to inform an optimal 
multidisciplinary care pathway. 
1.1.6 Summary 
Head and neck cancer is complex due to the nature of its location in relation to key 
structures involved in respiration, swallowing, speech, voice, vision, and hearing. This patient 
population is recognised as a group for whom specialist multidisciplinary care is required to 
optimise the diagnosis and treatment of this complex disease. Diagnosis requires extensive 
clinical workup with information from clinical examination, radiological investigation and 
pathology. Management decisions are based on both patient and tumour-related factors, and are 
made in conjunction with input from the MDT, the patient, and their family. Surgical 
management can result in altered anatomy and subsequent changes in function. Whilst described 
as organ preserving, non-surgical treatment including radiotherapy and chemotherapy are 
recognised to have significant treatment related morbidity requiring specialised supportive care. 
The specific effects of non-surgical treatment (delivered either as definitive (C)RT or PORT) on 
swallowing and other related toxicities will be discussed in more detail in Sections 1.2 and 1.3. 
Considering the potential specific deficits to swallowing function and oral intake created by both 
the tumour and its treatment, SP is recognised as one of the key clinical services involved in 
HNC support and rehabilitation. Hence optimising SP services is an integral part of continuing to 
improve HNC care. This will be discussed in Section 1.4. 
1.2 Toxicities Associated with Head and Neck Cancer and Non-Surgical Treatment  
Patients with HNC may experience pain or functional changes, particularly to swallowing 
prior to diagnosis caused by the presence of the tumour, often prompting initial medical 
investigation. Swallowing is defined as ‘the function of clearing food and fluid through the oral 
cavity, pharynx, and oesophagus at an appropriate speed’ by the International Classification of 
Functioning, Disability and Health (World Health Organization, 2001). Dysphagia is a disorder 
of swallowing, and specifically oropharyngeal dysphagia involves difficulty or inability to form 
or move the food bolus safely from the mouth to the oesophagus. This may involve difficulty 
chewing or controlling the food/fluid bolus in the oral cavity, transferring the bolus from the oral 
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cavity to the pharynx, the entry of secretions/food/fluids into the trachea or lungs (aspiration), 
and choking. Oropharyngeal dysphagia can result from organic or structural causes or disease 
affecting the movement of the oropharyngeal musculature (Clave & Shaker, 2015). 
Oropharyngeal dysphagia is a common multifactorial symptom of HNC and its treatment and 
can occur at any stage of a patient’s HNC journey. Dysphagia can occur pre-treatment as a result 
of the tumour presence and associated pain; it can follow surgical management due to the change 
in anatomy, neurophysiology, and musculature; it can develop during non-surgical treatment as a 
result of acute treatment related toxicities; or it can develop post-treatment as a result of late-
onset side effects (Manikantan et al., 2009; Mittal et al., 2003; Murphy & Gilbert, 2009; Raber-
Durlacher et al., 2012).  
In HNC, the prevalence and severity of pre-treatment dysphagia varies depending on 
tumour site and stage, with some tumour sites resulting in greater difficulty due to their 
proximity to key swallowing apparatus (Nguyen et al., 2008; Pauloski et al., 2000). Nguyen et al 
(2008) reported mild to severe pre-treatment dysphagia in 5% of patients with oral cancer, 29% 
with laryngeal cancer, 33% with oropharyngeal, and 52% with hypopharyngeal cancer. Pauloski 
et al (2000) reported 4% of patients in their study of 352 mixed site HNC patients experienced 
aspiration (food or fluid passing below the vocal folds). Results from videofluoroscopic 
swallowing studies (VFSS)3 conducted during this study, found pharyngeal transit time, 
pharyngeal delay time, percent oral residue, and percent pharyngeal residue all increased as 
tumour stage advanced, with significantly lower oropharyngeal swallow efficiency scores for 
patients diagnosed with T3-4 tumours than T1-2 disease. Patient’s perceptions of pre-treatment 
swallowing difficulty also indicated that those with T1-2 tumours or oral cavity tumours were 
significantly less likely to report pre-treatment dysphagia than those with T3-4 disease or 
pharyngeal tumours. Pre-treatment dysphagia is important to identify and manage as it can 
influence patients’ QOL and has been found to be an important predictor of post-treatment 
swallowing function (Frowen, Cotton, Corry, & Perry, 2010).   
In addition to potential difficulties caused by the tumour presence, HNC treatment is 
associated with further morbidity. Surgical management of HNC can result in anatomical 
 
3 Videofluoroscopic swallow study (VFSS) will be the term adopted throughout this thesis for any study 
reporting results from either a Modified Barium Swallow (MBS) or VFSS. 
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changes or neurological insult to the swallow mechanism resulting in site-specific dysphagia. 
The severity and type of post-operative dysphagia is dependent on tumour site and stage, the 
extent of resection, and the type of reconstruction (Manikantan et al., 2009; Mittal et al., 2003). 
Non-surgical treatment, then adds another layer of side-effects for the patient whether they 
receive PORT or definitive RT. Whilst referred to as organ preserving treatment, it is well 
documented that multiple negative side effects including dysphagia are associated with the 
effects of RT with or without chemotherapy and are commonly referred to as adverse events or 
toxicities (Argiris et al., 2008a; Logemann et al., 2008; Manikantan et al., 2009; Patterson et al., 
2014; Siddiqui & Movsas, 2017). 
Toxicities occur as a result of the normal healthy tissue surrounding the tumour receiving 
a dose of radiation. This causes depletion of tissue stem cells and progenitor cells, and damage to 
vascular endothelial microvessels combined with dynamic secondary reactive processes in 
response to the cell death, resulting in cell loss, tissue damage, fibrosis, necrosis, and subsequent 
functional deficits (Kim, Jenrow, & Brown, 2014). Hence, there is increasing focus on dose 
constraints to reduce the radiation dose received by key structures. Radiotherapy technique 
influences the ability to achieve dose constraints with the use of conformal RT techniques. 
Significant advancement has been observed in the last 20-30 years with the introduction of new 
forms of RT. The potential benefit of these new RT techniques to minimise treatment related 
effects is a particular focus in this thesis, hence RT techniques including new RT delivery 
methods will be discussed in detail in Section 1.3.  
The toxicities associated with non-surgical treatment are frequently categorised as 
‘acute’, which occur from the beginning of treatment up to 3 months post-treatment, and those 
that are considered ‘late’, which are either acute effects persisting beyond 3 months or new 
symptoms that develop beyond 3 months post-treatment. The toxicities most frequently 
associated with non-surgical treatment will be discussed below in greater detail, with particular 
focus on dysphagia and its related toxicities, as these have the greatest impact on oral intake for 
the patient and are most relevant for the speech pathologist in managing this population. 
1.2.1 Dysphagia and Related Toxicities 
Radiation induced dysphagia is a common, but often underestimated sequela of (C)RT 
due to the proximity of DARS and organs at risk (OAR) to the RT field (De Felice, de Vincentiis, 
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et al., 2018; Denaro, Merlano, & Russi, 2013; Eisbruch et al., 2004; Logemann et al., 2008; 
Manikantan et al., 2009; Roe et al., 2010; Xinou, Chryssogonidis, Kalogera-Fountzila, 
Panagiotopoulou-Mpoukla, & Printza, 2018). The nature and severity of dysphagia is dependent 
on a number of treatment and patient factors including: total radiation dose, fraction size and 
schedule, target volumes, treatment field, treatment delivery techniques, concurrent 
chemotherapy, genetic factors, prolonged periods (> 2 weeks) of nil by mouth (NBM), smoking, 
and psychological factors (Frowen et al., 2010; Hawkins et al., 2018; Platteaux, Dirix, Dejaeger, 
& Nuyts, 2010; Roe, Carding, Drinnan, Harrington, & Nutting, 2016; Roe et al., 2010).   
Consequences of dysphagia are significant, including aspiration pneumonia, altered 
dietary intake, unintentional weight loss, and enteral feeding resulting in decreased patient QOL 
and associated caregiver burden (Brown et al., 2015; Ganzer, Touger-Decker, Byham-Gray, 
Murphy, & Epstein, 2015; Murphy & Gilbert, 2009; Nguyen et al., 2004; Nund et al., 2014a, 
2014b; Raber-Durlacher et al., 2012; Roe, Drinnan, Carding, Harrington, & Nutting, 2014). 
Dysphagia has impacts for the patient, their family, and the healthcare system. Until recently 
there had been no systematic investigation of the impact of oropharyngeal dysphagia on 
healthcare utilisation and its influence on cost. However, a recent systematic review has 
highlighted the need to recognise oropharyngeal dysphagia as an important contributor to 
pressure on healthcare systems and for economic analysis to be included in research evaluating 
dysphagia (Attrill, White, Murray, Hammond, & Doeltgen, 2018). An increase of 40.36% was 
found in dysphagia related expenditure compared with non-dysphagic groups, and dysphagia 
related length of stay was significantly longer with a mean addition of four extra days. Similarly, 
a large scale retrospective economic study in the US found a dysphagia diagnosis in adult 
inpatients was associated with significantly increased inpatients costs, a likelihood of being 
discharged to a post-acute care facility, and longer length of stay compared with non-dysphagic 
adults (Patel et al., 2018). These results confirm the significant additional cost to the patient and 
health service associated with the presence of dysphagia. 
Radiation associated dysphagia can also result from the acute toxicities associated with 
treatment including but not limited to: mucositis, pain, xerostomia, thick saliva, dysgeusia, 
nausea, fatigue, altered sensation, and fibrotic tissue changes within the head and neck region 
(Barnhart et al., 2018; Cartmill, Cornwell, Ward, Davidson, & Porceddu, 2013; Chera et al., 
2014; Hj Wu, 2009; Holländer-Mieritz et al., 2019; Logemann et al., 2008; Siddiqui & Movsas, 
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2017). These related toxicities will be discussed in detail in the below sections as they relate to 
acute and late toxicity.  
1.2.1.1 Acute toxicities associated with non-surgical treatment.  A brief description of 
the toxicities commonly associated with non-surgical HNC treatment that are of relevance to the 
speech pathologist have been detailed in Table 1.2, including if they commonly occur as an acute 
or late toxicity, or present as an acute toxicity that frequently persist beyond 3 months post-
treatment. Some toxicities such as mucositis, hyposalivation, trismus, and fibrosis are a clinician 
graded toxicity based on assessment, whilst others such as dysphagia, lymphoedema, and 
dysphonia are both clinician graded based on assessment but influenced by patient report. 
Toxicities such as xerostomia, dysgeusia, thick saliva, odynophagia, nausea, vomiting, fatigue 
and anorexia are graded based upon patient report. These toxicities are known to be further 
intensified with the addition of chemotherapy and/or altered fractionation (accelerated) regimens 
(Cartmill, Cornwell, Ward, Davidson, & Porceddu, 2013; Russi et al., 2012). Acute mucositis is 
one of the most frequently occurring side-effects during the course of treatment for patients with 
HNC undergoing non-surgical management with incidence at 90-100%, and is commonly 
associated with infection, dysphagia, enteral nutrition, intravenous opioid administration, and 
hospitalisation (Siddiqui & Movsas, 2017). Increasing incidence of mucositis has also been a 
barrier to escalated, aggressive treatment regimens (Murphy et al., 2009). Xerostomia, dysguesia 
and mucositis have been reported as the physical side-effects most pervasively affecting 
swallowing function following non-surgical treatment of HNC (Barnhart et al., 2018), with 
patients surprised at the effect of reduced saliva production on their ability to eat certain foods 
(Nund et al., 2014b).  
Whilst the maximum incidence of acute toxicity over the entire treatment period is a 
frequently reported outcome measure, in contrast, specific data regarding patterns of acute 
toxicity, including the onset, peak, and recovery over the course of the acute treatment phase 
have been infrequently reported in the literature to date. However, one previous study detailing 
these parameters for a small cohort of patients with oropharyngeal SCC undergoing 
hyperfractionated 3DCRT reported the onset of acute toxicities (dysphagia, mucositis, and 
xerostomia) in week 1 of treatment with a peak for all symptoms in the final week of treatment. 
By week 3 of treatment, almost 75% of patients required diet modification with oral 
supplementation (Cartmill, Cornwell, Ward, Davidson, & Porceddu, 2013). The raw weekly 
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toxicity incidence data reported by Van Der Laan et al. (2015) indicated a symptom peak for oral 
mucositis, xerostomia, tube feeding use, and need for liquid diets in patients final week of 
treatment. Maurer, Hipp, Schäfer, and Kölbl (2011) also reported details of the pattern of 
dysphagia, mucositis, and xerostomia in their study of 35 patients with HNC undergoing 
intensity modulated arc therapy +/- chemotherapy. They found the incidence of grade 2-3 
xerostomia, dysphagia and mucositis peaked from week 4 (xerostomia and dysphagia) and week 
5 (mucositis) of treatment with a significant decrease in mucositis and dysphagia symptoms by 6 
weeks post-treatment and a return to baseline dysphagia after 6 months. This information on 
symptom, onset, progression, and recovery is crucial to assist the planning of SP support services 
during treatment. However, it is also important information for patients – with studies reporting 
patients want more information on treatment effects during pre-treatment education sessions to 
prepare for radiotherapy for HNC (Brockbank, Miller, Owen, & Patterson, 2015). 
There is also an emerging awareness of the correlation between acute and late toxicities, 
which has increased the importance of identification of patients at high risk for severe acute 
toxicities to implement appropriate preventative supportive cares (Denaro et al., 2013). A study 
by Van Der Laan et al. (2015) found acute xerostomia and dysphagia are strong prognostic 
factors for the development of grade 2-4 (moderate – severe) dysphagia at 6 months post-
treatment. In light of the significant burden acute toxicities carry, many members of the MDT 
including speech pathologists are involved in supporting patients to prevent and manage these 
acute toxicities. This is achieved through a combination of medications and strategies such as 
mouthwashes, swallowing exercises, alterations to food/fluid, and enteral nutrition in order to 
ultimately maintain adequate nutrition, complete their treatment and minimise the likelihood of 
late toxicities. Within this thesis, the impact of acute toxicities and the need for tailored 
supportive care models is a key issue. For this reason, more detailed discussion of the role of the 
speech pathologist will be provided later in this chapter within Section 1.4. 
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Table 1.2 
Definitions of Common Toxicities Associated with Non-surgical Treatment for Head and Neck 
Cancer 
Toxicity Acute/Late Definition 
Dysphagia Acute and Late Difficulty swallowing 
Dysguesia Acute and Late Abnormal or absent taste of foodstuffs/fluids 
Xerostomia (dry mouth) Acute and Late Perception of a dry mouth 
Hyposalivation Acute and Late Reduced salivary flow in the oral cavity 
Thick Saliva Acute Thickened, ropy or sticky saliva that may be markedly altered in taste 
Oral Mucositis Acute Inflammation and ulceration of the oral mucosa 
Pharyngeal Mucositis Acute Inflammation and ulceration of the mucous membrane of the pharynx 
Odynophagia Acute Pain on swallowing 
Nausea Acute A queasy sensation and/or the urge to vomit 
Vomiting Acute 
Reflexive act of ejecting the contents of the 
stomach through the mouth 
Trismus Acute and Late 
Lack of ability to open the mouth fully due to a 
decrease in the range of motion of the muscles of 
mastication 
Fatigue Acute and Late 
A state of generalised weakness and inability to 
accomplish daily activities 
Anorexia Acute and Late Loss of appetite 
Lymphoedema Acute and Late Excessive fluid collection in the lymph tissues that causes swelling 
Fibrosis Late Fibrotic degeneration of the deep connective tissues 
Dysphonia Acute and Late Change or loss in the sound of the voice quality 
Note:  Adapted from National Cancer Institute Common Terminology Criteria for Adverse Events 
Version 4.0, 2009. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40). 
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1.2.1.2 Late toxicities associated with non-surgical treatment.  As previously 
discussed, late toxicities can either be acute toxicities that persist beyond the first 3 months post-
treatment or side effects of treatment that first present after the acute care phase and are 
described above in Table 1.2. Late toxicities can continue for months, years, or indefinitely, and 
understandably greatly impact the QOL of patients with HNC (Chundury et al., 2015; Ganzer et 
al., 2015; Maurer et al., 2011; Nund et al., 2014b; Roe et al., 2014). Meta-analysis has shown 
that while global QOL is recovered by 12 months post-treatment, a number of issues persist after 
non-surgical treatment, such as difficulties with xerostomia, sticky saliva, social eating issues, 
fatigue, and deterioration in physical function continuing at 12 months post-treatment (So et al., 
2012). Barnhart et al. (2018) found that despite patient reported improvements post-treatment, 
xerostomia and dysgeusia remain present and continue to be a barrier to oral intake up to 3 years 
post-treatment. However, the “barrier to oral intake” rating did become lower in comparison to 
the “presence of” rating over time, indicating a level of patient adjustment and acceptance to 
their “new normal”. These reports confirm a continued need for multidisciplinary survivorship 
support long after HNC treatment finishes and patients are considered to be “cured”. 
1.2.1.3 Monitoring toxicities associated with non-surgical treatment.  Routine 
outcome measurement is a crucial part of monitoring treatment related toxicities in HNC. Tools 
can either be clinician rated or patient reported outcome measures focussing on QOL (Holländer-
Mieritz et al., 2019). There are many outcome measures used internationally. Some are broad 
covering the range of toxicities experienced such as the Common Terminology Criteria for 
Adverse Events (CTCAE) (National Cancer Institute, 2009) or the Radiation Therapy Oncology 
Group (RTOG) Acute Radiation Morbidity Scoring Criteria (Cox, Stetz, & Pajak, 1995) and 
some are more specific to particular conditions such as the Functional Oral Intake Scale (FOIS) 
rating swallowing function (Crary, Mann, & Groher, 2005). Many HNC centres regularly use 
outcomes measures to monitor patient side effects during treatment and can serve as a means of 
communicating patient status between MDT members. They are also frequently used for research 
purposes. 
In this thesis the CTCAE version 4.0 was used to monitor toxicities as it was developed 
with international collaboration and consensus of the oncology research community and is a 
widely used tool for measuring toxicity in HNC treatment. Table 1.3 summarises the CTCAE 
rating scale for the toxicities monitored in this thesis. Another frequently used outcome measure 
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is the RTOG Acute Radiation Morbidity Scoring Criteria which has been included for the 
reader’s benefit as it is commonly used in HNC studies used for comparison of outcomes in this 
thesis. Table 1.4 summarises the RTOG rating scale of the relevant toxicities. It is important to 
note that while both these scales include a measure of dysphagia, the broad descriptions and 
ratings are not sensitive to the multiple characteristics of dysphagia evaluated by the speech 
pathologist. Indeed, a recent review by Nund et al. (2019) comparing the content of outcome 
measures used to measure dysphagia post HNC treatment and mapping those to the International 
Classification of Functioning Disability and Health (ICF) found there are large number of tools 
currently in use, with researchers frequently using more than one tool in order to capture all 
relevant information. Most frequently tools were matched to ICF categories relating to body 
function, with fewer concepts matched to activity, participation and environmental factors.   
In this thesis, several measures of dysphagia were used in order to capture functional 
swallowing information and increase the ability to compare results with the existing literature. As 
well as the CTCAE dysphagia rating, the nature of the diet and fluid texture tolerated by patients 
was recorded using the National Dysphagia Diet Descriptors (Dietitians Association of Australia 
& Speech Pathology Association of Australia, 2007), which used the terms Smooth Pureed, 
Minced and Moist, Soft, and Regular food descriptors and Extremely Thick, Moderately Thick, 
Mildly Thick, and Regular fluid descriptors. Two categories were also added to reflect diets 
frequently used by the HNC population during treatment, NBM and Liquids Only. Table 1.5 
summarises the diet textures and their definitions. The FOIS (Crary et al., 2005), a 7-point scale 
reflecting diet and need for enteral nutrition was also used and is shown in Table 1.6. Whilst 
initially developed in the stroke population it is increasingly used in the HNC population 
clinically and in research (Lawson & Ward, 2014; Shukla et al., 2017). No instrumental measures 
of oropharyngeal swallow function such as VFSS or Fibreoptic Endoscopic Swallow Study 
(FEES) were used in the studies within this thesis. Whilst highly desirable to include a more 
direct measure of oropharyngeal function, it was unfortunately beyond the scope, funding, and 
feasibility of this project, due to the number of patients and method of data collection. Data was 
collected during routine clinical practice and it is not routine practice at the study institution to 
perform an instrumental swallow assessment unless clinically indicated.  
Given the large number of dysphagia and related toxicity measures available and the 
different characteristics of swallowing and toxicity each one contributes it is prudent to discuss 
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how these measures relate to each other. Recent research has found instrumental measures of 
oropharyngeal swallow function such as FEES and VFSS poorly correlate to measures of oral 
intake such as the FOIS or Performance Status Scale Normalcy of Diet (Arrese et al., 2019; 
Pedersen, Wilson, McColl, Carding, & Patterson, 2016). Instrumental measures of swallow 
function were also found to have a weak relationship with patient reported swallow measures 
such as the Eating Assessment Tool-10 (EAT-10) or MD Anderson Symptom Inventory-Head and 
Neck (MDAS-HN) (Arrese et al., 2019; Pedersen et al., 2016). However, patient reported 
swallow measures were strongly correlated with measures of oral intake (Arrese et al., 2019; 
Kamal et al., 2019; Pedersen et al., 2016).  
When looking at the relationship of treatment related toxicities and oral intake, cluster 
analysis by Kamal et al.  (2019) found symptoms that join with others, such as choking, swallow, 
taste, mucous, and dry mouth were rated by patients more similarly and may be interrelated. 
They also found patient groups with poor oral intake shared similar symptom profiles and 
severity, indicating a possible link between symptom cluster grouping and oral intake status. 
Kamal et al. (2019) also found significant correlations between MDASI scores for appetite, 
choking, dry mouth, pain, swallow, taste, teeth/gums, and voice/speech with FOIS score, 
indicating a strong relationship between these symptoms and the nature of patient’s oral intake.  
These results confirm that oral intake in the HNC population is a multidimensional issue with 
many factors impacting on function. Measures are not necessarily interchangeable and currently 
a combination of measures is required. 
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Table 1.3  
Summary of Common Terminology Criteria for Adverse Events version 4.0 Rating Scale  
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Oral 
Mucositis 
Asymptomatic or mild 
symptoms; intervention 
not indicated 
Moderate pain; not 
interfering with oral 
intake; modified diet 
indicated 
Severe pain; interfering 
with oral intake 
Life-threatening 
consequences; urgent 
intervention indicated 
Death 
Pharyngeal 
Mucositis 
Endoscopic findings only; 
minimal symptoms with 
normal oral intake; mild 
pain but analgesics not 
indicated 
Moderate pain and 
analgesics indicated; 
altered oral intake; 
limiting instrumental 
ADL 
Severe pain; unable to 
adequately aliment or 
hydrate orally; limiting 
self care ADL 
Life-threatening 
consequences; urgent 
intervention indicated 
Death 
Dysgeusia Altered taste but no change in diet 
Altered taste with change 
in diet (e.g., oral 
supplements); noxious or 
unpleasant taste; loss of 
taste 
- - - 
Xerostomia 
(Dry Mouth) 
Symptomatic (e.g., dry or 
thick saliva) without 
significant dietary 
alteration; unstimulated 
saliva flow >0.2 ml/min 
Moderate symptoms; oral 
intake alterations (e.g., 
copious water, other 
lubricants, diet limited to 
purees and/or soft, moist 
foods); unstimulated 
saliva 0.1 to 0.2 ml/min 
Inability to adequately 
aliment orally; tube 
feeding or TPN indicated; 
unstimulated saliva <0.1 
ml/min 
- - 
Salivary duct 
Inflammation 
(Thick Saliva) 
Slightly thickened saliva; 
slightly altered taste (e.g., 
metallic) 
Thick, ropy, sticky saliva; 
markedly altered taste; 
alteration in diet 
indicated; secretion-
Acute salivary gland 
necrosis; severe 
secretion-induced 
symptoms (e.g., thick 
Life-threatening 
consequences; urgent 
intervention indicated 
Death 
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induced symptoms; 
limiting instrumental 
ADL 
saliva/oral secretions or 
gagging); tube feeding or 
TPN indicated; limiting 
self care ADL; disabling 
Dysphagia Symptomatic, able to eat regular diet 
Symptomatic and altered 
eating/swallowing 
Severely altered 
eating/swallowing; tube 
feeding or TPN or 
hospitalization indicated 
Life-threatening 
consequences; urgent 
intervention indicated 
Death 
Nausea Loss of appetite without alteration in eating habits 
Oral intake decreased 
without significant weight 
loss, dehydration or 
malnutrition 
Inadequate oral caloric or 
fluid intake; tube feeding, 
TPN, or hospitalization 
indicated 
- - 
Note:  ADL: Activity of Daily Living; TPN: Total Parenteral Nutrition. Adapted from National Cancer Institute Common Terminology Criteria for 
Adverse Events Version 4.0, 2009 (https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40). 
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Table 1.4  
Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring Criteria 
Organ Tissue Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Mucous 
Membranes 
No change 
over baseline 
Injection/may experience 
mild pain not requiring 
analgesia 
Patchy mucositis that 
may produce an 
inflammatory 
serosanguinous 
discharge/may experience 
moderate pain requiring 
analgesia 
Confluent fibrinous 
mucositis/may include 
severe pain requiring 
narcotic 
Ulceration, haemorrhage 
or necrosis 
Salivary 
Gland 
No change 
over baseline 
Mild mouth 
dryness/slightly thickened 
saliva/may have slightly 
altered taste such as 
metallic taste/these 
changes not reflected in 
alteration of baseline 
feeding behaviour, such 
as increased use of liquids 
with meals 
Moderate to complete 
dryness/thick, sticky 
saliva/markedly altered 
taste 
- Acute salivary gland necrosis 
Pharynx & 
Oesophagus 
No change 
over baseline 
Mild dysphagia or 
odynophagia/may require 
topical anaesthetic or 
non-narcotic 
analgesic/may require 
soft diet 
Moderate dysphagia or 
odynophagia/may require 
narcotic analgesics/may 
require puree or liquid 
diet 
Severe dysphagia or 
odynophagia with 
dehydration or weight 
loss > 15% from pre-
treatment baseline 
requiring enteral 
nutrition, IV fluids or 
hyperalimentation 
Complete obstruction, 
ulceration, perforation, 
fistula 
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Note: Adapted from “Toxicity Criteria of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of 
Cancer” by J. Cox, J. Stetz & T. Pajak, 1995, International Journal Radiation Oncology Biology Physics, 31, pp 1341. Copyright 1995 by Elsevier 
Science Ltd.  
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Table 1.5  
Australian Clinical Food and Fluid Texture Scale 
Texture Scale Definition 
Regular Diet Everyday foods of various textures. Some are hard and crunchy, others are naturally soft. 
Texture A Soft Diet 
Naturally soft foods (e.g. ripe banana, soft bread, pasta, pastry, moist meats, eggs) or may be 
cooked or cut to alter texture. Can be chewed but not necessarily bitten, minimal cutting required, 
easily broken up with a fork, targeted size 1.5cm x 1.5cm 
Texture B Minced and Moist Diet Soft and moist and should easily form into a ball and be mashed with a fork. Individual uses tongue rather than teeth to break the small lumps. Lumps are soft and rounded, targeted size 0.5cm. 
Texture C Smooth Pureed Diet Smooth and lump free, similar to the consistency of commercial pudding. Moist and cohesive enough to hold its own shape on a spoon. Food can be moulded, layered or piped. 
*Liquids Only Diet Only liquids (thickened or regular) are tolerated, e.g. smoothies, custard, yoghurt, smooth soups, regular drinks. 
*Nil By Mouth No oral intake is consumed. 
Regular Fluids Everyday fluids of various thickness levels, very fast – fast flow rate. 
Level 150 Mildly Thick Fluids Steady, fast flow, pours quickly from a cup but slower than regular fluids, may leave a coating film of residue in the cup. Subjectively fluids run fast through the prongs of a fork. 
Level 400 Moderately Thick Fluids Slow flow, cohesive and pours slowly, possible to drink very slowly from a cup, slowly drips in dollops through the prongs of a fork. Similar to room temperature honey or a thickshake. 
Level 900 Extremely Thick Fluids No flow, cohesive and holds its shape on a spoon, is not possible to pour from a cup, sits on the prongs of a fork and does not flow through. Similar to pudding or mousse. 
Note:  Adapted from “Texture-modified foods and thickened fluids as used for individuals with dysphagia: Australian standardised labels and 
definitions” by Dietitians Association of Australia and Speech Pathology Association of Australia Limited, 2007, Nutrition and Dietetics, 64 
(suppl. 2), pp S53-S76. Copyright 2007 by The Authors. 
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Table 1.6  
Functional Oral Intake Scale 
Score Description 
Level 7 Total oral diet with no restrictions 
Level 6 Total oral diet with multiple consistencies without special preparation, but with specific food limitations 
Level 5 Total oral diet with multiple consistencies, but requiring special preparation or compensations 
Level 4 Total oral diet or a single consistency 
Level 3 Tube dependent with consistent oral intake of food or liquid 
Level 2 Tube dependent with minimal attempts of food or liquid 
Level 1 Nothing by mouth (Tube dependent) 
Note:  Adapted from “Initial Psychometric Assessment of a Functional Oral Intake Scale for Dysphagia in Stroke Patients” by M. Crary, G. 
Carnaby Mann, M. Groher, 2005, Archives Physics Medicine Rehabilitation, 86, pp 1516-1520. Copyright 2005 by The American Congress of 
Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation. 
  29 
1.2.2 Non-Surgical Treatment: Impact of the Addition of Chemotherapy 
The addition of concurrent chemotherapy to radiotherapy treatment has been shown to 
improve treatment efficacy and has since become widely used as the standard of care for curative 
treatment where appropriate (Russi et al., 2012). However, the improved cure rates are known to 
come at a cost of increased toxicity and dysphagia. Chemoradiotherapy has been shown to 
significantly increase the likelihood of developing toxicities such as mucositis, dysphagia, 
nausea, vomiting, neutropenia, and fatigue (Denaro et al., 2013; Russi et al., 2012; Trotti, Bellm, 
et al., 2003). Furthermore, it is suggested the rate of dysphagia resulting in aspiration associated 
with CRT is under-reported, and combined with the neutropenia arising from the chemotherapy 
may result in aspiration pneumonia, sepsis or respiratory failure requiring hospital admission 
(Nguyen et al., 2004). The increase in treatment related toxicity has consequences for the 
supportive care needs of patients receiving CRT with implications for the MDT in consideration 
of optimal care pathways. 
1.2.3 Summary 
Patients with HNC undergoing non-surgical treatment are highly likely to experience 
some form of acute and/or late toxicity regardless of whether they receive definitive treatment or 
PORT. Dysphagia is a common sequela of HNC and can arise at any point during the patient’s 
journey, whether it is present pre-treatment, resulting from the tumour itself, caused by surgical 
management, or due to acute and/or late toxicities associated with non-surgical treatment. The 
focus of this thesis is non-surgical treatment methods of HNC and for this reason there will be 
little further discussion of pre-treatment dysphagia or surgical management related dysphagia in 
the subsequent sections.  
Given the debilitating nature of acute and late toxicities including dysphagia associated 
with non-surgical treatment of HNC, several de-escalation and detoxification treatment strategies 
are under investigation as highlighted earlier in this section. One of these strategies is the 
adoption of highly conformal radiation methods such as H-IMRT to protect normal tissues. 
Advances in radiotherapy techniques, and the subsequent impact on toxicity is the focus of the 
first 3 investigations in this thesis. For this reason, more detailed discussion of advanced 
radiotherapy techniques and their impact on treatment related acute toxicity and dysphagia will 
be outlined in the following Section 1.3.  
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1.3 Advances in Radiation Therapy: Helical IMRT 
As previously discussed, with improved cure rates in the face of a changing epidemiology 
in HNC, there is increased focus on survivorship and minimising the effects of treatment to 
maximise QOL for patients with HNC. Several strategies are under investigation, and one of 
these is the protection of normal tissues through dose constraints to key structures with the aim 
of reducing treatment related toxicity, particularly dysphagia and xerostomia (Hawkins et al., 
2018; Hutchison et al., 2019; Ursino et al., 2017). In order to achieve this, work has been 
conducted to determine which specific swallowing structures - and at what radiation dose and 
volume – can lead to improved dysphagia and xerostomia outcomes (Caudell et al., 2010; 
Charters, Bogaardt, Freeman-Sanderson, & Ballard, 2019; Christianen et al., 2016; Christianen et 
al., 2015; Dale et al., 2016; Dirix, Abbeel, Vanstraelen, Hermans, & Nuyts, 2009; Duprez, 
Madani, De Potter, Boterberg, & De Neve, 2013; Eisbruch et al., 2004; Hawkins et al., 2018; 
Hutchison et al., 2019; Van der Laan et al., 2013). The work conducted by many research groups 
in this area has led to the advent of “swallow sparing” and “parotid sparing” RT, with several 
models validated (Christianen et al., 2012; Christianen et al., 2016; Duprez et al., 2013; Eisbruch 
et al., 2004).  
The salivary glands, oral cavity, parotid glands, spinal cord, brain stem, and mandible are 
structures frequently contoured in the literature (Bentzen et al., 2010). In terms of parotid sparing 
RT, this work has facilitated reduced rates of xerostomia. Current recommendations, based on the 
body of evidence supporting parotid sparing treatment planning, suggests limiting the mean 
parotid gland dose to 26Gy, mean contralateral sub mandibular gland dose to <39Gy, and the 
mean oral cavity dose to <30Gy (Beetz et al., 2014; Hawkins et al., 2018).  
With regard to dysphagia, the superior pharyngeal constrictor muscle (PCM) and 
supraglottic larynx have been found to be the strongest dosimetric predictors of grade 2 or worse 
dysphagia at 6 months post-treatment (Christianen et al., 2016; Petkar et al., 2016). However, 
there is some variability in the most important structures depending on the primary tumour site, 
e.g. the superior PCM are most significant in oropharyngeal cancer, where the larynx and inferior 
PCM doses are more significant in the case of laryngeal cancer (Hawkins et al., 2018). A recent 
systematic review found, whilst there is still variation in guidelines for the selection of the 
structures delineated and their dose restriction, routine contouring of the PCM, glottic larynx, 
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supraglottic larynx, and oesophageal inlet muscle resulted in reductions in dysphagia toxicity and 
enteral nutrition periods which was associated with dose restriction of <50Gy to the glottic 
larynx and supraglottic larynx, and <60Gy to the PCMs (Hutchison et al., 2019).  
Avoidance of radiation dose to these key structures is achieved through advanced 
conformal radiation techniques such as intensity modulated radiation therapy (IMRT) or image 
guided radiation therapy (IGRT). The evolution of RT techniques over the last 20-30 years and 
their impact on treatment related toxicities will be discussed in the following sections, with a 
particular focus on rotational IMRT techniques.   
1.3.1 Prior 2D and 3D Conformal Radiotherapy Techniques 
In previous decades, a robust radiotherapy technique was used to deliver simple-shaped 
radiation fields based on the bony anatomy. This was called two-dimensional radiotherapy (2D 
RT). However, as this technique used simple fields aimed at the tumour to ensure adequate 
coverage, large volumes of normal tissue were also irradiated causing significant toxicity (Van 
der Veen & Nuyts, 2017). In the 1970’s the introduction of CT scans enabled greater 
visualisation of the tumour and OARs and contributed to advancements in RT. Three-
dimensional conformal radiotherapy (3D CRT) guided by CT scan information emerged in the 
1980’s and was used to plan and deliver radiation to the head and neck region for several 
decades. In 3D CRT beams from several directions were shaped to fit the size and shape of the 
tumour using a multileaf collimator aimed at the PTV with shielding to protect normal structures 
in the beam path (Van der Veen & Nuyts, 2017). The total sum of the doses delivered by each of 
the beams ensured the required dose was received by the PTV (Kelly, 2014).  
Despite the advancement from 2DRT to 3DCRT, significant volumes of normal tissue 
still received a high radiation dose as the radiation was delivered in approximately 3 fields with a 
uniform dose in each field (Van der Veen & Nuyts, 2017). The incidence of acute dysphagia and 
treatment related toxicity remained very high, with 100% of patients experiencing ≥ grade 2 
dysphagia, 72% grade 3 dysphagia, and 82% patients reporting grade 3 mucositis (Al-Mamgani 
et al., 2013). Dysphagia and toxicities resulting from 3DCRT can persist, becoming late effects, 
with the same group reporting rates of 20% grade 3 late dysphagia, and 23% grade 3 late 
xerostomia, and another study reporting dysphagia lasting for up to a decade post-treatment 
(Cartmill, Cornwell, Ward, Davidson, Nund, et al., 2013).  
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1.3.2 Intensity Modulated Radiotherapy (IMRT) 
To address these imperfections in delivery, in the 1990’s dynamic multileaf collimators 
were designed, enabling the radiation beams to have a different shape, directed from different 
angles, and the capability to modify the intensity of each beam. Thus a new type of radiation 
called intensity modulated radiotherapy (IMRT) was introduced. This technique modulates the 
number of radiation fields and the intensity of each beam is optimised to deliver a high dose of 
radiation to specified volumes, whilst reducing the dose to adjacent normal tissues (Argiris et al., 
2008a; Mendez, Moraes, Poon, & Marta, 2016). This technique has supported advances in 
radiation planning and delivery. In conjunction with complex planning by the radiation 
oncologists and radiation therapist, computer software programs are given the PTV and dose 
limitations to sensitive structures, then the software uses inverse planning to work backwards to 
calculate a complex combination of radiation arcs and beams (Kelly, 2014). This evolution has 
enabled an infinite range of dose distributions adaptable to the target volume to be offered, 
resulting in greater unique contouring of each individual tumour shape and size, and its 
surrounding normal healthy tissue (Daly-Schveitzer, Julieron, Tao, Moussier, & Bourhis, 2011). 
The introduction of IMRT has enabled greater protection of key anatomy involved in 
salivation and swallowing with the aim of reducing treatment related toxicity (Eisbruch et al., 
2004; Hawkins et al., 2018). These targeted radiation treatment plans have been called parotid 
sparing IMRT and swallowing sparing or dysphagia optimised IMRT. The PARSPORT trial 
conducted by Nutting et al. (2011) validated the superiority of IMRT over 3DCRT to spare the 
parotid glands with significantly lower incidence of xerostomia; improved recovery of saliva 
secretion; and improvements in dry mouth and global QOL scores reported at 12, and 24 months 
post-treatment. A systematic review by Kouloulias et al. (2013) concluded that IMRT 
significantly reduces the radiation dose to the parotid glands and reduces late xerostomia, with a 
trend for improvement in mucositis rates as compared with 2DRT and 3DCRT. It has also been 
demonstrated that the use of IMRT aimed at sparing specific swallowing structures may achieve 
positive gains in dysphagia outcomes (Eisbruch et al., 2011; Eisbruch et al., 2007; Hawkins et 
al., 2018; Paleri et al., 2014).  
The systematic review by Ursino et al. (2017) found though direct comparison was 
difficult, the current literature suggests better subjective and objective (instrumental assessment) 
 33 
swallowing outcomes for patients with HNC treated with IMRT compared to 3DCRT due to the 
greater sparing of normal tissues. Studies have demonstrated the use of IMRT to reduce the 
volume of the glottic larynx and supraglottic larynx receiving >50Gy and the PCMs receiving 
>60Gy without compromising target dose (Christianen et al., 2016; Eisbruch et al., 2004; Feng et 
al., 2010; Hutchison et al., 2019; Van der Laan et al., 2013). Recently work by Christianen et al. 
(2016) validated swallowing sparing IMRT (reducing the dose to the parotids, superior PCM and 
the supraglottic larynx) as a means of reducing grade 2-4 dysphagia at 6 months post-treatment, 
compared with standard IMRT. Such evidence highlights the potential to use radiation planning 
and delivery techniques to reduce the nature and severity of dysphagia.  
Similar to Ursino et al. (2017) the systematic review by Roe et al. (2010) found 
comprehensive evaluation of the impact of IMRT on swallowing outcomes was difficult due to 
the heterogeneous nature of studies with variable assessment methods, outcome measures, and 
limited prospective data. More prospective, longitudinal studies with baseline assessments and 
pre-determined evaluation at multiple time-points are required for developing a comprehensive 
understanding of the impact of IMRT on swallowing outcomes. To address this, the landmark 
DARS trial, a phase III randomised multicentre study of dysphagia-optimised IMRT versus 
standard IMRT for patients with oropharyngeal and hypopharyngeal cancer aims to 
comprehensively evaluate whether improvements in long term swallowing function are actually 
realised through using this technique (Petkar et al., 2016). Once published, the outcomes of the 
primary and secondary endpoints of this study will have many implications and applications for 
non-surgical HNC treatment.  
1.3.3 Helical Intensity Modulated Radiotherapy (H-IMRT) 
Since the advent of static beam IMRT, further evolution of RT techniques has continued 
with the introduction of rotational IMRT techniques such as volumetric rotational IMRT 
(VMAT) - originally introduced as Intensity Modulated Arc Therapy (IMAT) and helical IMRT 
(Van Gestel, Verellen, et al., 2013). Helical IMRT is a fan beam form of rotational IMRT, often 
referred to as serial TomoTherapy®, or helical tomotherapy. For consistency throughout this 
thesis, it will be referred to as helical IMRT (H-IMRT) as this is the term used by the institution 
where the research has been undertaken.  
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Helical-IMRT combines the characteristics of a linear accelerator and a CT scanner. It is 
delivered by a CT-like machine, combining continuous H-IMRT with high precision image-
guided radiotherapy via an integrated CT scanner. Treatment is usually delivered by a 
TomoTherapy Hi-Art (TomoTherapy Inc., Madison, WI, USA) or TomoHD system (dedicated 
helical IMRT linear accelerator). Proponents of this approach describe the potential to achieve 
even greater precision and homogeneity of dose to the target volume, with increased control of 
dose distributions using steep dose gradients to minimise volumes received by healthy tissue 
without compromising target coverage (Fiorino et al., 2006; Gielda et al., 2010; Murthy et al., 
2010; Van Gestel, Van Vliet-Vroegindeweij, et al., 2013). This is achieved through more precise 
contouring of the target volume and OAR; daily CT scanning of the target volume and OAR for 
comparison with the planning CT scan; fully automatic patient positioning using millimetre-
precision; and the manner in which radiation is delivered. The radiation field rotates around the 
patient, delivering multiple overlapping 360-degree slices of radiation (like a corkscrew), whilst 
the radiation beam aperture and intensity changes every 7 degrees facilitating these high dose 
gradients, i.e. a 50% radiation dose difference can be achieved within a few millimetres (Rong & 
Welsh, 2011; Van Gestel, Verellen, et al., 2013).  
Several planning studies have reported a superiority of H-IMRT over traditional IMRT 
with better target coverage and sparing of the OAR (Fiorino et al., 2006; Gielda et al., 2010; 
Murthy et al., 2010; Van Gestel, Van Vliet-Vroegindeweij, et al., 2013). One planning study 
found H-IMRT significantly improved the quality of dose distribution with better dose 
homogeneity within the PTV whilst more efficiently sparing the spinal cord, parotids and 
mandible (Fiorino et al., 2006). Gielda et al. (2010) reported the ability to successfully spare the 
uninvolved larynx without compromising target dose or other OAR sparing whilst treating 
patients with stage IVa or greater oropharyngeal SCC with H-IMRT. A study comparing 
treatment plans of traditional IMRT, VMAT, and H-IMRT found H-IMRT had the lowest mean 
dose to the parotid, oral mucosa, cricopharyngeus muscle, glottic and supraglottic larynx (Van 
Gestel, Van Vliet-Vroegindeweij, et al., 2013). Such potential tissue sparing may indeed provide 
further opportunities to protect the DARS and enable better functional swallowing outcomes for 
patients with HNC. 
1.3.3.1 Helical IMRT and dysphagia and related toxicities.  Whilst the potential 
benefits of H-IMRT have been discussed in theoretical planning studies, there are currently a 
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limited number of studies that quantify patient outcomes and toxicity rates to determine if the 
proposed benefits reported in planning studies translate to actual clinical improvements in 
patients’ toxicity profiles and QOL. A small number of retrospective studies and an even smaller 
number of prospective studies have reported outcomes for xerostomia, dysphagia, and mucositis 
only, generally as a maximum incidence. The incidence of acute grade 2 xerostomia in the 
available H-IMRT literature ranges from 10-67% (Hsieh et al., 2011; Kong, Hong, Choi, & Kim, 
2013; Kreps et al., 2016; Van Gestel et al., 2015). A study by Kreps et al. (2016) found H-IMRT 
reduced the incidence and severity of xerostomia due to reduced parotid gland doses and 
volumes, at 6 months, followed by an increase in values at 12 months for all salivary glands and 
a return to close to baseline values at 18 months for the parotid gland.  
Rates of grade 2 dysphagia range widely from 11-70%, and grade 3 dysphagia ranged 
from 0-53% (Donato et al., 2013; Hsieh et al., 2014; Santa Cruz et al., 2018; Van Gestel et al., 
2015), with a combined grade 2/3 report at 80% (Kong et al., 2013). One retrospective study 
found younger patients had higher rates of dysphagia, whilst older patients experienced worse 
xerostomia and pain (Santa Cruz et al., 2018). With regards to oral mucositis, the reported 
incidence of grade 3 mucositis also ranges widely from 0-76%, with the majority of reports 
greater than 50% (Chen et al., 2011; Donato et al., 2013; Kreps et al., 2016; Kruser et al., 2013; 
Nguyen, Ceizyk, et al., 2013; Santa Cruz et al., 2018; Shueng et al., 2010; Van Gestel et al., 
2015). There are a smaller number of studies reporting results for grade 2 mucositis ranging from 
30-90% (Donato et al., 2013; Kreps et al., 2016; Kruser et al., 2013; Shueng et al., 2010). Table 
1.7 summarises available outcomes reported in the published H-IMRT literature.  
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Table 1.7  
Summary of Toxicity Outcomes for Helical IMRT in Head and Neck Cancer 
Study Population Design Treatment N Outcome Mucositis Dysphagia Xerostomia Gastrostomy 
     Measure Gr 1 Gr 2 Gr 3 Gr 1 Gr 2 Gr 3 Gr 1 Gr 2 Gr 3 >12 months 
Chen et al. 
(2011) Mixed Retrospective 
Helical IMRT 
+/- chemotherapy 96 RTOG - - 18% - - - - - - 8% 
Donato et al. 
(2013) 
Oropharynx 
Oral Cavity Prospective 
Helical IMRT 
+/- chemotherapy 24 CTCAE v4 13% 88% 0% 29% 71% 0% - - - 0% 
Hsieh et al. 
(2014) 
Oral Cavity 
post op Retrospective 
Helical IMRT 
+/- chemotherapy 53 CTCAE v3 9% 57% 34% 76% 11% 13% 64% 36% 0% - 
Kimura et al. 
(2016) Oropharynx Retrospective 
Helical IMRT 
+/- chemotherapy 93 CTCAE v4 - - 45% - - - - - - 2% 
Kong et al. 
(2013) Mixed Retrospective 
Helical IMRT  
+/- chemotherapy 30 RTOG 13% 37% 50% 17% 40% 40% 30% 50% 17% - 
Kruser et al. 
(2013) Oropharynx Prospective 
Helical IMRT 
Chemotherapy 81 Unknown - 30% 70% - - - - - - - 
Nguyen, 
Ceizyk, et al. 
(2013) 
Oropharynx Retrospective Helical IMRT Chemotherapy 33 RTOG - - 72% - - - - - - 6% 
Nguyen et al. 
(2012) Larynx Retrospective 
IMRT, Helical 
IMRT  
Chemotherapy 
27 RTOG - - 59% - - - - - - 16% 
Shueng et al. 
(2010) Oropharynx Prospective 
Helical IMRT 
Chemotherapy 10 CTCAE v3 - 90% 10% - - - - - - - 
Van Gestel et 
al. (2015) Mixed Retrospective 
Helical IMRT 
+/- chemotherapy 147 RTOG - - 76% - - 45% - 54% - 5% 
Kreps et al. 
(2016) Mixed Prospective 
Helical IMRT 
+/- chemotherapy 30 RTOG 23% 53% 20% - - - 67% 10% 0% - 
Santa Cruz et 
al. (2018) Mixed Retrospective 
Helical IMRT 
+/- chemotherapy 72 CTCAE v3 - - 31% - - 52% - - 7% 21% 
Note: IMRT: Intensity Modulated Radiation Therapy, CTCAE: Common Terminology Criteria for Adverse Events, RTOG: Radiation Therapy 
Oncology Group Acute Radiation Morbidity Scoring Criteria
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1.3.3.2 Potential benefit of helical IMRT over traditional IMRT.  A small number of 
published studies have compared outcomes of H-IMRT with traditional IMRT with mixed 
results. A retrospective study by Fortin et al. (2014) of 119 patients with OPSCC demonstrated 
superior parotid sparing, with significantly reduced mean doses to the ipsilateral and 
contralateral parotids, and a significantly reduced incidence of ≥ grade 2 xerostomia at 6, 12 and 
24 months post-treatment with the use of H-IMRT compared to traditional IMRT. A prospective 
study found H-IMRT resulted in lower mean doses and dose/volume ratios for the parotid glands 
with reduced late salivary gland toxicity when compared with the traditional IMRT literature 
(Kreps et al., 2016). Another retrospective study comparing H-IMRT with traditional IMRT for 
non-laryngeal and non-hypopharyngeal HNC, reported the mean dose to the uninvolved larynx 
and pharyngeal muscles was almost halved. The mean laryngeal dose was 22.8 Gy versus 41.2 
Gy and the mean pharyngeal dose was 26 Gy versus 52 Gy in the H-IMRT and traditional IMRT 
groups respectively (Nguyen et al., 2010). In a subsequent study, Nguyen, Smith-Raymond, et al. 
(2013) reviewed the instrumental swallowing assessments of a mixed cohort of 48 HNC patients 
who received H-IMRT. The cohort was observed to have aspiration rates lower than those 
reported in the traditional IMRT literature, which the authors attributed to the reduced mean 
pharyngeal radiation dose.  
However, in a retrospective study of 149 patients with mixed tumour sites receiving H-
IMRT vs IMRT, despite achieving reduced radiation doses to the contralateral parotid, there was 
no reported statistically significant differences in rates of xerostomia, mucositis or dysphagia 
(Chen et al., 2011). Similarly, Kruser et al. (2013) reported no statistical difference in rates of 
grade 2 and 3 mucositis in their cohort of patients (n=178) with mixed tumour sites comparing 
3DCRT, IMRT, and H-IMRT techniques. Whilst promising, it is difficult to draw firm 
conclusions on the superiority of H-IMRT over traditional IMRT from the current evidence base. 
1.3.3.3 Limitations of helical IMRT literature reporting dysphagia and related 
toxicity outcomes.  There remain significant gaps in the current H-IMRT literature that limit our 
understanding of toxicity outcomes for patients undergoing this treatment technique and how 
they are best supported from a SP perspective. The limited evidence base quantifying dysphagia 
and related toxicity outcomes, particularly the limited number of prospective studies, is the 
primary barrier. Furthermore, the studies that have been conducted have often focused on one or 
two key symptoms (e.g. xerostomia or mucositis) and have not provided a comprehensive report 
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of the extent and severity of the range of treatment related toxicities, including dysphagia. As the 
relationship between acute toxicities and late effects is better understood, greater focus is being 
placed on comprehensive symptom assessment. Chera et al. (2014) recommended a core set of 
12 patient reported head and neck specific symptoms and health-related QOL domains to be 
assessed in HNC trials to more comprehensively assess the range of symptoms experienced and 
recognise the interdependence of these symptoms. These included, swallowing, pain/oral, skin 
changes, dry mouth, dental health, mouth opening/trismus, taste, excess/thick mucous/saliva, 
shoulder disability, voice/hoarseness, social domain and functional domain.  
Furthermore, toxicity rates in many published studies are typically reported as purely a 
“maximum incidence” figure (e.g., 30% reached grade 3 toxicity) and fail to detail patterns of 
first presentation, symptom peak and recovery (Donato et al., 2013; Kruser et al., 2013; Shueng 
et al., 2010). In a 2015 study exploring the views of HNC patients on desired pre-treatment 
information regarding dysphagia, one of the key themes found was ‘expectations about treatment 
effects’, including onset of symptoms, their timing and nature (gradual or sudden), the recovery 
time, and the severity of swallowing problems (Brockbank et al., 2015). Without information 
regarding the pattern of toxicity onset and progression, the wide range of toxicity outcomes, and 
the limited reports of dysphagia in the H-IMRT literature, health professionals are unable to draw 
firm conclusions regarding toxicity incidence and adequately provide patients with the evidence 
based pre-treatment education they have requested. Furthermore, this is information is crucial to 
planning patient centred MDT supportive care services, incorporating SP.   
1.3.4 Further Advances in Radiation Therapy 
In more recent years intensity modulated proton therapy (IMPT) has emerged as another 
potential de-intensification strategy, with dosimetry studies reporting further reductions of 
incidental radiation of normal tissues with IMPT compared to IMRT (Holliday et al., 2016). 
However, despite early evidence from retrospective and small prospective studies suggesting 
reduced toxicity for patients with IMPT, large scale randomised control trials are in progress to 
comprehensively evaluate the functional outcomes of patients with HNC treated with this 
technique (Frank et al., 2018; Gunn et al., 2016; Jakobi et al., 2015). As the data and literature 
surrounding IMPT for HNC started to emerge after the commencement of this thesis further 
discussion of this technique is beyond the thesis scope. 
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1.3.5 Summary 
The protection of normal tissues and key structures such as the DARS or SWORs to 
minimise treatment related dysphagia and toxicity to ultimately improve QOL for patients with 
HNC has become increasingly important. Advancing RT techniques have enabled greater 
protection of these structures with the introduction of IMRT. Early work has confirmed superior 
swallowing outcomes for patients using IMRT, however, more robust evidence is required. 
Helical IMRT represents a further advancement in radiation technique from traditional IMRT 
with planning and dosimetric studies reporting a superiority of H-IMRT to reduce radiation doses 
to critical OAR and the DARS. However, studies reporting dysphagia and related toxicity 
outcomes are limited. Studies comparing outcomes of H-IMRT with conventional IMRT have 
varied results, with some studies reporting superior results and others reporting no difference. 
The literature supporting outcomes for patients with HNC undergoing H-IMRT is limited with 
more prospective studies needed to confirm the superiority of H-IMRT and whether this 
translates to improved QOL for HNC patients. This information is crucial to health services to 
ensure that supportive care, such as that provided by SP, is provided to the right patients, when 
they need it most. 
1.4 Non-Surgical Head and Neck Cancer Treatment and Speech Pathology Services 
As previously discussed, optimal management for patients with HNC should occur 
through an integrated HNC MDT due to the complexity of the disease and its many associated 
toxicities and psychosocial factors (De Felice, Tombolini, et al., 2018; Friedland et al., 2011). 
The literature also recommends that MDT services be provided using a clear systematic approach 
throughout the cancer care journey. This form of co-ordinated and integrated MDT service can 
be facilitated via clinical pathways (Messing et al., 2019).  
As previously discussed, speech pathologists are recognised as integral members of the 
MDT, providing specialist intervention regarding swallowing and communication pre-treatment, 
during treatment, in the weeks to years post-treatment, and into long-term survivorship (Cancer 
Council Victoria and Department of Health and Human Services Victoria, 2015; Messing et al., 
2019; National Comprehensive Cancer Network, 2016). Specialist SP input may involve pre-
treatment dysphagia assessment and management, and education in preparation for potential 
short and long-term treatment effects. During treatment speech pathologists assist with symptom 
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management including acute dysphagia management and prevention. There is a growing body of 
evidence supporting the use of prophylactic swallowing exercises during treatment to improve 
swallowing outcomes post RT (Messing et al., 2017; Mortensen et al., 2015; Paleri et al., 2014; 
Schindler et al., 2015; Van der Molen et al., 2011; Van Der Molen, Van Rossum, Rasch, Smeele, 
& Hilgers, 2014; Wall et al., 2018). Post-treatment speech pathologists continue to support 
patients with acute and late toxicity, including long term dysphagia, trismus, and voice 
rehabilitation. Dysphagia assessment can occur through several methods: screening using 
standardised tools e.g. the Eating Assessment Tool 10 (Belafsky et al., 2008), clinical swallow 
examination to ascertain the presence of dysphagia, and/or conducting and interpreting 
instrumental swallowing assessments such as VFSS or Fibreoptic Endoscopic Evaluation of 
Swallowing to objectively assess swallow function 
1.4.1 Speech Pathology Service Delivery Practices in Head and Neck Cancer 
Despite recognition of the importance of SP services in integrated HNC management, 
studies have reported variation in SP service provision for HNC patients internationally 
(Krisciunas, Sokoloff, Stepas, & Langmore, 2012; Roe et al., 2012). A web-based survey of 
usual practice in the USA (Krisciunas et al., 2012) reported the nature of SP intervention for the 
majority of respondents was of a reactive rather than proactive nature (n = 759 respondents). The 
timing of first intervention was routine for all patients only in 13.3% of respondents prior to RT 
and 5% of respondents during RT. The study found 10.8% of respondents first intervened only if 
patients reported swallowing difficulties prior to RT and 19.1% during RT. Interestingly the 
largest proportion of respondents (28.6%) first intervened in the first 3 months post treatment 
only with patients who reported swallowing difficulties. Results indicated that speech 
pathologists with greater than 5 years experience working in HNC were more likely to intervene 
proactively and recommend dysphagia therapy to patients during treatment (Krisciunas et al., 
2012). In the United Kingdom, a similar study using a web-based survey found that 50% of SP 
teams (n=46) routinely saw patients pre-treatment with >85% conducting oromotor assessment; 
clinical swallowing examination; provision of information on potential treatment effects on 
swallowing and communication functioning; and prophylactic swallowing exercise programs. 
During treatment 25.6% of teams saw patients weekly, 2.6% fortnightly and 46.2% on request or 
as required (Roe et al., 2012).  
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In Australia it is common practice for cancer centres to have dedicated speech 
pathologists within their multidisciplinary HNC teams (Lawson, Langmore, Krisciunas, & 
Sokoloff, 2013; Lawson & Ward, 2014; Maclean, Ward, Findlay, & Rees, 2013), typically 
providing pre-treatment intervention, weekly reviews during treatment to all HNC patients, and 
ongoing follow up post-treatment as required in conjunction with dietetic services (Lawson et al., 
2013). The same intensity of SP care is generally provided to all HNC patients undergoing (C)RT 
regardless of differences in diagnosis or treatment plan. Early examination of this type of service 
delivery model reported a reduction in unplanned hospital admissions due to the proactive nature 
of management (Hughes et al., 2013; Riddle, Davidson, Elliott, Balsillie, & Porceddu, 2005). 
This is also the service delivery model used at the institution where this PhD research has been 
undertaken.  
A recent Australian study reviewed their institution’s weekly SP/dietetic service delivery 
model provided during treatment for HNC (Wall, Cartmill, Ward, Hill, Isenring, & Porceddu, 
2016). They found that 58% of all patients during the study reported swallowing or nutritional 
issues and 27% reported general distress, with 42% wanting to discuss these issues with a health 
professional. However, although many patients experienced difficulty, the issue of whether all 
patients needed weekly SP reviews was questioned. Specifically it was found that 24% of the 
weekly scheduled reviews were judged unnecessary by both clinician and patients, with a further 
18% of reviews proactively cancelled by clinicians (Wall, Cartmill, Ward, Hill, Isenring, & 
Porceddu, 2016). Furthermore, the sessions deemed unnecessary occurred at varying times 
during the radiation treatment period, with only 35% occurring in the later weeks. This data 
indicates that a weekly service model has the potential to introduce over-servicing, and as such, a 
one-size-fits-all approach may not be the most efficient model in centres with high-volume 
patient numbers.  
Although providing routine and ongoing SP support for patients undergoing non-surgical 
treatment is still considered a clinical priority, the current service models are resource intensive. 
In a time of rationalised health services in the face of a growing, younger HNC population with 
longer survivorship, more evidence is required to ensure the right patients are receiving the right 
intervention, at the right time (Department of Health, 2014). Triaging strategies are necessary to 
assist supportive services to balance demand with provision of optimal patient centred care.  
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One form of triaging that has been examined in the literature is the use of screening 
models to assist identification of patients with on-treatment symptoms that require services and 
support. A recent study has reported on the utility and validity of a patient reported computerised 
screening process (ScreenIT) to efficiently monitor swallowing, nutrition, and distress status 
during CRT (Wall, Cartmill, Ward, Hill, Isenring, Byrnes, et al., 2016). The study found 
ScreenIT was effectively able to triage prioritised referrals for swallowing, nutrition, and distress 
in real time based on the patient’s report. This type of model could help to facilitate clinically 
appropriate, prioritised referrals for supportive care, improving the potential to optimise the 
efficient use of SP resources for those patients most in need. 
Another model is to triage patients into routine services based on the known risk of pre-
treatment factors and associated treatment consequences. With this type of triaging, known 
predictive factors associated with dysphagia post radiotherapy can be used to prioritise patients 
at higher risk versus lower risk of developing more severe treatment effects. There has been a 
large and ongoing body of research examining what tumour and treatment related factors could 
help identify those patients at high risk. Current evidence supports multiple factors including 
tumour site, advanced T stage, treatment volume, concurrent chemotherapy, bilateral neck 
irradiation, altered fractionation, pre-treatment dysphagia, and weight loss as all possible - 
however, some inconsistencies in the study designs and findings still leave clinicians with no 
clear consensus (Caudell et al., 2009; Frowen et al., 2010; Langendijk et al., 2009; Logemann et 
al., 2006; Machtay et al., 2008; Patterson et al., 2014). However, across the studies conducted, 
tumour site is typically one of the highest predictors with all reporting tumours of the 
hypopharynx most at risk of long term dysphagia, followed by tumours of the larynx and 
oropharynx (Caudell et al., 2009; Frowen et al., 2010; Langendijk et al., 2009; Logemann et al., 
2006; Machtay et al., 2008). 
There is an acknowledged limitation in the current evidence for using tumour site as a 
triaging tool, in that most studies have focused on those groups at higher risk, and as such not all 
HNC tumour sites are considered in those studies. Reviewing the published studies, it is clear 
that research into predictors of swallowing outcomes rarely document factors for tumours outside 
the major sites. This is an important omission, as patients with tumours of the parotid, thyroid, 
salivary glands, and skin are often managed with the same SP service delivery model as other 
tumour sites in Australian centres (Wall, Cartmill, Ward, Hill, Isenring, & Porceddu, 2016). 
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Currently we have little information to determine whether this is the best method of support 
those patients. 
1.4.2 A Call for “Research Informed” Speech Pathology Service Delivery Guidelines 
Clinical pathways are recommended as a means of delivering consistent, safe, and 
evidence based multidisciplinary care (Lawal et al., 2016; Rotter et al., 2012). They are 
associated with positive patient outcomes, increased efficiency, and reduced healthcare costs and 
reduced hospital length of stay in the HNC population (Chen et al., 2000; Gendron et al., 2002; 
Gordon & Reiter, 2016; Kwon et al., 2018; Messing et al., 2019). However, at present there are 
no clear SP HNC service delivery prioritisation guidelines published that detail which patients 
most benefit from support and the optimal timing of services for specific patient groups. The 
Clinical Oncology Society of Australia has published guidelines for the nutritional management 
of HNC patients, recommending weekly dietetic reviews during RT and a minimum of 
fortnightly reviews for at least 6 weeks post-treatment (Findlay, Bauer, Brown, & Head and Neck 
Guideline Steering Committee, 2011; Isenring et al., 2013). There are no similar guidelines for 
SP services.  
Currently, HNC guidelines tend to contain general statements only, or utilise a one-size-
fits-all approach that does not account for the specific needs of different HNC patient groups and 
the peaks and troughs of treatment related toxicities. Specifically for SP, The National 
Comprehensive Cancer Network Guidelines (National Comprehensive Cancer Network, 2016) 
recommend speech pathologists provide baseline evaluation, regular review, and follow up until 
a stable baseline is reached for patients with or at risk of dysphagia. However, ‘regular’ is a 
generic term open to interpretation and there are no details clarifying when patients need 
intervention the most. Similarly, the National Institute for Health and Care Excellence (National 
Institute for Health and Care Excellence, 2016) give only general recommendations for SP 
involvement for swallowing and trismus. Likewise, locally in Australia, the 2015 ‘Optimal care 
pathway for people with head and neck cancers’ includes SP input as required for management of 
swallowing and communication disorders at all stages of the pathway, including at diagnosis, 
pre-treatment, during treatment, and post-treatment (Cancer Council Victoria and Department of 
Health and Human Services Victoria, 2015). Unlike the specific timeframes that are provided in 
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that document regarding medical investigations, intervention, and surveillance - no details on the 
timeframes or intensity of SP services are given.  
A contributing factor to the lack of detail in existing clinical guidelines regarding SP 
intervention, is that the evidence base to inform these documents doesn’t exist. Hence, although 
it is globally recommended that SP services are an important component of the HNC care 
pathway, specific studies examining service models that provide optimal SP services are yet to be 
conducted. A recent study examined the implementation of a multidisciplinary head and neck 
clinical pathway in a USA cancer centre. They found positive long-term swallowing outcomes 
were achieved for most patients following implementation of the new pathway, which included 
planned SP intervention at baseline, week 1, week 3/4 of treatment and 1, 3, 6, 12, and 24 
months post treatment (Messing et al., 2019). Although this model provided an improved, co-
ordinated pathway of care compared to the previous model of care in that service, it is unknown 
if this level of intensive support was critical for the outcomes achieved. Interestingly, the 
scheduled reviews in that pathway were not conducted in the last weeks of treatment or in the 
first month post-treatment when symptoms have been reported to peak (Cartmill, Cornwell, 
Ward, Davidson, & Porceddu, 2013; Maurer et al., 2011; Van Der Laan et al., 2015). In addition, 
the authors note that sustaining such a complex pathway requires extensive staff resources, 
financial investment and perseverance with communication (Messing et al., 2019).  
Given the limitations of the existing literature and guidelines, more information regarding 
toxicity profiles, particularly the temporal pattern of treatment symptoms/toxicity and recovery 
for a range of tumour sites, is needed to guide SP service planning to prevent both the under-use 
and potential over-use of clinical services. This will inform which patients will most benefit from 
SP services and the optimal frequency of intervention. As such this information is required to 
guide supportive care both during treatment and after treatment completion while patients 
recover from their acute toxicities and beyond. 
1.4.3 Summary 
As discussed in this section, speech pathologists are recognised as core members of the 
integrated HNC MTD providing supportive care to patients pre-treatment, during treatment and 
post-treatment. However, there are gaps in existing SP guidelines, with details regarding which 
HNC patients most benefit from SP support, when, and at what intensity, currently lacking. This 
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has led to wide variation in service delivery practice for speech pathologists world-wide, with 
most Australian HNC centres utilising a one-size-fits-all service delivery model which has been 
found to lead to possible over-servicing for some patients and may not be the most efficient use 
of resources. Whilst investigation into predictive factors for dysphagia is ongoing, there is 
currently no clear consensus on which are the most critical, with a large number of potential 
factors identified. Further research is needed to help guide new methods of triaging patients into 
services in order to ensure appropriate levels of support are available and improve service 
efficiency. Evidence based SP HNC guidelines with information detailing which HNC patients 
require supportive care, when during their treatment journey, and at what intensity would provide 
a basis for services to build effective and efficient healthcare models to optimise patient centred 
care. 
1.5 Summary of Issues to be Addressed in This Thesis 
Head and neck cancer is a complex condition due to its location and proximity to key 
structures of swallowing and respiration. Non-surgical treatment of HNC, whilst called “organ 
sparing”, is acknowledged to be associated with significant acute treatment related toxicity, 
including dysphagia, with some toxicities persisting as “late effects”. With the changing 
epidemiology of HNC due to the effects of the HPV, research is examining treatment de-
escalation and detoxification strategies with the aim of improving patient QOL whilst 
maintaining cure rates. Conformal RT techniques such as H-IMRT is one such strategy. 
However, greater evidence is needed regarding dysphagia and related toxicity outcomes for HNC 
patients following H-IMRT to inform whether such new treatment approaches deliver improved 
functional benefits. Currently evidence is largely based on retrospective studies, with 
inconsistent and limited reporting of dysphagia and toxicity outcomes, frequently reported as a 
maximum grade 3 incidence only. Further understanding of the severity, peak incidence, and the 
pattern of early recovery of a range of acute toxicities, including dysphagia, is needed to help 
inform clinical services and enhance patient education regarding anticipated treatment effects. 
Evidence regarding dysphagia and related toxicity outcomes for patients with tumour sites 
outside the oral cavity, oropharynx, hypopharynx, larynx and nasopharynx is also required to 
determine the specific supportive care needs of the wide variety of patients with HNC. Such 
evidence can be used to inform SP services to develop models of care that better meet the needs 
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of specific patient groups and reduce the volume of over and under-servicing observed in current 
services.  
1.6 Aims of Thesis 
The overall objective of this thesis is to evaluate the extent and severity of swallowing 
dysfunction and swallowing related radiation induced toxicities of patients undergoing non-
surgical treatment for HNC, in particular H-IMRT, to guide streamlined SP patient support 
services.  
The specific aims of this project include:  
1. Describe severity, peak incidence, and the pattern of early recovery of a range of 
acute toxicities, including dysphagia, in a prospective cohort of HNC patients 
undergoing either H-IMRT only or H-IMRT with concurrent chemotherapy (CH-
IMRT). This aim is addressed in Chapter 2. 
Hypothesis: Patients will continue to experience treatment related toxicity and 
dysphagia that require SP support. Patients receiving concurrent chemotherapy will 
experience greater toxicity. 
2. Prospectively evaluate the extent, severity and pattern of presentation, peak incidence 
and early recovery of dysphagia and a range of acute toxicities in a prospective cohort 
of OPSCC patients undergoing H-IMRT with concurrent chemotherapy. This 
information will help inform patient education regarding treatment and its effects, and 
guide clinical support services. This aim is addressed in Chapter 3. 
Hypothesis: This subgroup of patients will experience high levels of treatment related 
toxicity and dysphagia that requires SP support. 
3. Describe the nature, severity and pattern of treatment related toxicities, including 
dysphagia in patients with parotid gland cancer and cutaneous HNC during and in the 
acute stage post RT. This aim is addressed in Chapter 4. 
Hypothesis: These subgroups of HNC patients would experience low levels of 
treatment related toxicity and dysphagia, presenting the potential for alternative SP 
service delivery models to be developed for these low risk groups, compared to those 
at high risk of treatment related impacts. 
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4. Evaluate a new clinical pathway, incorporating dysphagia screening via an 
interdisciplinary service model, to help ensure patients with HNC who are at low risk 
of dysphagia during RT, receive appropriate levels of SP support. The Royal Brisbane 
and Women’s Hospital Head and Neck Cancer Low Risk Speech Pathology Pathway 
(The Pathway) was developed as an alternative service delivery model for patients 
with HNC subtypes identified by our prior research (Moroney, Helios, Ward, 
Crombie, Burns, et al., 2018 = Chapter 4) to be at low risk of developing dysphagia. 
Secondary aims were to determine SP service efficiencies and cost benefits as well as 
patient and clinician perceptions of need for SP review when managed within The 
Pathway. This aim is addressed in Chapter 5. 
Hypothesis: The Pathway will be a safe and effective method of managing this 
subgroup of patients with cost benefits for the health service. 
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1.7 Thesis Outline 
This thesis comprises of six chapters with an introductory chapter (Chapter 1), four 
separate research studies (Chapter 2, 3, 4, and 5) and a final conclusion chapter (Chapter 6). 
Figure 1.2 illustrates the series of studies and their corresponding chapters.  
Chapter 1 has been provided to introduce the reader to HNC, its management and 
associated side effects, the role of SP in supportive care and SP service delivery for HNC 
patients. The current literature has been examined and critiqued, highlighting gaps in the existing 
literature and identifying areas requiring further research. Chapters 2-5 detail four studies, each 
addressing these areas and the previously detailed thesis aims. Prior to each of these studies 
(Chapter 2-5) a short description is provided to link each study and integrate the studies with the 
overall thesis objective of evaluating the extent and severity of dysphagia and related radiation 
induced toxicities of patients undergoing non-surgical treatment for HNC, in particular H-IMRT, 
to guide streamlined SP patient support services. Data for Chapters 2-4 was derived from a large 
prospective cohort study and the data for Chapter 5 comprised a separate prospective study. 
Chapter 6 will conclude the thesis by summarising the key findings of each of the chapters and 
drawing together conclusions in relation to the research aims. Additionally, Chapter 6 will 
broadly discuss the clinical implications, research limitations, and potential directions for future 
research. 
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Figure 1.2 Overview of individual investigations in respect to thesis chapters 
 
  
Study 1
Analysis of HNC 
patient with mixed 
tumour sites 
Chapter 2:
Patterns of dysphagia and toxicities in 
patients with head and neck cancer 
undergoing helical IMRT +/-
concurrent chemotherapy
Study 2
Subsite analysis of 
patients with 
oropharyngeal SCC
Chapter 3:
Helical IMRT with concurrent 
chemotherapy for oropharyngeal 
SCC: A prospective investigation of 
acute swallowing and toxicitiy 
patterns
Study 3
Subsite analysis of 
patients with parotid 
tumours and 
cutaneous HNC
Chapter 4: 
Radiotherapy for cutaneous HNC and 
parotid tumours: A prospective 
investigation of a treatment related 
acute swallowing and toxicity 
patterns 
Study 4
Prospective evaluation 
and validation of a 
new service delivery 
model
Chapter 5:
Evaluation of a speech pathology 
service delivery model for patients 
at low dysphagia risk during 
radiotherapy for HNC 
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1.8 Ethical Approval 
Prior to the commencement of all of the research studies contained in this thesis – with 
the exception of Study 4 (Chapter 5), ethical approval was granted by the Human Research 
Ethics Committee of the Royal Brisbane and Women’s Hospital (Appendix A-B) and the Medical 
Research Ethics Committee at the University of Queensland (Appendix C-D). A waiver of 
individual patient consent was approved in accordance with National Statement 2.3.6 as data 
collected was routine clinical information, collected during usual care SP appointments. Study 4 
(Chapter 5) was granted exemption from ethical review as it was an audit and was found to be 
compliant with the National Health and Medical Research Council guidance “Ethical 
Considerations in Quality Assurance and Evaluation Activities” 2014 by the Chair of the Royal 
Brisbane and Women’s Hospital Human Research Ethics Committee. 
 
1.9 Formatting and Terminology Used Within Thesis 
Following the ‘thesis by partial publication’ format, all published or submitted 
manuscripts have been included in this thesis as published/submitted, with the exception of all 
referencing which has been changed to be consistent with American Psychological Association 
(6th ed.) standards. In addition, all references cited in each of the six thesis chapters have been 
combined and presented in a single reference list (pp 162 - 192) at the end of the thesis. Prior to 
each of the following chapters, a short section has been included to outline the authorship 
contributions (UQ Thesis requirement) followed by a brief explanation to link and introduce each 
chapter across the thesis. As four of the manuscripts in this thesis were published during the PhD 
candidature, reference is made to these publications where relevant in other chapters with the 
following notation to direct the reader to the associated chapter e.g. Moroney et al., 2017 = 
Chapter 2.   
 51 
CHAPTER 2: Patterns of dysphagia and toxicities in 
patients with head and neck cancer undergoing helical 
IMRT +/- concurrent chemotherapy  
Moroney, L. B., Helios, J., Ward, E. C., Crombie, J., Wockner, L., Burns, C. L., Spurgin A., 
Blake, C., Kenny L., & Hughes B. G. M. (2017). Patterns of dysphagia and acute toxicities in 
patients with head and neck cancer undergoing helical IMRT +/- concurrent chemotherapy. Oral 
Oncology, 64, 1-8. doi: 10.1016/j.oraloncology.2016.11.009 
Contributor Statement of contribution 
Laura Moroney (Candidate) Study design (60%) 
Recruitment & Data collection (50%) 
Analysed results (60%) 
Wrote the paper (90%) 
Jennifer Helios Study design (25%) 
Recruitment & Data collection (50%) 
Edited the paper (10%) 
Professor Elizabeth Ward  Study design (15%) 
Analysed results (20%) 
Edited the paper (20%) 
Jane Crombie Analysed results (5%) 
Edited the paper (15%) 
Leesa Wockner (statistician) Analysed results (30%) 
Wrote the paper (statistical analysis) (10%) 
Edited the paper (5%) 
Dr Clare Burns Study design (5%) 
Analysed results (5%) 
Edited the paper (10%) 
Ann-Louise Spurgin Edited the paper (5%) 
Claire Blake Study design (5%) 
Edited the paper (5%) 
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Dr Lizbeth Kenny Edited the paper (5%) 
Dr Brett Hughes Edited the paper (5%) 
Chapter 1 provided an introduction to HNC, its diagnosis, treatment, and sequelae 
associated with the different treatment modalities, in particular those associated with non-
surgical management. Advances in radiation therapy techniques were detailed including 
associated treatment related toxicities and what benefits have been gained for the patient. The 
role of SP in HNC management was introduced with particular focus on guidelines for 
management and service delivery models.  
Although studies have reported a reduction in treatment related toxicity and dysphagia 
with advanced radiation techniques, as highlighted in Chapter 1 there is a paucity of published 
prospective studies detailing the wide range of acute toxicity including dysphagia experienced by 
patients with HNC receiving H-IMRT. Furthermore, few studies detail the temporal pattern of 
symptom presentation, peak, and recovery. It is important to thoroughly assess and report a more 
comprehensive range of treatment related acute toxicity including dysphagia. Such information is 
required to help make fully informed decisions regarding the potential improvements advanced 
radiation techniques have made for patients with HNC - and if there are any subsequent 
implications for SP supportive care for this population.  
To achieve this overall objective, Chapter 2 describes the severity and temporal pattern of 
a range of treatment related toxicities including dysphagia in a cohort of heterogeneous patients 
with HNC from all tumour sites undergoing H-IMRT with and without concurrent chemotherapy. 
The outcomes of this study provide critical clinical information to help understand any realised 
benefits of this advanced radiation technique and the subsequent implications for the timing 
and/or intensity of SP supportive care during the acute phase of treatment. 
The following manuscript, entitled “Dysphagia and related toxicity outcomes in head and 
neck cancer patients undergoing Helical Intensity Modulated Radiation Therapy (H-IMRT) +/- 
chemotherapy” was published in the journal Oral Oncology in 2017 and is inserted as Chapter 2 
of this thesis as published, with the exception of formatting changes that have been made to align 
with style guidelines (6th edition) as set out by the American Psychological Association for 
consistency throughout the thesis. For references to the manuscripts published by the PhD 
candidate during the candidature, these have been clarified by the following notation (e.g. 
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Moroney et al., 2017 = Chapter 2). Additionally, all abbreviations defined previously in the thesis 
are listed on page xxv and not re-defined in this chapter. All references are listed in a single 
reference list on pages 162 -192 at the end of the thesis.  
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Patterns of dysphagia and acute toxicities in patients with head and neck cancer 
undergoing helical IMRT +/- concurrent chemotherapy. 
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2.1 Abstract 
There is limited prospective data reporting the extent of treatment related toxicities associated 
with H-IMRT for HNC. The study aim was to investigate severity, peak incidence and recovery 
patterns of dysphagia and related toxicities in patients undergoing H-IMRT +/- chemotherapy to 
examine when patients are experiencing symptoms requiring supportive clinical care. 
Prospective study of 212 patients undergoing H-IMRT. Dysphagia and associated acute toxicities 
were monitored weekly during treatment and at weeks, 2, 4 and 12 post treatment using the 
CTCAE v4, Functional Oral Intake Score and National Dysphagia Diet Descriptors. 75% 
experienced Grade 2-3 dysphagia. Over 70% had grade 2-3 dysguesia, xerostomia, and thick 
saliva, and >50% experienced grade 2-3 pharyngeal mucositis, oral mucositis, and nausea. 13% 
patients declined to NBM requiring complete enteral nutrition, 25% required enteral nutrition but 
maintained some form of oral intake. Symptoms peaked in final week of treatment, consistently 
improving thereafter, with the majority better than baseline by 12 weeks post-treatment. 
Concurrent chemotherapy at least doubles the odds of experiencing most symptoms excepting 
xerostomia, taste and fluid level. Despite advancements in radiation techniques, results confirm a 
high proportion of HNC patients experience dysphagia and related toxicities requiring supportive 
care during H-IMRT. Patients receiving H-IMRT alone experience a lower incidence of 
symptoms compared with those receiving concurrent chemotherapy. The data confirms the 
ongoing need for active on treatment monitoring with implications for the timing and intensity of 
patient support services.  
 
Keywords: swallowing, dysphagia, head and neck cancer, toxicity, helical tomotherapy, intensity 
modulated radiotherapy, chemoradiotherapy.   
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2.2 Introduction 
Radiotherapy with or without chemotherapy as definitive treatment for HNC aims to cure 
the malignancy but to also maintain organ preservation and ensure structural integrity is retained. 
However, it is well documented that multiple negative functional consequences are associated 
with the effects of treatment (Argiris, Karamouzis, Raben, & Ferris, 2008b; Logemann et al., 
2008; Manikantan et al., 2009; Patterson et al., 2014). Dysphagia following radiotherapy +/- 
chemotherapy is common, up to two-thirds of HNC patients experience some degree of 
swallowing difficulty following CRT (Cartmill, Cornwell, Ward, Davidson, Nund, et al., 2013; 
Russi et al., 2012) with reports of penetration ranging from 7 - 95.9% and aspiration from 0 – 
100% (Wall, Ward, Cartmill, & Hill, 2013). Largely due to the proximity of key swallowing 
structures to the radiation treatment field (Eisbruch et al., 2004; Logemann et al., 2008; 
Manikantan et al., 2009; Roe et al., 2010). The nature and severity of dysphagia is also 
influenced by both tumour presence and multiple toxicities associated with treatment including 
mucositis, pain, xerostomia, thick saliva, dysguesia, nausea, fatigue, altered sensation and 
fibrotic tissue changes within the head and neck region (Cartmill, Cornwell, Ward, Davidson, 
Nund, et al., 2013; Chera et al., 2014; Hj Wu, 2009; Logemann et al., 2008). These symptoms are 
further intensified with the addition of chemotherapy (Russi et al., 2012).   
Emerging studies support that the nature and severity of dysphagia experienced during 
non-surgical treatment is influenced by the dose, field and mode of radiation delivery (Frowen et 
al., 2010; Roe et al., 2016; Roe et al., 2010). In the past decade, the introduction of new 
conformal methods of radiotherapy delivery have highlighted the potential for increased 
protection of key anatomy involved in swallowing, often referred to as the DARS (Eisbruch et 
al., 2004). Studies have demonstrated the use of IMRT to reduce the volume of the DARS 
receiving >50Gy without compromising target dose (Eisbruch et al., 2004). It has also been 
demonstrated that the use of IMRT aimed at sparing specific swallowing structures may achieve 
positive gains in dysphagia outcomes (Eisbruch et al., 2011; Eisbruch et al., 2007; Paleri et al., 
2014). Recent evolution of static beam IMRT has led to the introduction of rotational IMRT 
techniques such as volumetric rotational IMRT and H-IMRT (Van Gestel, Verellen, et al., 2013). 
Helical IMRT is delivered by a dedicated H-IMRT linear accelerator, combining H-IMRT and 
image guided radiation therapy. Proponents of this approach describe the potential to achieve 
greater homogeneity of dose and control of dose distributions using steep dose gradients to 
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minimise volumes received by healthy tissue without compromising target coverage (Fiorino et 
al., 2006; Gielda et al., 2010; Murthy et al., 2010; Van Gestel, Van Vliet-Vroegindeweij, et al., 
2013). Studies have now demonstrated superior parotid sparing with reduced xerostomia 
incidence with the use of H-IMRT compared to linac based IMRT (Fortin et al., 2014; Kimura et 
al., 2016).  
Whilst the potential benefits of H-IMRT have been discussed in both retrospective and 
theoretical planning studies, there are currently a limited number of prospective studies that 
quantify a change in patient outcomes and toxicity rates, particularly dysphagia. The studies that 
have been conducted, have focused on only one or two key outcomes (e.g. mucositis), and have 
not provided a comprehensive report of the extent and severity of dysphagia and critical 
dysphagia-related treatment toxicities. Furthermore, toxicity data is typically reported using only 
“maximum incidence” figures (e.g. 30% reached grade 3 toxicity). Whilst this informs our 
understanding of the overall treatment impact, it fails to elucidate the first presentation, symptom 
peak and recovery patterns. Such detailed information on the pattern of presentation during 
treatment is necessary to inform when and to what extent patients require supportive services, 
such as SP, for management of the dysphagia and related toxicities (Donato et al., 2013; Kruser 
et al., 2013; Shueng et al., 2010).  
Evidence is needed regarding outcomes for patients following H-IMRT to ultimately 
support whether such new treatment approaches are resulting in improved functional benefit for 
patients. This information is needed to help inform clinical services and enhance patient 
education regarding anticipated treatment effects. Hence, the aim of this study was to describe 
severity, peak incidence and the pattern of early recovery of a range of acute toxicities, including 
dysphagia, in a prospective cohort of HNC patients undergoing either H-IMRT only or H-IMRT 
with concurrent chemotherapy (CH-IMRT). 
2.3 Materials and Methods 
2.3.1 Participants 
Patients who commenced wither H-IMRT or CH-IMRT between September 2013 and 
November 2014 were prospectively recruited through the Combined Head and Neck Clinic 
(CHNC) at a large tertiary referral hospital. Patients were excluded if they were: managed by 
surgical methods only; receiving a radiation technique other than helical IMRT; or were 
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scheduled for less than 60Gy of radiation (including palliative management). Consensus 
decisions regarding which patients undertook helical IMRT as opposed to 3D conformal 
radiation treatment methods were made at the institution’s Tomotherapy Triage Meeting. Only 
complex patients were accepted for H-IMRT, usually requiring bilateral cervical lymph node and 
complex primary cancer radiotherapy. All patients who attend CHNC and proceed to radiation 
treatment are seen by the joint SP/dietetic service. The decision to place a prophylactic PEG is 
made as per published guidelines of the institution (Brown et al., 2013; Hughes et al., 2013) 
though management may be altered on the decision of the treating medical officer. Ethical 
clearance was obtained through the local Human Research Ethics Committee (approval number: 
HREC/13/QRBW/444). 
2.3.2 Treatment Planning and Delivery 
 Helical IMRT (often referred to as helical tomotherapy) was delivered by TomoTherapy 
(TomoTherapy Inc., Madison, WI, USA). All patients were immobilised with thermoplastic shell 
and custom neck and head rest, and treated by simultaneous integrated boost technique. IMRT 
inverse planning was generated using the Hi-Art Planning Station (TomoTherapy Inc.). Patients 
received H-IMRT in standard 2Gy per fraction to the high dose volume dosing 5 days per week. 
Patients receiving definitive radiotherapy received a total dose of 70Gy over 7 weeks to gross 
disease whereas patients receiving post-operative adjuvant radiotherapy received 60-66Gy over 6 
to 6 ½ weeks. Dose constraints guidelines for the following organs at risk (OARs) were routinely 
contoured where possible: median dose 1) parotids <26 Gy, 2) constrictors <50Gy, 3) oral cavity, 
larynx, oesophagus, trachea <25Gy 4) spinal cord maximum point dose 40Gy. 
The concurrent chemotherapy regime delivered with H-IMRT, comprised of either high 
dose cisplatin 100mg/m2 intravenous (IV) q3weekly (weeks 1, 4 and 7), weekly cisplatin 
40mg/m2 IV, or cetuximab 400mg/m2 IV loading dose 1 week prior to radiotherapy followed by 
weekly 250mg/m2 for the duration of radiotherapy.  
2.3.3 Procedure 
Toxicity data relating to dysphagia and treatment induced side effects was prospectively 
collected for both the H-IMRT and CH-IMRT cohorts through routine SP and dietetic joint 
clinics, at set time intervals including: (a) baseline assessment (week 1 or 2 of treatment); (b) 
weekly over weeks 3 – 6/7 during treatment; (c) then at 2, 4, and 12 weeks post treatment. All 
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data was collected on standard forms during routine clinical examinations and entered into a 
secure database by the chief researchers. 
Severity of acute toxicities resulting from treatment were rated using the CTCAE version 
4.0 including: symptoms of dysphagia, oral mucositis, pharyngeal mucositis, dysgeusia, 
xerostomia, salivary duct inflammation (thick saliva) and nausea. CTCAE v4 was chosen as it 
uses functional descriptors for grading symptoms and all treating clinicians had 5+ years of 
experience in HNC. The national dysphagia diet descriptors (Dietitians Association of Australia 
& Speech Pathology Association of Australia, 2007) for fluids (unmodified/regular, mildly thick, 
moderately thick, extremely thick) and foods (unmodified/regular, soft, minced and moist, puree) 
were used to record the nature of patients’ oral intake with the addition of two categories of 
liquids only and NBM. In addition, an overall functional diet rating was collected using the FOIS 
a 1-7 scale where 1 represents complete enteral nutrition and 7 normal intake (Crary et al., 2005). 
For any patients who received a prophylactic PEG, their FOIS reflected enteral nutrition once 
enteral feeding had commenced based on nutritional need. 
2.3.4 Statistical Methods 
Differences in baseline characteristics between the H-IMRT and the CH-IMRT groups 
were assessed via Pearson’s Chi-squared or Fisher’s Exact test for categorical variables and t-test 
for continuous variables. Dysphagia at baseline was defined as a FOIS score less than or equal to 
5 at week 1 of treatment or if unavailable, on initial assessment at CHNC. Initial descriptive 
analysis involved calculating the maximal incidence data (i.e. proportion of patients achieving a 
maximum of a Grade 1, 2 or 3 toxicity across all timepoints) for the CTCAE toxicities monitored 
in the study. As the study objective was to provide information on symptom presentation 
requiring management, and the temporal patterns of symptom peak and recovery, toxicities were 
re-grouped into “need for supportive care” or “no need for supportive care” at each timepoint. 
“Need for supportive care” was defined as a CTCAE toxicity grade ≥2, FOIS ≤5 and diet/fluid 
descriptor other than soft or regular. Generalised estimating equations (GEE) were then used to 
model the incidence of a symptom needing supportive care over time utilising an exchangeable 
correlation structure. An interaction term with time was used to assess whether temporal patterns 
differed between those that received additional chemotherapy and those that did not. Radiation 
dose was adjusted for in all models (<65GY vs ³65GY) and baseline dysphagia in dysphagia, 
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FOIS, food and fluid models. Sensitivity analysis (assessing assumption of data missing 
completely at random) was conducted using a linear mixed effects (LME) model fitted to the 
data. This indicated no major differences suggesting the assumption of data missing at random 
was correct. GEEs were fitted using the R statistical package (version 3.1.3) and all other 
analysis was performed in SPSS version 22. All analysis was completed by the study statistician 
(L.W.) and significance was set at p < 0.05 for all analyses. 
2.4 Results 
2.4.1 Participants 
Of the 734 patients who presented to CHNC in the 14 month period, a total of 212 
patients met inclusion/exclusion criteria. Of these, 90 received H-IMRT alone and 122 received 
CH-IMRT (Table 2.1). Comparisons between the demographics of the two groups revealed the 
CH-IMRT group had lower mean age, a higher proportion of males, and a higher prevalence of 
dysphagia at baseline with more receiving a prophylactic PEG according to the institution’s 
guidelines (Brown et al., 2013). The CH-IMRT group also had a greater proportion of larger 
volume tumours, predominantly of the oropharynx with nodal disease and positive P16 status. 
CH-IMRT patients were more likely to be undergoing definitive treatment and H-IMRT patients 
were more likely to be undergoing adjuvant treatment. 
Of the total participants, 12% H-IMRT and 4% CH-IMRT patients had missing baseline 
dysphagia assessments. Only 15% H-IMRT and 16% CH-IMRT patients were not observed in 
their final week of treatment. There was a degree of missing data in the post-treatment 
assessment, largely due to regional patients returning to local services. Missing data was roughly 
equally distributed in the H-IMRT and CH-IMRT groups. Numbers available for analysis at each 
timepoint are reported in all data tables. 
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Table 2.1 
Patient Demographics 
Parameters 
No. of patients (%)  
H-IMRT 
(n = 90) 
CH-IMRT 
(n = 122) 
p value 
Mean age, y (SD) 66 (13.8) 60 (9.3) <0.01 
Gender    
Female 30 (33) 18 (15)  
Male 60 (67) 104 (85) <0.01 
Primary site    
Oral cavity 25 (28) 13 (11) <0.01 
Oropharynx 8 (9) 77 (63)  
Hypopharynx 3 (3) 7 (6)  
Larynx 8 (9) 6 (5)  
Nasopharynx 2 (2) 7 (6)  
Unknown primary 3 (3) 8 (7)  
Othera 41 (46) 4 (3)  
T Classification    
T0 29 (32) 16 (13) <0.01 
T1 11 (12) 14 (12)  
T2 19 (21) 35 (29)  
T3 7 (8) 22 (18)  
T4 22 (24) 35 (29)  
is 2 (2) 0 (0)  
N Classification    
N0 53 (59) 18 (15) <0.01 
N1 12 (13) 7 (6)  
N2 24 (27) 94 (77)  
N3 1 (1) 3 (3)  
M Classification    
M0 90 (100) 120 (98) 0.51 
M1 0 (0) 2 (2)  
Pathology    
SCC 63 (70) 121 (99) <0.01 
Other 27 (30) 1 (1)  
P16 +ve 5 (6) 71 (58) <0.01 
Treatment    
Adjuvant 71 (79) 17 (14) <0.01 
Definitive 19 (21) 105 (86)  
Scheduled dose    
65Gy > & ³ 60Gy 57 (63) 15 (12) <0.01 
> 65Gy 33 (37) 107 (88)  
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Baseline Dysphagia 15 (18) 44 (37) <0.01 
Nutrition Riskb    
High Risk 9 (10) 102 (84) <0.01 
Prophylactic PEG 6 (7) 68 (56) <0.01 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical 
Intensity Modulated Radiation Therapy; SCC, Squamous Cell Carcinoma; PEG, Percutaneous 
Endoscopic Gastrostomy. 
a Includes parotid, salivary, thyroid, skin, nasal cavity 
b As per Royal Brisbane & Women’s Hospital: Swallowing and Nutrition Management Guidelines for 
Patients with Head and Neck Cancer (Brown et al., 2013; Hughes et al., 2013) 
 
 
2.4.2 Maximal Incidence of Dysphagia and Related Toxicities 
Maximum incidence data revealed grade 3 dysphagia (41%), oral mucositis (21%), 
pharyngeal mucositis (19%), thick saliva (27%), and nausea (14%). A maximum of grade 2 
severity was noted for xerostomia (72%) and dysguesia (86%). No patient experienced greater 
than grade 3 toxicity. Detailed information regarding the maximum incidence of all seven 
CTCAE outcomes for each group is summarised in Table 2.2. Notably, a higher incidence of 
grade 2 toxicity was reported for all outcomes in both groups, excepting dysphagia in the CH-
IMRT group. The addition of systemic treatment increased toxicity across all CTCAE symptoms 
with a greater maximum incidence of toxicities in the CH-IMRT group (p<0.01; Table 2.2). With 
regard to maximal severity reached on FOIS, 13% of patients’ oral intake declined to a FOIS of 1 
(complete enteral nutrition), 16% FOIS 2, 9% FOIS 3, 19% FOIS 4, 20% FOIS 5, and 13% FOIS 
6.  Ten percent did not require any modified intake (FOIS 7). Exploration of fluid and food levels 
found 10% of patients required modified fluids (predominantly mildly thick fluids), and the 
nature of the food levels were 13% NBM, 33% liquids only, 17% puree, 10% minced, 15% soft, 
and 12% regular/unmodified.  
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Table 2.2 
Maximal Incidence for the 7 CTCAE Acute Toxicities 
Toxicity 
H-IMRT (n=90) CH-IMRT (n=122) All (n=212)  
Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3 p-value 
Xerostomia 32% (29) 60% (54) N/A 16% (20) 81% (99) N/A 23% (49) 72% (153) N/A 0.003 
Dysguesia 13% (12) 76% (68) N/A 3% (3) 94% (115) N/A 7% (15) 86% (183) N/A <0.001 
Oral 
Mucositis 19% (17) 29% (26) 13% (12) 13% (16) 41% (50) 26% (32) 16% (33) 36% (76) 21% (44) <0.001 
Pharyngeal 
Mucositis 
13% (12) 29% (26) 7% (6) 11% (13) 46% (56) 29% (32) 12% (25) 39% (82) 19% (41) <0.001 
Thick Saliva 28% (25) 38% (34) 13% (12) 13% (16) 48% (58) 37% (45) 19% (41) 43% (92) 27% (57) <0.001 
Dysphagia 17% (15) 40% (36) 21% (19) 8% (10) 29% (35) 56% (68) 12% (25) 34% (71) 41% (81) <0.001 
Nausea 17% (15) 22% (20 1% (1) 16% (19) 31% (38) 23% (28) 16% (34) 27% (58) 14% (29) <0.001 
Note:  CTCAE: Common Toxicity Criteria for Adverse Events version 4; H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, 
Chemotherapy with Helical Intensity Modulated Radiation Therapy. Bold indicates > 50% of cohort experiencing toxicity  
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2.4.3 Toxicities Requiring Supportive Care Over Time 
Proportion of patients with toxicities requiring supportive intervention across time are 
reported in Figures 2.1 and 2.2. GEE analysis indicated that the temporal patterns of clinically 
important symptoms did not differ between the two groups. Both groups demonstrated symptom 
peaks (except for fluid level) in the final week of treatment. Symptoms consistently and 
significantly (p<0.05) improved after the final week of treatment (for all outcomes, estimated 
odds ratios and p-values can be seen in supplementary material, Appendix G). For the majority 
of outcomes, the incidence of symptoms requiring supportive care had returned to baseline levels 
at 12 weeks post treatment. Up to a third of patients continued to experience xerostomia, 
dysguesia and dysphagia (as per FOIS score and Food Level) which needed management at 12 
weeks post treatment. Detailed patterns of specific FOIS and Food levels across time are 
presented in Figure 2.3. In the H-IMRT group approximately 10% required supplementary 
enteral nutrition as opposed to half of the CH-IMRT group. However, the majority placed on 
enteral nutrition still continued some oral intake with only 7% of H-IMRT and 17% CH-IMRT 
deteriorating to NBM, though almost half of the CH-IMRT group were eventually limited to a 
liquid only diet. 
 
  
 65 
 
Figure 2.1 Pattern of CTCAE toxicities needing supportive care across timepoints. Symptoms 
needing supportive care defined as CTCAE Grade ≥2. 
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Figure 2.2 Pattern of dysphagia related outcomes needing supportive care across timepoints. 
Symptoms needing supportive care defined as: FOIS ≤5, CTCAE Dysphagia Grade ≥2, Diet 
other than soft or regular 
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Figure 2.3 Pattern of FOIS and Food Levels across timepoints.  
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Comparison of the H-IMRT and CH-IMRT groups indicated that once radiation dose was 
adjusted for, the odds of having a symptom requiring supportive care were greater in the CH-
IMRT group for oral mucositis, pharyngeal mucositis, thick saliva, nausea, dysphagia, food type 
and FOIS (Table 2.3). Additional chemotherapy did not have a significant effect on the odds for 
dry mouth and taste, although the taste symptom approached significance (p=0.06). Adjusting for 
baseline dysphagia indicated that concurrent chemotherapy still increased the odds of needing 
supportive care except in the case of fluids level. The only predictor of the need for supportive 
care for managing fluids level was the presence of baseline dysphagia (odds ratio 8.13; p<0.001).  
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Table 2.3 
Estimated Odds Ratios for the Effect of Chemotherapy and Radiation Dose Greater than 65Gy. 
 Treatment Group Radiation Dose 
Symptom H-IMRT CH-IMRT p-value <65Gy >65Gy p-value 
Xerostomia 1 1.41 0.149 1 3.39 <0.001 
Dysguesia 1 1.61 0.062 1 3.84 <0.001 
Oral Mucositis 1 2.63 0.001 1 0.64 0.136 
Pharyngeal 
Mucositis 1 2.97 <0.001 1 3.18 <0.001 
Thick Saliva 1 3.36 <0.001 1 1.89 0.026 
Nausea 1 2.49 0.006 1 2.33 0.017 
Dysphagia 1 2.54 0.001 1 1.40 0.248 
Food 1 2.28 0.002 1 1.54 0.133 
Fluids 1 0.99 0.989 1 1.79 0.394 
FOIS 1 3.27 <0.001 1 1.88 0.035 
Note: CTCAE: Common Toxicity Criteria for Adverse Events version 4; FOIS,  
Functional Oral Intake Score; H-IMRT, Helical Intensity Modulated Radiation Therapy;  
CH-IMRT, Chemotherapy with Helical Intensity Modulated Radiation Therapy 
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2.5 Discussion 
The findings of the current study revealed that patients undergoing H-IMRT for treatment 
of HNC continue to experience a range of clinically important toxicities and dysphagia 
symptoms in the acute phase, with symptoms typically peaking in the final week of treatment, 
consistently improving thereafter. Concurrent chemotherapy at least doubles the odds of 
experiencing most symptoms when increased radiation treatment dose and baseline dysphagia 
are adjusted for.  
Direct comparison of our results with previously reported H-IMRT data is problematic 
and limited due to the heterogeneous patient populations, the variability in the assessment and 
scoring of acute toxicities, limited numbers of toxicities studied, cohorts combining patients with 
and without concurrent chemotherapy and the manner in which results are presented (Goepfert, 
Yom, Ryan, & Cheung, 2015). Currently, the incidence of grade 2 xerostomia in the available H-
IMRT literature ranges from 54-67% (Kong et al., 2013; Van Gestel et al., 2015), which is 
comparable to our rate of 72% for both groups. Dysphagia rates were also comparable to rates of 
grade 3 dysphagia reported as 45% (Van Gestel et al., 2015), and combined grade 2/3 at 80%. 
One exception to this pattern is the data reported by Donato et al (Donato et al., 2013) in 2013 
who found no incidence of grade 3 dysphagia (0%) though a higher rate of grade 2 (70%). This 
discrepancy may be due to the smaller sample size, the difference between medical officer and 
speech pathologist toxicity rating and a lower maximum radiation dose of 67.5Gy. With regards 
to oral mucositis, the reported incidence of grade 3 mucositis ranges widely from 0-76% (Chen 
et al., 2011; Donato et al., 2013; Kruser et al., 2013; Nguyen, Ceizyk, et al., 2013; Shueng et al., 
2010; Van Gestel et al., 2015), with the majority of reports greater than 50%, considerably higher 
than our finding of 21% for both groups. There are a smaller number of studies reporting results 
for grade 2 mucositis ranging from 30-90% (Donato et al., 2013; Kruser et al., 2013; Shueng et 
al., 2010), with the lower endpoint similar to our result of 36%. The lower rates of oral mucositis 
found in our study may be due to differences in patient groups (some cohorts were all treated 
with CRT), differences in rating scales (CTCAE ver 3 versus ver 4 or the RTOG criteria), and the 
distinction our study made between oral and pharyngeal mucositis with scoring for both these 
outcomes. 
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There is limited published data capturing rates of thick saliva. Thickened saliva 
associated with mucositis can affect taste, diet texture, and can result in nausea and dysphagia by 
inducing gagging from the saliva itself or difficulty swallowing foods. This study found 38% of 
H-IMRT and 48% of CH-IMRT patients were affected by grade 2 thick saliva with a further 13% 
of H-IMRT and 37% of CH-IMRT patients experiencing grade 3 thick saliva.  
Though CTCAE or RTOG dysphagia rates are sometimes reported in the H-IMRT 
literature, the criteria are broad. This study examined actual food and fluid textures maintained 
by patients in order to assist clinical intervention and service planning. The FOIS results for our 
cohorts combined reveal that 77% patients experienced a clinically important FOIS, indicating a 
need for clinical intervention. Almost 40% required supplemental PEG use, with 13% NBM 
requiring full PEG feeds, with the majority of these patients in the CH-IMRT group. In terms of 
actual diet textures maintained, of note 15-20% of patients in both groups were tolerating a puree 
diet and 33% of patients at some point reached a diet of liquids only. Patients on diets of this 
nature require significant clinical support to persevere with oral intake, maintain nutrition and are 
associated with care giver burden in food preparation (Nund et al., 2014a).  
The influence of concurrent chemotherapy on toxicity profiles is documented in the 
IMRT and 3DCRT literature (Maurer et al., 2011; Platteaux et al., 2010; Russi et al., 2012) with 
confirmation of increased rates of mucositis, dysphagia and PEG usage in studies of H-IMRT 
(Van Gestel et al., 2015). This data is supported by our current findings, with lower a lower 
incidence of toxicity found in patients receiving H-IMRT alone compared to at least a two-fold 
effect observed in the symptoms of mucositis, dysphagia and PEG use, pharyngeal mucositis, 
thick saliva, nausea, food type and FOIS score. 
Given the proposed potential of H-IMRT as a means to further reduce treatment 
associated toxicity, comparison with published traditional IMRT toxicity outcomes was sought. 
Again comparison is limited due to the heterogeneous patient cohorts of the published studies 
and differences in toxicity reporting. However, the pattern of toxicity profile in the current study 
appears comparable to the rates of grade 2 and 3 mucositis (~44% and 28%), dysphagia (~25% 
and 28%) and ≥ grade 2 xerostomia (~72%) reported by Toledano et al (Toledano et al., 2012) in 
the prospective GORTEC 2004-03 study. Reports of mucositis in studies with mixed tumour sites 
vary significantly with several studies reporting similar (15-32%) grade 3 rates to those in our 
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study (Lambrecht, Nevens, & Nuyts, 2013; Stromberger et al., 2014; Studer et al., 2006), 
compared with a much higher rate of 82% (Van Gestel, Van Den Weyngaert, Schrijvers, & 
Weyler, 2011), and much lower rates of 0-6% (Ghosh-Laskar et al., 2015; Gupta et al., 2012). 
However, these 2 studies had much higher rates of grade 2 mucositis and the difference in reports 
may reflect a difference in speech pathologist vs medical officer scoring. Grade 2 xerostomia 
rates were comparable (Ghosh-Laskar et al., 2015; Gupta et al., 2012), however, grade 3 
dysphagia reports also vary widely from 10-74% (Gupta et al., 2012; Lambrecht et al., 2013; 
Stromberger et al., 2014; Studer et al., 2006), with the 41% found in this study falling in the mid-
range. It is therefore difficult to draw firm conclusions regarding the toxicity profiles of HNC 
patients undergoing H-IMRT vs traditional IMRT with such varied results available for 
comparison.  
There is currently limited documentation of patterns of presentation and resolution of 
early toxicities for patients undergoing new radiation techniques in the literature.  Maurer et al 
(Maurer et al., 2011) in 2011 reported some details on patterns of dysphagia, mucositis and 
xerostomia presentation in their study of 35 HNC patients undergoing intensity modulated arc 
therapy +/- chemotherapy. They found the incidence of grade 2-3 xerostomia, dysphagia and 
mucositis (CTCAE v2) peaked from weeks 4 (xerostomia and dysphagia) and 5 (mucositis) of 
treatment with a significant decrease in mucositis and dysphagia symptoms by 6 weeks post 
treatment and a return to base level dysphagia after 6 months. In comparison, the present study 
found all clinically important symptoms (excepting modified fluids) peaked later, in the final 
week of treatment. There was consistent improvement thereafter and return to baseline levels at 4 
weeks post treatment for mucositis, taste, thick saliva, diet type and FOIS. Levels better than 
baseline were seen for all symptoms by 12 weeks post treatment, excepting xerostomia. This 
information can be used to inform the timing of clinical service planning to ensure provision of 
supportive care when it is needed most. Some evidence from the current data suggests it can be 
hypothesised that H-IMRT may offer a faster recovery or shorter duration of Grade 3 toxicity, but 
this requires further investigation to confirm. 
Further large cohort prospective studies documenting the range of treatment related 
toxicities is required to accurately determine the possible benefit of H-IMRT in reducing 
dysphagia and related toxicities compared with traditional IMRT. Further research is also needed 
to examine progression and outcomes beyond acute treatment effects. Finally, details of 
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dysphagia outcomes and how this may compare to other forms of radiotherapy would be best 
explored using instrumental measures, such as videofluoroscopy to more comprehensively 
evaluate any differences in treatment effects.  
2.6 Conclusion 
The findings of this study confirm that despite advancements in radiation techniques, 
HNC patients undergoing H-IMRT experience a range of treatment related toxicities including 
dysphagia that peak in the final week of treatment. However, patients receiving H-IMRT alone 
experience a lower incidence of symptoms requiring supportive intervention than patients 
receiving CH-IMRT, whose treatment effects are intensified. This data confirms the ongoing 
need for active on-treatment support for HNC patients, with implications for the timing and 
intensity of SP services to support this population during treatment. 
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CHAPTER 3: Helical intensity-modulated radiotherapy 
with concurrent chemotherapy for oropharyngeal squamous 
cell carcinoma: A prospective investigation of acute 
swallowing and toxicity patterns. 
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As outlined in Chapter 2, in a cohort of patients with HNC from mixed tumour sites 
undergoing H-IMRT, patients continue to experience a wide range of treatment related acute 
toxicity requiring SP supportive care. Toxicity was found to peak in the final week of treatment 
and improve thereafter. In comparison to the existing literature documenting outcomes for 
patients with HNC undergoing traditional IMRT, toxicity severity was comparable with some 
indication that patients undergoing H-IMRT may recover quicker or have a shorter duration of 
grade 3 toxicity. However, firm conclusions were difficult to state due to the varied results 
reported in the traditional IMRT literature. These results, together with prior research indicating 
patients with oropharyngeal tumours are at high risk of dysphagia and related toxicity during RT 
suggested they were a subgroup of patients for whom evidence of functional outcomes following 
H-IMRT would be beneficial (Caudell et al., 2009; Langendijk et al., 2009; Logemann et al., 
2006). Thus, Chapter 3 reports on a subsite analysis of patients with OPSCC undergoing H-
IMRT with concurrent chemotherapy. The objective of this study was to better understand the 
trajectory of treatment related side-effects and support needs of this high-risk patient group to 
inform patient centred care. 
The OPSCC population is known to be one of the most highly dependent on SP services 
within the Australian clinical setting. Most studies relating to patterns of treatment toxicity have 
studied heterogeneous groups such as the study reported in Chapter 2. However, with greater 
focus on patient centred care, there is increasing recognition that patients experience differential 
treatment effects according to not only the nature of treatment but also the subsite of HNC. 
Hence, now there is the need to provide more refined, subsite specific information on the 
predicted toxicities associated with specific tumour sites in order to better inform care. 
The following manuscript, entitled “Helical intensity-modulated radiotherapy with 
concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective 
investigation of acute swallowing and toxicity patterns” was published in the journal Head & 
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Neck in 2018. It is inserted here as Chapter 3 of this thesis as published, with the exception of 
the inclusion of Table 3.4 which was originally published under “supplementary materials”. The 
use of the acronym “H-IMRT” is used for helical IMRT throughout the chapter and formatting 
changes have been made to align with style guidelines (6th edition) as set out by the American 
Psychological Association for consistency throughout the thesis. For references to the 
manuscripts published by the PhD candidate during the candidature, these have been clarified by 
the following notation (e.g. Moroney et al., 2018 = Chapter 3). Additionally, all abbreviations 
defined previously in the thesis are listed on page xxv and not re-defined in this chapter. All 
references are listed in a single reference list on pages 162 – 192 at the end of the thesis.  
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3.1 Abstract 
Conformal radiotherapy modalities may minimize treatment toxicities. The purpose of this study 
was to document the extent and timing of dysphagia and related toxicities during H-IMRT with 
chemotherapy for OPSCC. We conducted a prospective study of 76 patients with OPSCC 
undergoing helical IMRT with chemotherapy. Dysphagia and acute toxicity data were collected 
weekly during treatment and at 2, 4, and 12 weeks posttreatment using the Functional Oral 
Intake Scale, diet descriptors, and Common Terminology Criteria for Adverse Events (CTCAE) 
version 4.0. Patients experienced maximum incidence of grade 3 dysphagia (61%), mucositis 
(30%), and thick saliva (38%), with grade 2 xerostomia (87%) and dysgeusia (97%). Only 14.5% 
were nil-by-mouth. Symptoms peaked in week 7 and improved thereafter. Grade 3 dysphagia 
was twice as common for T3 to T4 tumors compared with T2. Results confirm that patients with 
oropharyngeal SCC undergoing helical IMRT with chemotherapy continue to experience 
incidences of acute toxicities comparable with other conformal techniques, and need supportive 
cares.  
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3.2 Introduction 
The incidence of OPSCC has significantly increased in recent years due to the 
carcinogenic effects of the HPV. OPSCC is now the leading site of HPV related cancer (Pytynia 
et al., 2014). The increase in patient numbers, as well as the younger average age and improved 
prognosis associated with HPV mediated cancers has heightened the need for management 
solutions that not only ameliorate the cancer but also optimise outcomes for survivorship (Cleary 
& Cmelak, 2017). Currently, CRT is considered the standard of care for locally advanced 
OPSCC (Langendijk & Steenbakkers, 2017; Marur & Forastiere, 2016), offering 5 year survival 
rates of 74% for HPV positive disease(Huang et al., 2015) with the benefit of organ function 
preservation. However, symptom burden amongst patients with OPSCC undergoing CRT 
remains significant with a wide range of acute and late toxicities reported (Al-Mamgani et al., 
2013; Masoud Rahbari et al., 2016).  
Within this population, pain, mucositis, dysphagia, dysguesia, xerostomia, thick saliva, 
nausea, fatigue and dermatitis are frequently reported during treatment, whilst xerostomia, 
dysphagia, fibrosis and pain can become chronic issues known to negatively influence QOL (Al-
Mamgani et al., 2013; Cartmill, Cornwell, Ward, Davidson, & Porceddu, 2012; Falchook et al., 
2016; Feng et al., 2010; Goepfert et al., 2015; So et al., 2012). Grade 3 mucositis during CRT for 
OPSCC is common, with incidence rates ranging from 21-80% reported in the literature (Al-
Mamgani et al., 2013; Feng et al., 2010; Lohia et al., 2014; Masoud Rahbari et al., 2016; 
Samuels et al., 2016; Setton et al., 2012). Oropharyngeal dysphagia is of particular concern for 
this patient group (Dawe, Patterson, & O'Hara, 2016; Guo et al., 2016), with aspiration 
pneumonia an under-reported consequence of CRT for OPSCC (Hunter et al., 2014; Starmer et 
al., 2014). Oropharyngeal tumours are associated with greater difficulty in managing semisolid 
diets (Frowen et al., 2010), with one to two thirds of patients experiencing grade 3 dysphagia 
requiring enteral nutrition support when undergoing CRT using IMRT (Al-Mamgani et al., 2013; 
Feng et al., 2010; Masoud Rahbari et al., 2016). Despite the high rate of acute toxicities 
experienced by patients with OPSCC undergoing CRT, clinical practice guidelines for SP 
intervention are currently broad with recommendations only for the type of involvement, and no 
details regarding the timing and intensity of supportive care (National Comprehensive Cancer 
Network, 2016; National Institute for Health and Care Excellence, 2016).  
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Recognising the risk for severe acute and long term toxicities (Denaro et al., 2013), 
treatment de-escalation strategies are currently being investigated to minimise toxicities and 
improve QOL after CRT, particularly for patients at high risk such as the OPSCC group. 
Strategies include chemotherapy and radiation de-escalation, immunotherapy trials, surveillance 
and conformal methods of RT (Cleary & Cmelak, 2017; Langendijk & Steenbakkers, 2017; 
Marur & Forastiere, 2016). In the field of radiotherapy, technology has continued to evolve since 
the introduction of three-dimensional conformal radiation. IMRT has become widely adopted as 
standard care (Daly-Schveitzer et al., 2011) with pioneering work by Eisbruch demonstrating the 
potential of IMRT to reduce the volume of radiation received by critical swallowing structures 
without compromising target dose (Eisbruch et al., 2004; Feng et al., 2010). This work has led to 
the development of parotid sparing IMRT and swallow sparing IMRT techniques (Christianen et 
al., 2016; Nutting et al., 2011; Van der Laan et al., 2013). Static beam IMRT has subsequently 
further evolved into rotational IMRT techniques such as volumetric modulated arc therapy and 
H-IMRT (Van Gestel, Verellen, et al., 2013). Theoretical H-IMRT planning and dosimetry studies 
describe the potential for improved normal tissue sparing through steep dose gradients in 
different directions, greater homogeneity of dose control and increased precision of dose 
distributions whilst achieving better target coverage (Fiorino et al., 2006; Gielda et al., 2010; 
Murthy et al., 2010; Van Gestel, Van Vliet-Vroegindeweij, et al., 2013). Planning studies have 
reported a superiority of H-IMRT to reduce the radiation dose to critical swallowing structures in 
patients with OPSCC (Fortin et al., 2014; Gielda et al., 2010; Van Gestel, Van Vliet-
Vroegindeweij, et al., 2013). Despite the theoretical potential to assist in reducing the extent of 
radiation dose, there is as yet a limited number of studies reporting swallowing and toxicity 
outcomes for OPSCC patients undergoing H-IMRT. The studies that have been conducted are 
largely retrospective, reporting a limited number of patient outcomes, primarily mucositis as a 
‘maximum incidence’ figure only, and dysphagia outcomes are rarely documented. These studies 
report a wide range of results (e.g. grade 3 mucositis ranging from 10 – 72%) (Kimura et al., 
2016; Kubrak, Olson, & Baracos, 2013; Nguyen, Ceizyk, et al., 2013; Shueng et al., 2010). 
There is no information to date regarding the pattern of symptom presentation, peak and early 
recovery. As a patient group at high risk for toxicities, particularly dysphagia due to the 
proximity of the tumour and treatment field to the swallowing apparatus, this information is 
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necessary to inform when and to what extent OPSCC patients undergoing H-IMRT require SP 
services during treatment (Moroney et al., 2017 = Chapter 2).  
More evidence is needed regarding outcomes for OPSCC patients undergoing H-IMRT to 
determine whether more conformal treatment approaches minimise toxicity and optimise 
functional outcomes for these patients. Thus, the aim of this study was to prospectively evaluate 
the extent, severity and pattern of presentation, peak incidence and early recovery of dysphagia 
and a range of acute toxicities in a prospective cohort of OPSCC patients undergoing H-IMRT 
with concurrent chemotherapy. This information will help inform patient education regarding 
treatment and its effects, and guide clinical support services. 
3.3 Methods 
3.3.1 Participants 
The data represented in this study were collected as part of a larger published study of 
outcomes relating to a heterogeneous cohort of 212 patients with HNC undergoing H-IMRT 
which can be found described in full elsewhere (Moroney et al., 2017 = Chapter 2). For the 
current study, data was analysed for the subset of patients with OPSCC and planned for H-IMRT 
with concurrent chemotherapy who had been prospectively recruited between September 2013 
and November 2014. Recruitment occurred through the joint SP/dietetic service which receives a 
blanket referral for all HNC patients attending the combined head and neck clinic of a large 
tertiary referral hospital. Patients from the larger cohort were excluded if they: had a tumour site 
other than the oropharynx; were not planned to receive H-IMRT; were not planned for concurrent 
chemotherapy; or were planned for less than 60Gy. The local Human Research Ethics Committee 
provided ethical clearance for this study, including a waiver of individual consent (approval 
number: HREC/13/QRBW/444). 
3.3.2 Radiation Treatment Planning 
A non-contrast CT simulation was performed with 2mm slice thickness whilst patients 
were immobilised with custom thermoplastic shell and head and neck rest. If prescribed, custom 
skin bolus of appropriate thickness was outlined by the radiation oncologist. The Hi-Art Planning 
Station (TomoTherapy Inc., Madison, WI, USA) with a simultaneous integrated boost technique 
was used for planning H-IMRT.  Gross tumour volume and nodal disease was delineated with the 
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assistance of fused contrast-enhanced CT, PET and/or MRI where available, with a minimum 
expansion of 10mm to achieve the high-dose PTV.  Elective nodal regions were delineated with 
the use of international contouring guidelines (Grégoire et al., 2003). All patients with T3/4 
disease and/or N2c disease had elective irradiation to bilateral neck nodes.   
The following OAR were contoured where appropriate with the following dose constraint 
guidelines: median dose 1) pharyngeal constrictors mean <50Gy, 2) parotids mean <26 Gy each, 
3) oral cavity, larynx, oesophagus, trachea mean <25Gy 4) spinal cord maximum point dose 
40Gy. 
3.3.3 Treatment Delivery 
All patients received H-IMRT (also known as helical tomotherapy) delivered by 
TomoTherapy (TomoTherapy Inc., Madison, WI, USA). The prescription dose for definitive 
radiotherapy was a total dose of 70Gy in 35 fractions, five fractions per week over 7 weeks to 
gross disease, and 66Gy in 33 fractions over 6 ½ weeks for post-operative adjuvant radiotherapy.  
Elective nodal regions were treated to a dose of 54-60Gy in 35 fractions using a simultaneous 
integrated boost technique.   
Concurrent chemotherapy comprised of high dose cisplatin 100mg/m2 IV delivered 
q3weekly (weeks 1, 4 and 7), weekly cisplatin 40mg/m2 IV, or cetuximab 400mg/m2 IV loading 
dose 1 week prior to radiotherapy followed by weekly 250mg/m2 for the duration of radiotherapy 
at the discretion of the treating medical oncologist. The decision regarding the choice of systemic 
therapy was made depending upon any relative or absolute contraindications to cisplatin-based 
therapy. 
3.3.4 Procedure 
Outcomes were prospectively collected on standard data forms through routine joint SP 
and dietetic clinics at the following time-points: (a) baseline assessment (week 1 of treatment or 
if unavailable at combined head and neck clinic; (b) weekly over weeks 2 – 7 during treatment; 
(c) then at 2, 4, and 12 weeks post treatment. All HNC patients routinely attended an education 
lecture in week 1 of treatment and were therefore not always seen in the joint clinic until week 2 
of treatment. All data was then entered onto a secure database by the chief researchers. 
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During the SP and dietetic clinics the following outcome measures were collected: the 
CTCAE version 4.0 was used to rate the following treatment related symptoms: dysphagia, 
dysguesia, oral mucositis, pharyngeal mucositis, xerostomia, salivary duct inflammation (thick 
saliva) and nausea. The functional descriptors used in the CTCAE v4 made it a preferable choice 
for grading symptoms, with all treating clinicians having ≥5 years of experience in HNC. The 
texture of patients oral intake was recorded using the national dysphagia diet descriptors 
(Dietitians Association of Australia & Speech Pathology Association of Australia, 2007) for 
foods (unmodified/regular, soft, minced and moist, puree) with the addition of two categories of 
liquids only and NBM and fluids (unmodified/regular, mildly thick, moderately thick, extremely 
thick). A functional diet measure was collected using the seven-point FOIS, where 7 represents a 
normal diet and fluids and 1 represents complete enteral nutrition (Crary et al., 2005). Baseline 
dysphagia was defined as a FOIS score less than or equal to 5 at week 1 of treatment or if 
unavailable, at combined head and neck clinic.  
Patients were considered for a proactive gastrostomy due to anticipated treatment related 
side effects as per the institution’s published guidelines (Brown et al., 2013; Hughes et al., 2013). 
However, the final decision remained with the treating radiation oncologist. Gastrostomy data 
was followed until the time of removal, recording date of gastrostomy insertion and removal, 
feeding commencement, and feeding cessation. For patients with a proactive gastrostomy, FOIS 
ratings of 1-3 were only used once enteral feeding had commenced. Patients with a gastrostomy 
in-situ, which was either (a) not being used for enteral feeding support, or (b) no longer being 
used for enteral support and scheduled for removal, were scored 4-7 on the FOIS as appropriate. 
3.3.5 Statistical Methods 
Descriptive analyses were used to convey patient demographics, baseline characteristics, 
maximal incidence data across all timepoints and then at each isolated timepoint for the CTCAE 
v4.0, FOIS, diet/fluid descriptors and gastrostomy usage rates. Mean (standard deviation (SD)), 
median (interquartile range (IQR), range) or number (%) were reported as appropriate. In order 
to explore the temporal patterns of symptom presentation, peak and recovery, outcomes were re-
classified into “need for supportive care” or “no need for supportive care” and analysed with 
descriptive statistics at each timepoint. “Need for supportive care” was defined as a CTCAE 
toxicity grade ≥2, FOIS ≤5 or diet/fluid descriptor other than soft or regular indicating a need for 
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SP intervention. Chi-square tests were used to explore the association between tumour 
classification (T2 N2-3 versus T3/T4) and toxicity. Statistical significance was set at p<0.05. All 
analyses were performed in IBM SPSS Statistics for Windows, version 22.0 (2013, IBM Corp., 
Armonk, NY., USA) and R 3.3.1. 
3.4 Results 
3.4.1 Participants 
Over the 14-month study period, 76 patients met the inclusion criteria. Patients were 
predominantly male (84.2%) with a mean age of 59.6 years (Table 3.1). The majority of patients 
had stage IV disease, and 80.3% were P16 positive, indicating HPV mediated disease. Twenty-
two percent of patients had baseline dysphagia, 94.7% (72) were defined as ‘high risk’ for 
nutritional decline and considered for a proactive gastrostomy as per the institution’s guidelines 
(Brown et al., 2013), of which 67.1% (51) received a proactive gastrostomy tube. Regarding 
decision-making of the 21 patients who did not receive a gastrostomy, 14 were radiation 
oncologist-driven, and 7 were patient-driven. 
Of the total participants, 2 patients had missing baseline dysphagia assessments and 
17.1% (13) were not seen in their final week of treatment, 9 patients did not attend their 
scheduled review, 2 patients were admitted due to toxicity, and 2 patients died. Due to regional 
patients returning to local services, there was up to 46% missing data at the post-treatment time 
points. 
  
 85 
Table 3.1 
Patient Demographics 
Parameters No. of patients (%) 
n = 76 
Mean age, yrs (SD) 59.6 (9.0) 
Gender  
Female 12 (15.8%) 
Male 64 (84.2%) 
T Classification  
T0 2 (2.6%) 
T1 10 (13.2%) 
T2 26 (34.2%) 
T3 17 (22.4%) 
T4 21 (27.6%) 
N Classification  
N0 8 (10.5%) 
N1 3 (3.9%) 
N2 62 (81.6%) 
N3 3 (3.9%) 
M Classification  
M0 75 (98.7%) 
M1 1 (1.3%) 
TNM Staging  
I 0 (0%) 
II 1 (1.3%)  
III 3 (3.9%) 
IVa 68 (89.6%) 
IVb 3 (3.9%) 
IVc 1 (1.3%) 
P16 +ve 61 (80.3%) 
Treatment  
Adjuvant 2 (2.6%) 
Definitive 74 (97.4%) 
Chemotherapy Agent  
High Dose Cisplatin 45 (55.2%) 
Weekly Cisplatin 22 (28.9%) 
Cetuximab 12 (15.7%) 
Baseline Dysphagia 16 (21.6%) 
Nutrition Risk*   
High Risk 72 (94.7%) 
Proactive gastrostomy 51 (67.1%) 
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Note: As per Royal Brisbane & Women’s Hospital: Swallowing and Nutrition Management Guidelines 
for Patients with Head and Neck Cancer (Brown et al., 2013; Hughes et al., 2013) 
 
 
3.4.2 Incidence of Acute Dysphagia and Related Toxicities 
Dysphagia was the most frequently occurring grade 3 acute toxicity (60.5%) followed by 
thick saliva (38.2%), pharyngeal mucositis (30.3%), oral mucositis (28.9%), and nausea (27.6%). 
A maximum of grade 2 xerostomia was experienced by 86.8% and dysguesia by 97.4% of 
patients. Details of the maximum incidence for all grades of the CTCAE treatment related 
toxicities can be found in Table 3.2. Details for the maximum incidence of FOIS and diet/fluid 
texture can be found in Table 3.3. Of note, overall 61% of patients required enteral nutrition, 
however, only 14.5 % of patients became NBM requiring full enteral nutrition and 30.3% of 
patients were able to inconsistently manage some form of oral intake with enteral support (FOIS 
2). The most frequently occurring diet texture was “liquids only” and only 7 patients required 
modified fluids. Of the 51 patients who received a proactive gastrostomy, 1 was excluded due to 
a neurological event resulting in long term dysphagia, and 8 patients were excluded due to death 
with gastrostomy in-situ (non-gastrostomy related deaths), leaving data from 42 patients 
available for gastrostomy analyses. The median duration of gastrostomy feeding was 98.5 days 
(IQR 45.3 – 144, range 0 - 495) or 3.2 months (IQR 1.5 – 4.8, range 0 - 16.3) and 8 patients did 
not require enteral nutrition via the gastrostomy tube. Patients ceased enteral nutrition via the 
gastrostomy tube at a median of 2.1 months (IQR 0 – 3.6, range 0 - 14.5) post helical IMRT 
completion. Only 1 (2.4%) patient was still using their gastrostomy for nutrition support at 12 
months post-treatment and did not achieve gastrostomy removal, however, they remained 
suspicious for persistent disease post-treatment with confirmation of recurrence 14.5 months post 
H-IMRT completion. 
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Table 3.2 
Maximal Incidence of Acute Toxicities 
Toxicity 
Absent 
No. of patients (%) 
Grade 1 
No. of patients (%) 
Grade 2 
No. of patients (%) 
Grade 3 
No. of patients (%) 
Xerostomia 1 (1.3%) 9 (11.8%) 66 (86.8%) N/A 
Dysguesia 1 (1.3%) 1 (1.3%) 74 (97.4%) N/A 
Oral 
Mucositis 11 (14.5%) 12 (15.8%) 31 (40.8%) 22 (28.9%) 
Pharyngeal 
Mucositis 
8 (10.5%) 7 (9.2%) 38 (50%) 23 (30.3%) 
Thick Saliva 1 (1.3%) 8 (10.5%) 38 (50%) 29 (38.2%) 
Dysphagia 5 (6.6%) 3 (3.9%) 22 (28.9%) 46 (60.5%) 
Nausea 18 (23.7%) 11 (14.5%) 26 (34.2%) 21 (27.6%) 
Note: CTCAE: Common Toxicity Criteria for Adverse Events version 4; Bold indicates ³ 50% of cohort 
experiencing toxicity 
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Table 3.3 
Maximal Incidence of Diet Texture, Fluid Level and FOIS 
Outcome Category No. of patients (%) 
Diet Regular 5 (6.6%) 
 Soft 6 (7.9%) 
 Minced 5 (6.6%) 
 Puree 13 (17.1%) 
 Liquids only 36 (47.4%) 
 NBM 11 (14.5%) 
Fluids Thin 69 (90.8%) 
 Mildly thick 7 (9.2%) 
 Moderately thick 0 (0.0%) 
FOIS Level 7 3 (3.9%) 
 Level 6 1 (1.3%) 
 Level 5 13 (17.1%) 
 Level 4 13 (17.1%) 
 Level 3 12 (15.8%) 
 Level 2 23 (30.3%) 
 Level 1 11 (14.5%) 
Note: FOIS: Functional Oral Intake Scale 
 
 
3.4.3 Temporal Patterns of Toxicities Requiring Supportive Care 
The pattern of incidence for all toxicity grades and dysphagia outcomes at each time 
point can be found in Figure 3.1. Specific details of weekly incidence percentages for all 
symptoms can be found in Table 3.4.  
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Figure 3.1 Incidence of all dysphagia outcomes and CTCAE symptoms at each timepoint 
*Week 1: n = 40; week 2: n = 66; week 3: n = 72; week 4: n = 72; week 5: n = 73; week 6: n = 
69; week 7: n = 63; 2 weeks post: n = 38; 4 weeks post: n = 47; and 12 weeks post: n = 53. FOIS, 
Functional Oral Intake Scale
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Table 3.4.  
Weekly Incidence of all Toxicity and Dysphagia Outcomes   
    Week of treatment 
Outcome Level Wk 1  (n=40) 
Wk 2 
(n=66) 
Wk 3  
(n=72) 
Wk 4  
(n=72) 
Wk 5  
(n=73) 
Wk 6 
(n=69) 
Wk 7  
(n=63) 
2wks post 
Tx (n=38) 
4wks post 
Tx (n=47) 
12wks post 
Tx (n=53) 
Dry mouth Absent 30 (75%) 25 (37.9%) 10 (13.9%) 9 (12.5%) 15 (20.5%) 8 (11.6%) 6 (9.5%) 4 (10.5%) 6 (12.8%) 7 (13.2%) 
 Grade 1 9 (22.5%) 28 (42.4%) 37 (51.4%) 25 (34.7%) 16 (21.9%) 14 (20.3%) 9 (14.3%) 17 (44.7%) 18 (38.3%) 25 (47.2%) 
 Grade 2 1 (2.5%) 13 (19.7%) 25 (34.7%) 38 (52.8%) 42 (57.5%) 47 (68.1%) 48 (76.2%) 17 (44.7%) 23 (48.9%) 21 (39.6%) 
 Grade 3 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 ≥ Grade 2 1 (2.5%) 13 (19.7%) 25 (34.7%) 38 (52.8%) 42 (57.5%) 47 (68.1%)* 48 (76.2%) 17 (44.7%) 23 (48.9%) 21 (39.6%) 
Taste Absent 24 (60%) 18 (27.3%) 9 (12.5%) 3 (4.2%) 2 (2.7%) 1 (1.4%) 0 (0%) 0 (0%) 2 (4.3%) 10 (18.9%) 
 Grade 1 10 (25%) 29 (43.9%) 24 (33.3%) 14 (19.4%) 9 (12.3%) 3 (4.3%) 1 (1.6%) 5 (13.2%) 20 (42.6%) 29 (54.7%) 
 Grade 2 6 (15%) 19 (28.8%) 39 (54.2%) 55 (76.4%) 62 (84.9%) 65 (94.2%) 62 (98.4%) 33 (86.8%) 25 (53.2%) 14 (26.4%) 
 Grade 3 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 ≥ Grade 2 6 (15%) 19 (28.8%) 39 (54.2%) 55 (76.4%) 62 (84.9%)* 65 (94.2%)* 62 (98.4%) 33 (86.8%)* 25 (53.2%) 14 (26.4%) 
Oral Absent 38 (95%) 43 (65.2%) 35 (48.6%) 26 (36.1%) 27 (37%) 23 (33.3%) 19 (30.2%) 23 (60.5%) 32 (68.1%) 42 (79.2%) 
mucositis Grade 1 1 (2.5%) 18 (27.3%) 21 (29.2%) 14 (19.4%) 16 (21.9%) 13 (18.8%) 9 (14.3%) 5 (13.2%) 6 (12.8%) 4 (7.5%) 
 Grade 2 1 (2.5%) 4 (6.1%) 13 (18.1%) 28 (38.9%) 21 (28.8%) 23 (33.3%) 20 (31.7%) 7 (18.4%) 7 (14.9%) 6 (11.3%) 
 Grade 3 0 (0%) 1 (1.5%) 3 (4.2%) 4 (5.6%) 9 (12.3%) 10 (14.5%) 15 (23.8%) 3 (7.9%) 2 (4.3%) 1 (1.9%) 
 ≥ Grade 2 1 (2.5%) 5 (7.6%) 16 (22.3%) 32 (44.5%)* 30 (41.1%)* 33 (47.8%)* 35 (55.5%) 10 (26.3%) 9 (19.2%) 7 (13.2%) 
Pharyngeal Absent 37 (92.5%) 53 (80.3%) 35 (48.6%) 32 (44.4%) 30 (41.1%) 15 (21.7%) 12 (19%) 17 (44.7%) 32 (68.1%) 44 (83%) 
mucositis Grade 1 1 (2.5%) 7 (10.6%) 15 (20.8%) 15 (20.8%) 17 (23.3%) 13 (18.8%) 9 (14.3%) 7 (18.4%) 8 (17%) 5 (9.4%) 
 Grade 2 2 (5%) 6 (9.1%) 21 (29.2%) 21 (29.2%) 19 (26%) 27 (39.1%) 31 (49.2%) 9 (23.7%) 7 (14.9%) 4 (7.5%) 
 Grade 3 0 (0%) 0 (0%) 1 (1.4%) 4 (5.6%) 7 (9.6%) 14 (20.3%) 11 (17.5%) 5 (13.2%) 0 (0%) 0 (0%) 
 ≥ Grade 2 2 (5%) 6 (9.1%) 22 (30.6%) 25 (34.8%) 26 (35.6%) 41 (59.4%)* 42 (66.7%) 14 (36.9%) 7 (14.9%) 4 (7.5%) 
Thick  Absent 30 (75%) 32 (48.5%) 23 (31.9%) 17 (23.6%) 20 (27.4%) 8 (11.6%) 5 (7.9%) 6 (15.8%) 15 (31.9%) 35 (66%) 
saliva Grade 1 8 (20%) 26 (39.4%) 29 (40.3%) 19 (26.4%) 11 (15.1%) 9 (13%) 10 (15.9%) 11 (28.9%) 18 (38.3%) 10 (18.9%) 
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 Grade 2 2 (5%) 7 (10.6%) 19 (26.4%) 32 (44.4%) 37 (50.7%) 43 (62.3%) 28 (44.4%) 9 (23.7%) 10 (21.3%) 8 (15.1%) 
 Grade 3 0 (0%) 1 (1.5%) 1 (1.4%) 4 (5.6%) 5 (6.8%) 9 (13%) 20 (31.7%) 12 (31.6%) 4 (8.5%) 0 (0%) 
 ≥ Grade 2 2 (5%) 8 (12.1%) 20 (27.8%) 36 (50%) 42 (57.5%) 52 (75.3%)* 48 (76.1%) 21 (55.3%) 14 (29.8%) 8 (15.1%) 
Nausea Absent 31 (77.5%) 47 (71.2%) 62 (86.1%) 48 (66.7%) 44 (60.3%) 46 (66.7%) 32 (50.8%) 30 (78.9%) 39 (83%) 50 (94.3%) 
 Grade 1 5 (12.5%) 14 (21.2%) 5 (6.9%) 6 (8.3%) 10 (13.7%) 9 (13%) 6 (9.5%) 4 (10.5%) 4 (8.5%) 3 (5.7%) 
 Grade 2 3 (7.5%) 4 (6.1%) 3 (4.2%) 10 (13.9%) 15 (20.5%) 7 (10.1%) 17 (27%) 2 (5.3%) 4 (8.5%) 0 (0%) 
 Grade 3 1 (2.5%) 1 (1.5%) 2 (2.8%) 8 (11.1%) 4 (5.5%) 7 (10.1%) 8 (12.7%) 2 (5.3%) 0 (0%) 0 (0%) 
 ≥ Grade 2 4 (10%) 5 (7.6%) 5 (7%) 18 (25%) 19 (26%) 14 (20.2%) 25 (39.7%) 4 (10.6%) 4 (8.5%) 0 (0%) 
Dysphagia Absent 26 (65%) 41 (62.1%) 22 (30.6%) 16 (22.2%) 8 (11%) 11 (15.9%) 5 (7.9%) 6 (15.8%) 16 (34%) 31 (58.5%) 
Grade 1 4 (10%) 15 (22.7%) 23 (31.9%) 13 (18.1%) 11 (15.1%) 6 (8.7%) 5 (7.9%) 4 (10.5%) 7 (14.9%) 9 (17%) 
 Grade 2 9 (22.5%) 8 (12.1%) 15 (20.8%) 27 (37.5%) 28 (38.4%) 20 (29%) 20 (31.7%) 5 (13.2%) 9 (19.1%) 2 (3.8%) 
 Grade 3 1 (2.5%) 2 (3%) 12 (16.7%) 16 (22.2%) 26 (35.6%) 32 (46.4%) 33 (52.4%) 23 (60.5%) 15 (31.9%) 11 (20.8%) 
 ≥ Grade 2 10 (25%) 10 (15.1%) 27 (37.5%) 43 (59.7%) 54 (74%)* 52 (75.4%)* 53 (84.1%) 28 (73.7%)* 24 (51%) 13 (24.6%) 
Diet Regular 24 (60%) 43 (65.2%) 23 (31.9%) 16 (22.2%) 12 (16.4%) 12 (17.4%) 7 (11.1%) 6 (15.8%) 17 (36.2%) 33 (62.3%) 
 Soft 6 (15%) 13 (19.7%) 25 (34.7%) 18 (25%) 10 (13.7%) 8 (11.6%) 6 (9.5%) 6 (15.8%) 12 (25.5%) 7 (13.2%) 
 Minced 5 (12.5%) 4 (6.1%) 6 (8.3%) 11 (15.3%) 8 (11%) 7 (10.1%) 2 (3.2%) 4 (10.5%) 3 (6.4%) 3 (5.7%) 
 Puree 4 (10%) 5 (7.6%) 10 (13.9%) 12 (16.7%) 14 (19.2%) 9 (13%) 14 (22.2%) 2 (5.3%) 3 (6.4%) 0 (0%) 
 
Liquids 
only 1 (2.5%) 1 (1.5%) 7 (9.7%) 14 (19.4%) 26 (35.6%) 25 (36.2%) 26 (41.3%) 14 (36.8%) 8 (17%) 10 (18.9%) 
 NBM 0 (0%) 0 (0%) 1 (1.4%) 1 (1.4%) 3 (4.1%) 8 (11.6%) 8 (12.7%) 6 (15.8%) 4 (8.5%) 0 (0%) 
 ≤ Minced 10 (25%) 10 (15.2%) 24 (33.3%) 38 (52.8%) 51 (69.9%)* 49 (70.9%)* 50 (79.4%) 26 (68.4%)* 18 (38.3%) 13 (24.6%) 
FOIS Level 7 23 (57.5%) 39 (59.1%) 23 (31.9%) 15 (20.8%) 9 (12.3%) 8 (11.6%) 3 (4.8%) 6 (15.8%) 14 (29.8%) 30 (56.6%) 
 Level 6 6 (15%) 13 (19.7%) 23 (31.9%) 15 (20.8%) 10 (13.7%) 5 (7.2%) 5 (7.9%) 4 (10.5%) 6 (12.8%) 6 (11.3%) 
 Level 5 8 (20%) 4 (6.1%) 9 (12.5%) 13 (18.1%) 11 (15.1%) 10 (14.5%) 12 (19%) 5 (13.2%) 2 (4.3%) 2 (3.8%) 
 Level 4 0 (0%) 0 (0%) 2 (2.8%) 4 (5.6%) 9 (12.3%) 9 (13%) 8 (12.7%) 3 (7.9%) 1 (2.1%) 0 (0%) 
 Level 3 2 (5%) 9 (13.6%) 6 (8.3%) 13 (18.1%) 11 (15.1%) 15 (21.7%) 10 (15.9%) 3 (7.9%) 12 (25.5%) 7 (13.2%) 
 Level 2 1 (2.5%) 1 (1.5%) 8 (11.1%) 11 (15.3%) 20 (27.4%) 14 (20.3%) 17 (27%) 11 (28.9%) 8 (17%) 8 (15.1%) 
  Level 1 0 (0%) 0 (0%) 1 (1.4%) 1 (1.4%) 3 (4.1%) 8 (11.6%) 8 (12.7%) 6 (15.8%) 4 (8.5%) 0 (0%) 
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 ≤ FOIS 5 11 (27.5%) 14 (21.2%) 26 (36.1%) 42 (58.5%) 54 (74%)* 56 (81.1%)* 55 (87.3%) 28 (73.7%)* 27 (57.4%) 17 (32.1%) 
Note: FOIS: Functional Oral Intake Score; n = no of patients available for analysis at each datapoint; bold denotes symptom peak; * denotes 
results within 15% of the peak  
 
  93 
Figure 3.2 demonstrates the pattern of symptoms needing supportive care (CTCAE 
toxicity grade ≥2, FOIS ≤5 or diet/fluid descriptor other than soft or regular) at each time point. 
The onset of symptoms needing supportive care occurred at week 3 for 20-30% of patients for all 
symptoms excepting nausea and fluid level. A sharp increase in incidence was seen from week 3 
to 4 of treatment (except pharyngeal mucositis which escalated from week 2 – 3). This rapid 
increase was likely due to the second round of high dose cisplatin. Symptoms peaked in the final 
week of treatment and improved thereafter. Notably all the swallowing related outcomes 
demonstrated an incidence within 15% of the peak (almost 70% and greater) from week 5 of 
treatment to 2 weeks post-treatment. Five patients became NBM for > 2 weeks (most had T3-4 
tumours), however, at 12 weeks post treatment no patient remained NBM, though 28.3% 
required some enteral support and 18.9% remained on a liquids only diet. Grade 2 dysguesia 
continued to be observed in 26.4% of patients at 12 weeks post-treatment. 
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Figure 3.2 Percentage of cohort needing supportive care over time. Symptoms needing 
supportive care defined as Common Terminology Criteria for Adverse Events grade ³2, 
Functional Oral Intake Scale (FOIS) ≥5, and diet other than soft or regular. 
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A sub analysis of patients with stage IV disease was conducted to investigate any 
differences in the toxicity profile of patients with T2 N2-3 classification (n=24) versus those with 
T3-4 N2-3 (n-29) as tumour classification can be a determining factor in decisions regarding 
neck treatment and influence the recommendation for a proactive gastrostomy at the study 
institution. Sub analysis revealed that more patients with T3-4 tumours compared to T2 tumours 
presented with baseline dysphagia (29.6% versus 12.5%), although this difference was not 
statistically significant (p=0.14). However, patients with T3-4 tumours were identified as having 
double the incidence of grade 3 dysphagia (86.2% versus 37.5%, p<0.001) and 4 times the 
incidence of grade 3 oral mucositis (48.3% versus 12.5%, p=0.005) and pharyngeal mucositis 
(51.7% versus 12.5%, p=0.003) compared to the T2 group. There were no differences observed 
in the temporal pattern of symptom presentation, peak and recovery. 
3.5 Discussion 
To our knowledge, this study represents the largest and most comprehensive prospective 
report of acute toxicity and dysphagia outcomes for patients with OPSCC treated with H-IMRT 
and concurrent chemotherapy. Overall the current data indicates patients continue to require 
supportive care for a range of treatment related toxicities including dysphagia, particularly 
beginning in weeks 3-4, until the final weeks of treatment with symptoms improving thereafter.  
3.5.1 Comparison with Existing Helical IMRT Literature 
Direct comparison with the available H-IMRT literature is limited primarily due to the 
paucity of published papers specifically investigating outcomes for patients with OPSCC 
receiving H-IMRT with concurrent chemotherapy, and limited data reported on the full range of 
treatment toxicities. However, key literature available for comparison has been outlined in Table 
3.5, and data available suggests similarities between the current data and prior H-IMRT results.  
Specifically, the low rate of long term gastrostomy use (>12 months) was comparable to 
the rates reported by Kimura et al. (2016); Nguyen, Ceizyk, et al. (2013). Oral mucositis data is 
the only other acute toxicity available for comparison, however, across the studies which have 
reported results, the incidence of grade 3 mucositis varies widely from 0 – 72% (Kimura et al., 
2016; Kruser et al., 2013; Nguyen, Ceizyk, et al., 2013; Shueng et al., 2010). Similarly, grade 2 
rates also had substantial variation ranging from 30 – 90% (Kruser et al., 2013; Shueng et al., 
2010) with the current study results falling in the mid-range for both grades. Dysphagia 
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outcomes have only been reported in one H-IMRT study to date (Donato et al., 2013). The 
incidence of grade 2 dysphagia in that study was more than twice the rate of 29% observed in the 
current study. The disparity of results may be related to different patient cohorts, as well as 
models of supportive care.
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Table 3.5 
Comparison of Current Results with Comparable Published Literature for Patients with Oropharyngeal Squamous Cell 
Carcinoma/Oropharyngeal Cancer Receiving Helical IMRT/traditional IMRT with Concurrent Chemotherapy 
Study Design RT n Outcome Mucositis Dysphagia Xerostomia Gastro-stomy 
Enteral 
Duration|| > 12m 
     Gr 1 Gr 2 Gr 3 Gr 1 Gr 2 Gr 3 Gr 1 Gr 2 Gr 3 usage Median (range) gastrostomy 
Current Study                 
 Prospective Helical IMRT 76 
CTCAE 
v4 16% 41% 29% 4% 29% 61% 12% 87% 0% 61% 
3.2 months 
(0-16.3) 2% 
Available Helical IMRT Literature               
Shueng et al. 
(2010) Prospective 
Helical 
IMRT 10 
CTCAE  
v3 - 90%
† 10% - - - - - - - - - 
Nguyen, Ceizyk, 
et al. (2013) Retrospective 
Helical 
IMRT 33 
RTOG 
Gr3/4 - - 72%
† - - - - - - - - 6% 
Kruser et al. 
(2013) Prospective 
Helical 
IMRT 108* Unknown - 30% 70%
† - - - - - - - - - 
Kimura et al. 
(2016) Retrospective 
Helical 
IMRT 93 
CTCAE 
v4 - - 45% - - - - - - - - 2% 
Available Traditional IMRT Literature               
Masoud Rahbari 
et al. (2016) Retrospective IMRT 61 
CTCAE 
v4 
Gr1/2 
 11%§ 23%  44% 36%§  54%§ 8% - - - 
Samuels et al. 
(2016) Prospective IMRT 27 
CTCAE 
v3 - - 55%
† - - - - - - 22%§ - - 
Al-Mamgani et 
al. (2013) Prospective IMRT 139 
CTCAE 
v3 - 12%
§ 68%† - 41% 49% - - - 63% - - 
Kruser et al. 
(2013) Prospective IMRT 108* Unknown - 40% 58%
† - - - - - - - - - 
Setton et al. 
(2012) Retrospective IMRT 442 
CTCAE 
v3 23% 46% 21% 37%
† 40% 16%§ 61%† 26%§ 2% 83%† 4 months  (0-68) 7% 
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Feng et al. (2010) Prospective IMRT 73 CTCAE v2 - 44% 55%
† - - 29%§ - - - 29%§ - 1% 
Huang et al. 
(2008) Retrospective IMRT 71 
? RTOG 
Gr3/4 8% 38% 54%
† - - - - - - 35%§ - - 
De Arruda et al. 
(2005) Retrospective IMRT 50 RTOG 8% 54% 38% 16% 62%
† 16%§ 48%† 52%§ - 84%† 3.3 months (0.6-23.1) 14% 
Lee et al. (2006) Retrospective IMRT 41 RTOG - - 66%† - - - - - - 95%† - 7% 
Note:  *Comparison study of both IMRT and helical IMRT no. of oropharynx patients not given for each technique; † indicates results 
20% or higher than the current study; § indicates results 20% or lower than the current study;|| median no of months enteral nutrition 
via gastrostomy was required.  
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3.5.2 Comparison with Linac Based IMRT lLterature 
Helical IMRT has been proposed to have the potential to minimise toxicity events for 
OPSCC patients due to its capability for greater dosimetric control and contouring the organs at 
risk compared with traditional linac based IMRT (Gielda et al., 2010; Murthy et al., 2010; Van 
Gestel, Van Vliet-Vroegindeweij, et al., 2013). However, there are limited prospective studies 
directly comparing outcomes for the two techniques to allow definitive conclusions at this time. 
Kruser et al. (2013) prospective study comparing conventional 3D CRT, linac based IMRT and 
helical tomotherapy based IMRT for 178 patients with mixed tumour sites receiving concurrent 
weekly cisplatin, found no statistical difference in the rates of grade 2 and 3 mucositis or the rate 
of narcotic usage for the OPSCC patients. Similarly, Chen et al. (2011) found no statistical 
difference in acute mucositis, dysphagia and xerostomia rates between helical tomotherapy 
IMRT and a step and shoot IMRT in a study of 149 patients with mixed tumour sites. In contrast 
to this, Fortin et al. (2014) reported a statistically significant improvement in observer and 
patient reported xerostomia with helical tomotherapy based IMRT vs linac based IMRT in their 
retrospective study of 119 patients with OPSCC.  
Although limited, direct comparison of the current results with key selected literature for 
OPSCC and OPC patients undergoing traditional IMRT with concurrent chemotherapy, can also 
be seen in Table 3.5. Overall, results indicate there is a pattern of improved outcomes in the 
current study, with the exception of dysphagia and xerostomia. The rates of acute grade 3 
mucositis found in the current study are similar or lower than those reported in the traditional 
IMRT literature (Al-Mamgani et al., 2013; De Arruda et al., 2005; Feng et al., 2010; Huang et al., 
2008; Kruser et al., 2013; Lee et al., 2006; Masoud Rahbari et al., 2016; Samuels et al., 2016; 
Setton et al., 2012). In contrast to the current study, most studies reported lower rates of grade 3 
dysphagia, but a higher rate of grade 2 dysphagia (De Arruda et al., 2005; Falchook et al., 2016; 
Masoud Rahbari et al., 2016). However, the median months of gastrostomy use for enteral 
nutrition support and the 1-year dependence rate is comparable or lower in the current study (De 
Arruda et al., 2005; Falchook et al., 2016; Feng et al., 2010; Lee et al., 2006; Lohia et al., 2014; 
Setton et al., 2012). The 1-year gastrostomy dependence rate is also lower than the 7.9% reported 
in Setton et al. (2015) multi-institution pooled study. These differences in dysphagia may reflect 
institutional practice regarding proactive gastrostomy tube insertion and the different outcome 
measures used, and differences in gastrostomy usage may reflect clinical practice variances in 
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patient education and SP support for continued oral intake where possible. For xerostomia, all 
studies reported a lower incidence of grade 2 xerostomia but at least 4 times the incidence of 
grade 1 xerostomia (De Arruda et al., 2005; Masoud Rahbari et al., 2016; Setton et al., 2012) 
indicating a likely difference between speech pathologist and medical officer rating as the 
descriptors rely on the impact of saliva on diet texture which the speech pathologist may address 
in more detail during their assessment. Only one study reported outcomes for dysguesia, with a 
finding of 48% incidence of acute grade 1-2, almost half that found in the present study (Masoud 
Rahbari et al., 2016). However, the present study’s post-treatment results are consistent with 
those reported by Sapir et al. (2016). 
3.5.3 Sub-analysis of T2N2-3 versus T3-4N2-3 tumours 
The difference observed between toxicity profile for patients with T2 vs T3-4 tumours 
despite both groups being stage IV indicates a significant relationship between toxicity and 
tumour size, despite the greater conformity of H-IMRT compared to 3D conformal radiotherapy.  
This is likely due to the volume of primary tumour and normal tissue within the high dose PTV, 
as all patients received 70Gy and similar distributions of chemotherapy agents.  Additionally, 
patients with T3/4 disease are likely to receive greater dose to normal tissue structures such as 
pharyngeal constrictors and minor salivary glands, and are generally ineligible for isolated 
ipsilateral elective neck irradiation. These results are in line with previous reports of advanced T 
classification being associated with severe late toxicity (Machtay et al., 2008), worse swallowing 
outcomes (Frowen et al., 2010) and greater pre-treatment dysphagia (Pauloski et al., 2000) in 
HNC patients. This information reflects the need to identify patients with T3-4 tumours at greater 
risk of developing grade 3 dysphagia and mucositis to receive proactive supportive cares to 
minimise extended periods of NBM.  
3.5.4 Comparison of Temporal Pattern with Reports from Helical IMRT or Linac Based 
IMRT Literature 
There is an emerging awareness of the correlation between acute and late toxicities 
(Denaro et al., 2013). In particular acute xerostomia and dysphagia have been found to be strong 
predictors for grade 2-4 dysphagia at 6 months post treatment (Van Der Laan et al., 2015), thus 
highlighting the importance of identifying patients at risk prospectively. Understanding the 
temporal pattern of acute symptom presentation, peak and recovery during H-IMRT is key to 
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ensuring supportive cares are provided at the right time to prevent the development of severe 
acute toxicities and optimise patient QOL during treatment. Unfortunately, there is limited 
discussion of this in the HNC literature, with only one study examining outcomes for OPSCC 
patients reporting this information (Samuels et al., 2016). Samuels et al. (2016) found physician 
reported mucositis rates started low, rose in weeks 3 - 4, peaked in weeks 5 - 7 and generally 
improved by 4 weeks post treatment.  Similarly, we found an onset of symptoms requiring 
supportive care from weeks 2 – 3 of treatment, with a dramatic increase in incidence from weeks 
3 – 4 and a peak in weeks 7 (see Figure 3.2). Post treatment, symptoms improved with the 
incidence of symptoms requiring supportive care at 4 weeks post treatment similar to that 
observed at week 3, with even greater improvement seen by 12 weeks post treatment. Notably, 
all dysphagia related measures reflect a peak from week 5 to 2 weeks post-treatment. This 
indicates a need for more intensive intervention in this period to maintain oral intake for swallow 
function preservation. This need continued for one third of patients whose FOIS indicated a need 
for supportive care for dysphagia at 12 weeks post-treatment.  
Currently there are no published Australian guidelines for SP services with 
recommendations for the timing and frequency of supportive care for HNC patients during 
treatment. The National Comprehensive Cancer Network (2016) recommend baseline evaluation, 
regular review and follow up until a stable baseline is reached for patients with or at risk of 
dysphagia. However, ‘regular’ is a generic term open to interpretation and there are no specific 
details clarifying when patients need intervention the most. Similarly, the National Institute for 
Health and Care Excellence (2016) provide only general recommendations for SP involvement 
for swallowing and trismus. The Clinical Oncology Society of Australia has published guidelines 
for nutritional management of adult HNC patients (Findlay et al., 2011), recommending weekly 
dietetic review during radiotherapy and a minimum of fortnightly follow up appointments for at 
least 6 weeks post treatment. However, there are limitations in directly applying these 
recommendations to SP practice, and it does not detail if and when patients require support 
during treatment to maximise outcomes. The information reported in this study contributes to an 
emerging evidence base, filling a gap in the current literature to inform the timing and intensity 
of clinical services for OPSCC patients undergoing H-IMRT with concurrent chemotherapy. 
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Further prospective studies with large cohorts of OPSCC patients undergoing H-IMRT 
are required to accurately evaluate any differences and benefits in treatment related toxicities for 
H-IMRT compared with traditional IMRT. Whilst this study is among the first to document the 
wide range of treatment related toxicities OPSCC patients undergoing H-IMRT with concurrent 
chemotherapy experience, the authors acknowledge several limitations to the study. An 
instrumental swallow assessment would have more comprehensively evaluated treatment effects. 
The addition of a patient QOL measure and a longer follow up period would have also provided 
a more comprehensive evaluation. 
3.6 Conclusion 
This study confirms that OPSCC patients undergoing H-IMRT with concurrent 
chemotherapy experience a range of treatment related toxicities including dysphagia. The study 
revealed rates of mucositis were similar or better than those reported for traditional IMRT. Grade 
3 dysphagia rates were worse but grade 2 rates were the same or better. Toxicities escalated in 
weeks 3 - 4 of treatment, peaking in week 7 and improving thereafter. Patients with T3-4 
tumours were more likely to develop grade 3 dysphagia and mucositis during treatment. These 
results have implications for the timing and intensity of SP services during treatment, identifying 
the need for a contemporary evidence base to help guide the delivery of timely supportive care. 
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The results from Chapter 3 found that patients with OPSCC undergoing H-IMRT with 
concurrent chemotherapy continue to experience high rates of treatment related toxicity. In 
particular, grade 3 dysphagia requiring SP support, with a temporal pattern of treatment related 
toxicity similar to that found in the study reported in Chapter 2. The results confirmed despite 
reductions in toxicity, patients with OPSCC receiving H-IMRT with concurrent chemotherapy 
experience high levels of severe dysphagia. As such they are a subgroup of patients with HNC 
that continue to require intensive SP support during and after treatment to rehabilitate their 
swallowing function and ultimately resume a normal diet.  
Whilst Chapter 3 confirmed prior evidence that patients with OPSCC are at “high risk” 
for dysphagia and need to be prioritised for supportive care, little is documented regarding the 
specific needs of patients with HNC tumours outside the major sites. As discussed in Section 1.1 
in Chapter 1, anecdotally it is theorised that due to the location of the tumour and treatment 
regimen patients with tumour sites of the parotid, thyroid, cutaneous HNC, and lymphoma in the 
head and neck region, should experience less treatment related side effects and hence may 
require less supportive care. However, there is a paucity of literature documenting the severity 
and temporal pattern of treatment related toxicity for this subgroup of patients, resulting in varied 
levels of SP care provided across HNC centres. Some centres provide the same level of SP 
supportive care to this patient group as those at high risk of developing dysphagia, whilst other 
centres do not routinely review this group during treatment. Therefore, a further subsite analysis 
of patients with parotid tumours and cutaneous HNC examining both the severity and temporal 
pattern of a range of treatment related toxicities including dysphagia, is required in order to 
better ascertain the needs of this select sub-group of patients. This data will then help to inform 
the extent of SP service support required for this subgroup of the HNC population. 
The following manuscript, entitled “Radiotherapy for cutaneous head and neck cancer 
and parotid tumours: A prospective investigation of treatment related acute swallowing and 
toxicity patterns” was published in the journal Supportive Care in Cancer in 2018. It is inserted 
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here as Chapter 4 of this thesis as published, with the exception of formatting changes that have 
been made to align with style guidelines (6th edition) as set out by the American Psychological 
Association for consistency throughout the thesis. For references to the manuscripts published by 
the PhD candidate during the candidature, these have been clarified by the following notation 
(e.g. Moroney et al., 2018 = Chapter 4). Additionally, all abbreviations defined previously in the 
thesis are listed on page xxv and not re-defined in this chapter. All references are listed in a 
single reference list on pages 162 -192 at the end of the thesis.  
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4.1 Abstract 
Reports of acute treatment related dysphagia and toxicities for patients with parotid tumours or 
cutaneous HNC are limited. This study aimed to describe the severity and timing of dysphagia 
and related toxicities experienced during radiotherapy for cutaneous HNC and parotid tumours, 
to inform the nature of future SP service models required during treatment. Prospective study of 
32 patients with parotid tumours and 36 with cutaneous HNC undergoing curative non-surgical 
management. Dysphagia and acute toxicity data was collected weekly during treatment and at 2, 
4 and 12 weeks post-treatment using the Functional Oral Intake Scale, diet descriptors and 
CTCAE v4.0. In both groups, minimal treatment toxicities (Grade 0-1) were observed. 
Xerostomia and dysgeusia were the most frequently reported grade 2 toxicities. Only 3% of 
parotid patients and 6% with cutaneous HNC experienced grade 3 dysphagia. Full or soft texture 
diets were maintained by >70% of patients in both groups. Symptoms peaked in the final week 
of treatment and rapidly improved thereafter. Apart from xerostomia <10% of patients had any 
grade 2 toxicity at 12 weeks post treatment. Patients in these subgroups of HNC experienced 
minimal treatment related toxicity during radiotherapy. As such, the need for supportive 
symptom management by SP is low. Models that involve interdisciplinary surveillance of 
symptoms with referral to SP only when required, may be best suited for these individuals to 
ensure issues are identified whilst minimising patient burden created by unnecessary routine SP 
appointments. 
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4.2 Introduction 
Skin (cutaneous) cancer, including SCC, basal cell carcinoma (BCC) and melanoma 
accounts for the largest number of cancers diagnosed in Australia each year (Australian Institute 
of Health and Welfare [AIHW], 2016), and is frequently located in the head and neck region due 
to sun exposure (Leibovitch et al., 2005; Riffat et al., 2015). Cutaneous SCC metastasising to the 
parotid lymph nodes in particular is more common in Australia compared to the northern 
hemisphere (O'Hara et al., 2011), whilst primary parotid gland carcinoma is a relatively rare 
disease, accounting for less than 1% of all cancers (Al-Mamgani, van Rooij, Verduijn, Meeuwis, 
& Levendag, 2012; Chung et al., 2013) and 3% of HNC (Nutting et al., 2001; Papadogeorgakis, 
Goutzanis, Petsinis, & Alexandridis, 2012). For both cutaneous HNC and parotid cancers 
(primary and metastatic), RT is offered as either a single treatment modality or in combination 
with surgery, to help reduce the risk of recurrence and the presence of metastases (Al-Mamgani, 
van Rooij, Sewnaik, Tans, & Hardillo, 2012; Chung et al., 2013; Mendenhall, Morris, Amdur, 
Werning, & Villaret, 2005; Nutting et al., 2001; Sykes, Logue, Slevin, & Gupta, 1995). The 
addition of radiotherapy into the management of any HNC has potential treatment impacts that 
may require supportive care. Non-surgical treatment related toxicities have been most 
extensively studied in cohorts of patients presenting with oral, oropharyngeal, hypopharyngeal 
and laryngeal cancers (Al-Mamgani et al., 2013; Bhide, Newbold, Harrington, & Nutting, 2012; 
Bressan et al., 2016; De Sanctis et al., 2016; Kouloulias et al., 2013). However, unlike other 
subgroups of HNC, the nature and extent of toxicities experienced by patients with cutaneous 
HNC and parotid cancer are currently less well defined. Comprehensive understanding of 
treatment impacts for all HNC subgroups is necessary to help inform appropriate supportive care 
models. 
Xerostomia is a recognised consequence of RT for parotid tumours, due to the sensitivity 
of the parotid gland to radiation and is the most commonly reported toxicity from RT for this 
patient group (Al-Mamgani, van Rooij, Verduijn, et al., 2012; Beetz et al., 2014; Chung et al., 
2013; Eisbruch, Ten Haken, Kim, Marsh, & Ship, 1999; Nutting et al., 2001; Patel et al., 2014). 
Furthermore, dysgeusia, dysphagia, osteoradionecrosis, trismus, sticky saliva, mucositis, 
dermatitis, and fibrosis have also been reported following irradiation of the parotid gland and its 
surrounding tissues (Al-Mamgani, van Rooij, Sewnaik, et al., 2012; Al-Mamgani, van Rooij, 
Verduijn, et al., 2012; Chung et al., 2013; Nutting et al., 2001; Olivier, Brown, Stafford, Ansell, 
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& Martenson, 2004; Patel et al., 2014). Despite evidence of potential toxicities following RT of 
the parotid, there is a paucity of data documenting the exact nature and severity of such 
toxicities. Most studies have focused on the survival and recurrence rates of patients with parotid 
tumours post-surgery and/or RT (Al-Mamgani, van Rooij, Sewnaik, et al., 2012; Al-Mamgani, 
van Rooij, Verduijn, et al., 2012; Garden et al., 1997; Tanvetyanon et al., 2009). Of the studies 
reporting treatment related toxicities, the majority have discussed only the late toxicities with no 
report of the acute toxicities experienced by patients during and immediately after RT (Chung et 
al., 2013; Garden et al., 1997; Nutting et al., 2001; Sykes et al., 1995). Three known studies have 
explored the incidence of acute toxicities occurring within three months of RT (Chung et al., 
2013; Olivier et al., 2004; Patel et al., 2014), however, reports are largely limited to mucositis 
with incidence rates ranging widely (e.g. 3-39% incidence of ≥ grade 2 mucositis at 3 months 
post treatment) (Chung et al., 2013; Olivier et al., 2004; Patel et al., 2014).  
In the case of RT for cutaneous HNC, there are negligible reports in the literature of 
treatment related toxicities including dysphagia. The most comprehensive report of RT related 
toxicity for patients with cutaneous SCC was by Nottage and colleagues (Nottage et al., 2017), 
which reported 81% of patients experienced some degree of mucositis and 19% grade 3-4 
mucositis; whilst 66.7% of patients experienced some degree of dysphagia, xerostomia and 
salivary gland dysfunction and 4.7% grade 3 dysphagia and xerostomia. However, that study 
involved a cohort of patients with cutaneous SCC receiving definitive CRT limiting comparison 
with cohorts receiving RT alone.  
Due to limited evidence regarding the nature and severity of toxicities experienced by 
patients with parotid and cutaneous HNC, there is minimal information on which to base the 
development of optimal supportive care service models for these subgroups of patients during 
and acutely post RT. International HNC guidelines have highlighted the importance of SP in the 
management of swallowing, trismus and voice changes related to radiation treatment (National 
Comprehensive Cancer Network, 2016; National Institute for Health and Care Excellence, 2016). 
However, to date there is a lack of consensus regarding the nature of, timing and ideal patient 
groups to receive this support (Krisciunas et al., 2012; National Comprehensive Cancer Network, 
2016; National Institute for Health and Care Excellence, 2016). This has led to wide variation in 
the intensity and timing of SP care provided to HNC patients internationally. In the USA, a 
survey of usual practice found only 18.3% of respondents intervene proactively with HNC 
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patients (Krisciunas et al., 2012), whist in the UK, a web based survey found 69% were actively 
involved with patients during treatment (Roe et al., 2012). Of those, 26% saw patients weekly, 
3% fortnightly and 46% on request. In contrast, 57% of Australian cancer care centres reported 
seeing patients, often in conjunction with a dietitian, weekly during treatment as well as 
providing post-treatment management (Lawson et al., 2017; Lawson & Ward, 2014; Maclean et 
al., 2013; Wall, Cartmill, Ward, Hill, Isenring, & Porceddu, 2016). These services are generally 
provided as a “one-size-fits-all” service delivery model and do not account for the specific needs 
of subgroups of HNC patients. A recent evaluation of this type of weekly service delivery model 
(Wall, Cartmill, Ward, Hill, Isenring, & Porceddu, 2016) found 24% of appointments were 
judged unnecessary by both patient and clinic, with a further 18% proactively cancelled by 
clinicians, indicating there may be patients within the broader group of HNC that are less likely 
to develop treatment related side effects requiring SP support. Hence, the aim of this study was to 
describe the nature, severity and pattern of treatment related toxicities, including dysphagia in 
patients with parotid gland cancer and cutaneous HNC during and in the acute stage post RT. It 
was hypothesised that these subgroups of HNC patients would experience low levels of 
treatment related toxicity and dysphagia, presenting the potential for alternative SP service 
delivery models to be developed for these low risk groups, compared to those at high risk of 
treatment related impacts. 
4.3 Methods 
4.3.1 Participants 
Patients were prospectively recruited over 15 months between September 2013 and 
November 2014 from the combined head and neck clinic of a tertiary referral hospital which sees 
approximately 600 new cases of HNC annually. Patients were suitable for inclusion if they had at 
least one parotid gland affected by either primary, metastatic, or recurrent disease; or had a 
cutaneous HNC; and were planned to receive either definitive RT or surgery with PORT to a 
prescription dose of ³60Gy with or without concurrent chemotherapy. Patients were excluded if 
they: had a tumour site other than the parotid or a cutaneous HNC; were managed by surgery 
alone; or were planned for less than 60Gy. Ethical clearance was provided by the local Human 
Research Ethics Committee (approval number: HREC/13/QRBW/444). 
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4.3.2 Treatment Planning 
All patients were immobilized with custom thermoplastic shell and head and neck rest 
while the non-contrast CT simulation was performed with 2mm slice thickness. If prescribed, 
custom skin bolus of appropriate thickness was outlined by the radiation oncologist. Dose 
constraints guidelines for the following organs at risk (OARs) were routinely defined where 
possible: median dose for: 1) contralateral partoid mean <26 Gy, 2) constrictors <50Gy mean, 3) 
oral cavity, larynx, oesophagus, trachea mean <25Gy, and 4) spinal cord maximum point dose 
45Gy. 
4.3.3 Treatment Delivery 
All patients underwent either 3DCRT or H-IMRT. Consensus decision regarding which 
patients undergo H-IMRT as opposed to 3DCRT was made at the institutional triage meeting. 
3DCRT treatments were planned in Oncentra Masterplan (Elekta, Stockholm, Sweden) using 
either 6-9MeV electrons alone at a set angle, 6-10MV photons, or a combination of photon 
treatment with an electron boost, and delivered on a Varian Clinac iX linear accelerator (Varian 
Medical Systems, Palo Alto, CA, USA).  H-IMRT was planned using a 6MV photon 
simultaneous integrated boost technique in the Hi-Art Planning Station (TomoTherapy Inc) and 
delivered on TomoTherapy (TomoTherapy Inc., Madison, WI, USA). 
 Patients receiving definitive RT received a total dose of 70Gy over 7 weeks to gross 
disease with a lower elective dose to ipsilateral neck, while patients receiving adjuvant PORT 
received 60-66Gy over 6 to 6 ½ weeks to the parotid bed with a lower elective dose to ipsilateral 
neck. Elective doses were a minimum of 50Gy equivalent dose in 2Gy fractions (assuming α/β 
ratio of 2).  All high dose volumes were administered in 2Gy per fraction, 5 fractions per week. 
In the 5 cases included in the cohort where additional chemotherapy was provided, the 
concurrent chemotherapy regime, comprised of either high dose cisplatin 100mg/m2 IV 
q3weekly (weeks 1, 4 +/- 7), weekly cisplatin 40mg/m2 IV, or carboplatin AUC 2mg/ml (Area 
Under the Curve, using the Calvert formula) for the duration of radiotherapy. 
4.3.4 Procedure 
Data was collected prospectively by the treating speech pathologist during routine joint 
SP and dietetic clinics at the following time points: (1) baseline assessment (week 1 of treatment 
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or, if unavailable, at pre-treatment combined head and neck clinic); (2) weekly over weeks 2 to 
6/7 during treatment; and (3) at 2, 4, and 12 weeks post-treatment. All HNC patients routinely 
attended an allied health education lecture in week 1 of treatment. At each time point, the 
presence of dysphagia and associated acute treatment related toxicities (dysphagia, dysguesia, 
xerostomia, oral mucositis, pharyngeal mucositis, salivary duct inflammation (thick saliva) and 
nausea) were rated using the National Cancer Institute CTCAE v4.0 (National Cancer Institute, 
2009). The CTCAE was developed with international collaboration and consensus of the 
oncology research community (Trotti, Colevas, et al., 2003), it is the standard approach to 
adverse event reporting in cancer trials and is a widely used outcome measure in HNC. Version 3 
has been validated in the HNC population (Gluck et al., 2008; Palazzi et al., 2008). The current 
version (v4.0) harmonised its terminology with the Medical Dictionary for Medical Affairs and 
has been reported to have some advantages over version 3 with regards to delegating quality of 
life (Liu, Zhu, & Guan, 2012). Version 4 was chosen for this study as it is the current version and 
the descriptors use a functional basis making it more amenable to speech pathologist rating. The 
texture of oral intake tolerated by patients was recorded using the National Dysphagia Diet 
descriptors (Dietitians Association of Australia & Speech Pathology Association of Australia, 
2007) for foods (unmodified/regular, soft, minced and moist, puree) with the addition of two diet 
categories, liquids only and NB) and fluid consistency (unmodified/regular, mildly thick, 
moderately thick, extremely thick) as this is the national standard for documenting oral intake in 
the study country. In addition, patients’ overall functional diet was coded using the FOIS (Crary 
et al., 2005). The FOIS is a 7 level scale where 1 represents complete enteral nutrition, 2 and 3 
represent some dependence on enteral nutrition with varied levels of oral intake, 4,5 and 6 
indicate modified oral intake, and Level 7 represents a normal diet and fluids. Though initially 
validated in the stroke population, the FOIS is increasingly used in HNC studies investigating 
dysphagia allowing for comparison across studies (Shukla et al., 2017). Baseline dysphagia was 
defined as a FOIS score £5 at week 1 of treatment or if unavailable, at combined head and neck 
clinic. 
4.3.5 Statistical Analyses 
Descriptive analyses in the form of mean (SD) or number (percent) were used to 
determine patient demographics, baseline characteristics, maximal incidence data summarised 
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across all time points, and then at each individual time point for all outcomes monitored in the 
study. The temporal patterns of symptom presentation, peak and recovery, were explored by re-
classifying each outcome into “need for supportive care” or “no need for supportive care” as per 
prior research (Moroney et al., 2017 = Chapter 2) and analysed with descriptive statistics at each 
time point. “Need for supportive care” was defined as indicating a need for SP intervention with 
the following criteria: CTCAE toxicity grade ≥2, FOIS ≤5 and diet/fluid descriptor other than 
soft or regular. All analyses were performed in IBM SPSS Statistics for Windows, version 22.0 
(2013, IBM Corp., Armonk, NY., USA). 
4.4 Results 
4.4.1 Patient Characteristics 
A total of 32 patients with parotid disease and 36 cutaneous HNC patients met the 
inclusion criteria during the 15 month study period. Patients in both groups were predominantly 
male with a mean age of 72 years (SD 11.4) and 69.4 years (SD 13) respectively. Distributions of 
TNM classification and histopathology for both groups are found in Table 4.1. Patients in the 
parotid group largely presented with metastatic or recurrent disease and received adjuvant 
treatment with only 7 (22%) patients receiving 7 weeks of treatment (66-70Gy). Twenty patients 
(63%) received 3DCRT, 12 patients (38%) received H-IMRT, and 1 patient (3%) received 
concurrent chemotherapy. In the cutaneous HNC group patients largely presented with T0, T1 or 
T3 disease and received adjuvant treatment with 12 patients (33%) receiving 7 weeks of 
treatment (66-70Gy). Nine patients (25%) received 3DCRT, 24 patients (67%) received H-IMRT, 
and 4 patients (11%) received concurrent chemotherapy. No patient in either group presented 
with baseline dysphagia or was recommended to receive a proactive gastrostomy as per the study 
institutions swallowing and nutrition risk guidelines (Brown et al., 2013). 
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Table 4.1 
Patient Demographics 
Parameters 
No. of patients (%) 
Parotid 
(n = 32) 
Cutaneous HNC 
(n = 36) 
Mean age, y (SD) 72 (11.4) 69 (13.0) 
Gender   
Female 9 (28.1) 6 (16.7) 
Male 23 (71.9) 30 (83.3) 
Type   
Primary 7 (21.9) 23 (63.9) 
Metastatic/recurrent 25 (78.1) 13 (36.1) 
T Classification   
T0 21 (65.6) 13 (36.1) 
T1 2 (6.3) 13 (36.1) 
T2 7 (21.9) 4 (11.1) 
T3 2 (6.3) 9 (25.0) 
T4 0 (0) 2 (5.6) 
N Classification   
N0 14 (43.7) 26 (72.2) 
N1 4 (12.5) 4 (11.1) 
N2 13 (40.6) 6 (16.7) 
N3 1 (3.1) 0 (0.0) 
M Classification   
M0 32 (100) 36 (100.0) 
Pathology   
SCC 20 (62.5) 25 (69.4) 
Adenocarcinoma 3 (9.4) N/A 
Pleomorphic adenoma 2 (6.3) N/A 
Melanoma N/A 3 (8.3) 
BCC N/A 7 (19.4) 
Othera 8 (25) 1 (2.9) 
Radiation Type   
Helical IMRT 12 (37.5) 24 (66.7) 
3DCRT 20 (62.5) 9 (25) 
Electrons N/A 3 (8.3) 
Treatment   
Adjuvant 25 (78.1) 31 (86.1) 
Definitive 7 (21.9) 5 (13.9) 
Scheduled dose   
60Gy 20 (62.5) 19 (52.8) 
63Gy 4 (12.5) 3 (8.3) 
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64Gy 1 (3.1) 2 (5.6) 
66-70Gy 7 (21.9) 12 (33.3) 
Chemotherapy   
Yes 1 (3.1) 4 (11.1) 
Baseline Dysphagia 0 (0) n = 31 0 (0) n = 28 
Note: SCC: Squamous Cell Carcinoma, a Includes in the parotid group: adenoid cystic, anaplastic, 
hydroadenocarcinoma, merkle cell, mucoepidermoid and Skin group: haemangiosarcoma 
 
 
4.4.2 Maximum Incidence of Treatment-Related Toxicities and Dysphagia 
The maximum incidence of all the CTCAE v4.0 outcomes monitored in the study for 
both groups can be found in Table 4.2. In the parotid group the majority of patients (75-84%) 
experienced no (grade 0) or grade 1 oral mucositis, pharyngeal mucositis, dysphagia and nausea 
over the data collection period. Dysguesia was the most frequently reported grade 2 toxicity 
(63%), followed by xerostomia (38%). There was minimal observed grade 3 toxicity in the 
cohort with only 1 patient (3%) experiencing grade 3 dysphagia. A similar pattern was found in 
the cutaneous HNC group with 72-97% experiencing no or grade 1 oral mucositis, pharyngeal 
mucositis, thick saliva, dysphagia or nausea. More cutaneous HNC patients experienced no 
xerostomia and dysguesia (14% and 28% respectively) with less experiencing grade 1 
xerostomia and dysguesia (36% and 14%). Similarly, dysguesia was the most frequently 
occurring grade 2 toxicity (58%), followed by xerostomia (50%), thick saliva (25%), and 
dysphagia (22%). There was a slightly higher incidence of grade 3 toxicity in the cutaneous HNC 
group with 2 patients (6%) experiencing grade 3 dysphagia, and 3% oral mucositis, pharyngeal 
mucositis, and thick saliva.    
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Table 4.2 
Maximal Incidence for the 7 CTCAE Acute Toxicities 
Toxicity 
Parotid (n=32) 
No. of patients (%) 
Cutaneous HNC (n=36) 
No. of patients (%) 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 0 Grade 1 Grade 2 Grade 3 
Xerostomia 2 (6.3) 18 (56.3) 12 (37.5) 0 (0) 5 (13.9) 13 (36.1) 18 (50) 0 (0) 
Dysguesia 6 (18.8) 6 (18.8) 20 (62.5) N/A 10 (27.8) 5 (13.9) 21 (58.3) N/A 
Oral Mucositis 14 (43.8) 11 (34.4) 6 (16.7) 0 (0) 19 (52.8) 10 (27.8) 6 (16.7) 1 (2.8) 
Pharyngeal 
Mucositis 
20 (62.5) 5 (15.6) 7 (21.9) 0 (0) 30 (83.3) 3 (8.3) 2 (5.6) 1 (2.8) 
Thick Saliva 11 (34.4) 15 (46.9) 6 (18.8) 0 (0) 14 (38.9) 12 (33.3) 9 (25) 1 (2.8) 
Dysphagia 14 (43.8) 9 (28.1) 8 (25) 1 (3.1) 16 (44.4) 10 (27.8) 8 (22.2) 2 (5.6) 
Nausea 20 (62.5) 7 (21.9) 5 (15.6) 0 (0) 28 (77.8) 7 (19.4) 1 (2.8) 0 (0) 
Note: CTCAE: Common Toxicity Criteria for Adverse Events version 4 
 
 
Most severe restriction to diet (food/fluid) levels and FOIS over the acute period is 
represented in Table 4.3. Regular and soft diet was the most frequently occurring diet in both 
groups, with 22% of parotid and 30% of cutaneous HNC patients requiring a modified diet. Two 
patients in the parotid group required a liquid only diet for short periods due to pain whilst in the 
cutaneous HNC group 4 patients required a liquid only diet due to dysguesia affecting appetite. 
One patient in the cutaneous HNC group receiving concurrent high dose cisplatin required 
mildly thick fluids from week 4-6 of treatment but returned to thin fluids from week 7 onwards. 
No patient in the parotid group required modified fluids.   
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Table 4.3 
Maximum Incidence of Diet, Fluids and FOIS 
Parameter Categories 
Parotid (n=32) 
No. of patients 
(%) 
Cutaneous HNC 
(n=36) 
No. of patients (%) 
Diet Regular 14 (43.8) 16 (44.4) 
 Soft 11 (34.4) 9 (25.0) 
 Minced 3 (9.4) 4 (11.1) 
 Puree 2 (6.3) 3 (8.3) 
 Liquids 
only 
2 (6.3) 4 (11.1) 
 NBM 0 (0) 0 (0) 
Fluids Thin 32 (100) 35 (97.2) 
 
Mildly 
Thick 
0 (0) 1 (2.8) 
FOIS 
(minimum) 
Level 7 14 (43.8) 16 (44.4) 
 Level 6 11 (34.4) 10 (27.8) 
 
Level 5 5 (15.6) 6 (16.7) 
 
Level 4 2 (6.3) 4 (11.1%) 
 Level 3 0 (0) 0 (0) 
 Level 2 0 (0) 0 (0) 
  Level 1 0 (0) 0 (0) 
Note: FOIS: Functional Oral Intake Scale 
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4.4.3 Patterns of Treatment-related Toxicities and Dysphagia Over Time 
The pattern of treatment related toxicity and dysphagia requiring support over time is 
represented for each group in Figure 4.1 and Fig. 4.2 respectively. Excluding xerostomia and 
dysguesia, less than 10% of patients presented with toxicity requiring support until week 5 of 
treatment, where it was still 20% or less for both cohorts. Symptoms, if present, peaked in week 
5 or 6 of treatment for those with parotid tumours and week 6 for those with cutaneous HNC. 
Post-treatment recovery was rapid with no more than 8% of patients in the parotid group and 
14% of patients in the cutaneous HNC group experiencing any toxicity other than xerostomia or 
dysguesia at 2 weeks post treatment. Weekly incidence data tables can be found in 
supplementary materials (Appendix H). 
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Figure 4.1 Symptoms requiring support at weeks 1-6 and 2, 4, 12 post-treatment for patients 
with Parotid tumours. *Week 7 data excluded as only 7 patients received 7 weeks of treatment 
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Figure 4.2 Symptoms requiring support at weeks 1-6 and 2, 4, 12 post-treatment for patients with 
cutaneous HNC. *Week 7 data excluded as only 12 patients received 7 weeks of treatment   
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4.5 Discussion 
This study provides descriptive information regarding the acute toxicity and dysphagia 
outcomes for patients with parotid and cutaneous HNC receiving RT which can be used to 
inform the design of future SP supportive care services for these patient groups. Overall, results 
indicate that both subgroups of patients present with low levels of treatment related toxicity. As 
such, current weekly SP service delivery models being implemented for other tumour groups that 
experience higher levels of toxicities, such as oropharyngeal cancer, would not appear to be 
appropriate. 
Within both the parotid and the cutaneous HNC subgroups, the most frequently occurring 
toxicities, with grade 2 severities, were dysguesia and xerostomia. This result is unsurprising 
given the RT fields for parotid tumours and many cutaneous HNCs involve irradiation of part of 
the buccal mucosa, palate, lateral tongue and floor of mouth, which may affect minor salivary 
glands and areas of the tongue responsible for taste production (Beetz et al., 2014; Tribius et al., 
2013). Particularly for those patients within the parotid group where RT occurs following 
surgical removal of a major salivary gland, xerostomia is a recognised long-term quality of life 
issue (Al-Mamgani, van Rooij, Verduijn, et al., 2012).  
Although both dysguesia and xerostomia were the most frequently occurring grade 2 
symptoms relative to the other parameters measured, the rates of acute toxicity of both were low 
in the two subgroups, consistent with the evidence reported to date. Within the parotid group, 
rates of grade 2 mucositis (15-23%) reported by Olivier et al (Olivier et al., 2004) and Spiro et al 
(Spiro, Wang, & Montgomery, 1993) are comparable with the 17% and 22% for oral and 
pharyngeal mucositis observed in this study. Other studies have reported even lower incidence 
rates, reporting only 3-5% grade 2 mucositis in their cohorts of the parotid patients (Chung et al., 
2013; Patel et al., 2014). Previously reported rates of acute xerostomia are also lower than those 
found in the current study, with prior studies reporting grade 2 xerostomia ranging from 5-22% 
(Chung et al., 2013; Patel et al., 2014; Spiro et al., 1993), compared to the 38% in this cohort. 
Rates of reported dysphagia have had limited discussion in the parotid literature to date. Chung 
et al (Chung et al., 2013) reported an incidence of grade 2 dysphagia at 3% (1 patient) which is 
once again lower than the 25% observed in the current cohort. Although both the prior studies 
and the current study suggest low rates of grade 2 toxicities, the higher incidence rates observed 
 122 
in the current study may simply reflect the different rating tools used (eg., RTOG and CTCAE v 
2.0), population differences, and the difference between retrospective versus prospective studies. 
It is well accepted that there is potential for underreporting of symptoms when relying on 
retrospective data collection methods. The discrepancies may also reflect differences in the rater 
(medical officer versus speech pathologist) conducting the measures between the current and 
prior studies.   
To the authors knowledge, Nottage et al. (Nottage et al., 2017) is the only prior study 
reporting acute toxicity outcomes for patients with cutaneous HNC receiving RT. Although 
conducted at the same institution as the current study, the entire cohort reported by Nottage et al 
received definitive concurrent chemotherapy. Concurrent chemotherapy is known to influence 
toxicity profiles (Moroney et al., 2017 = Chapter 2; Russi et al., 2012) and increase symptoms 
such as mucositis, which was observed in 81% of their cohort. As only 4 patients in the current 
study’s cutaneous HNC group received concurrent chemotherapy, there is little value in direct 
comparison between the two groups. However, greater incidence of grade 2 and 3 toxicity was 
observed in the 4 patients who received concurrent chemotherapy, indicating more significant 
issues can be expected in cutaneous HNC patients who receive additional systemic therapy.  
Details of the pattern of acute symptom onset, peak and recovery revealed the onset of 
symptoms requiring SP support occurred in weeks 3-4, with a slow increase in toxicities reaching 
peak incidence in the final week of treatment. Notably there was a steep increase in the incidence 
of dysguesia from weeks 2-4 of treatment for the parotid group and from weeks 3-4 for the 
cutaneous HNC group. Toxicities rapidly improved following treatment. For the parotid group at 
4 weeks post treatment, no patients required support for nausea, oral or pharyngeal mucositis, 
thick saliva or dysphagia. The only persistent toxicities at 12 weeks post treatment were grade 2 
dysguesia and dysphagia (6%) and grade 2 xerostomia (22%). Whilst rapid improvement post-
treatment was also observed in the cutaneous HNC group, a higher number of patients with 
dysphagia required support at 4 (11%) and 12 (9%) weeks post-treatment than in the parotid 
group. These patterns of symptom profile are similar to that found by the current study’s team in 
a larger cohort of mixed site HNC patients receiving H-IMRT with and without concurrent 
chemotherapy and a cohort of patients with oropharyngeal SCC receiving H-IMRT with 
concurrent chemotherapy (Moroney, Helios, Ward, Crombie, Pelecanos, et al., 2018 = Chapter 3; 
Moroney et al., 2017 = Chapter 2). Whilst the pattern is similar, the severity and incidence of 
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toxicities requiring SP support was far lower in the current study’s groups where the impact on 
swallowing function was minimal and largely transient, and no patient required alternative 
feeding. 
The low number of patients who experienced toxicities requiring support in the current 
data, confirms these subgroups of patients represent groups who may not require routine SP 
management in conjunction with their RT. Alternative service delivery models utilising screening 
or surveillance may better suit the needs of these patients to minimise unnecessary appointments 
for patients whilst allowing for re-allocation of services to patients at higher risk of dysphagia 
and related toxicities requiring support. Hence, the results of the current study fill a gap in the 
literature documenting the supportive needs of patients with parotid tumours and cutaneous HNC 
and can contribute to the evidence base required to develop more specific evidence based 
guidelines for SP support for HNC patients. 
While this is the first known prospective study reporting the incidence, severity, and 
pattern of dysphagia as well as a range of treatment-related toxicities following RT in patients 
with parotid tumours and cutaneous HNC the authors acknowledge several limitations. A larger 
cohort of patients would have strengthened the results, whilst the addition of a patient-reported 
quality of life measure and a longer data collection period post treatment completion would have 
provided a more comprehensive evaluation. An instrumental swallow assessment would have 
provided a more objective assessment of dysphagia, however, it is not routine practice at the 
study institution to conduct an instrumental swallow assessment unless clinically indicated. 
4.6 Conclusion 
This study confirms there is a low incidence of acute toxicities including dysphagia 
requiring SP intervention amongst patients with tumours of the parotid or cutaneous HNC 
undergoing RT. These subgroups of HNC patients are less likely to require regular weekly SP 
support during treatment and could be considered for an alternative service delivery model. 
These results have implications for SP service delivery planning and can inform service delivery 
guidelines. Development and evaluation of alternative service delivery models that are better 
suited to identify low incidence issues is required for these subgroups of low risk HNC patients.  
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The results of Chapter 4 confirmed that patients with tumours of the parotid and 
cutaneous HNC experience low levels of dysphagia and related toxicity as a consequence of RT. 
The results from that study provided evidence to support that there is a subgroup of patients with 
HNC who experience minimal treatment related toxicity (including dysphagia) and are thus 
unlikely to require intensive SP support. Chapter 4 also revealed that if this subgroup of patients 
was to experience difficulty, this was typically in week 5-7 of treatment. Thus, these results 
provide important treatment specific information for this subgroup of HNC patients in order to 
inform patient centred care. As discussed in Chapter 1 and 4, there is an absence of clinical 
guidelines with specific recommendations to inform the intensity and timing of SP supportive 
care for patients with HNC, in particular the needs of patients with tumours of the parotid, 
salivary gland, thyroid, and cutaneous HNC.  
As discussed in Chapter 1, managing all patients with HNC using the same service model 
can result in potential over-servicing of some patient populations. As such, a model of care 
whereby all patients, regardless of tumour site, are managed within a “one-size-fits-all” weekly 
joint SP and dietetic service delivery model may not be the most efficient use of clinical 
resources. The results of Chapter 4 confirm this finding, providing evidence supporting that 
patients with parotid tumours and cutaneous HNC constitute a subgroup of HNC who can be 
considered “low risk” for developing dysphagia and related treatment toxicities. As such they 
may benefit from an alternative service delivery model, where SP appointments are only 
scheduled when required, and benefits for both the patient and the health care service could be 
realised.  
Therefore, based on the results of Chapter 4, in Chapter 5 the outcomes of an alternative 
interdisciplinary service delivery model, developed in conjunction with the dietetics service is 
implemented and evaluated. Titled “The RBWH head and neck cancer low risk speech pathology 
pathway”, suitable patients are primarily managed by dietetics utilising dysphagia screening with 
access to SP when required. Chapter 5 presents the prospective evaluation of the implementation, 
clinical safety, and service efficiency of this new service delivery model, including the associated 
cost analysis. 
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The following manuscript, entitled “Evaluation of a speech pathology service delivery 
model for patients at low dysphagia risk during radiotherapy for HNC” was published in the 
journal Supportive Care in Cancer in 2019. It is inserted here as Chapter 5 of this thesis as 
published, with the exception of the inclusion of Tables 5.2 and 5.3 which were published under 
‘supplementary materials’ for the journal yet have been provided here in the thesis. Formatting 
changes that have been made to align with style guidelines (6th edition) as set out by the 
American Psychological Association for consistency throughout the thesis. For references to the 
manuscripts published by the PhD candidate during the candidature, these have been clarified by 
the following notation (e.g. Moroney et al., 2018 = Chapter 4). Additionally, all abbreviations 
defined previously in the thesis are listed on page xxv and not re-defined in this chapter. All 
references are listed in a single reference list on pages 162 -192 at the end of the thesis. 
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5.1 Abstract 
There are no evidence-based guidelines informing which patients with HNC require regular SP 
support during RT. Hence, some services use a “one-size-fits-all” model, potentially over-
servicing those patients at low risk for dysphagia. This study evaluated the clinical safety and 
efficiency of an interdisciplinary service model for patients identified prospectively as “low-risk” 
for dysphagia during RT. A prospective cohort of 65 patients with HNCs of the skin, thyroid, 
parotid, nose and salivary glands, receiving curative RT, were managed on a low-risk pathway. 
Patients with baseline dysphagia (FOIS £5) were excluded. The model involved dietitians 
conducting dysphagia screening at weeks 3, 5, and 6/7 within scheduled appointments. Patients 
at risk of dysphagia were referred to SP for assessment, then management if required. To validate 
the model, SP assessed swallow status/toxicities at week 5/6/7 during RT and confirmed 
dysphagia status at weeks 2 and 6 post RT. Most (89.3%) patients did not require dysphagia 
support from SP services. Of the 18 patients identified on screening, only 7 (10.7%) had 
sufficient issues to return to SP care. Week 5/6/7 SP review confirmed low levels of toxicity. No 
post-treatment dysphagia was observed. There was an incremental benefit of A$15.02 for SP 
staff costs and a recovery of 5.31 appointments per patient. The pathway is a safe and effective 
service model to manage patients with HNC at low risk for dysphagia during RT, avoiding 
unnecessary SP appointments for the patient and service. 
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5.2 Introduction 
Existing international HNC guidelines recognise speech pathologists as integral members 
of the multidisciplinary HNC team (Cancer Council Victoria and Department of Health and 
Human Services Victoria, 2015; National Comprehensive Cancer Network, 2016; National 
Institute for Health and Care Excellence, 2016), providing pre-treatment assessment and 
intervention, reviews during RT and ongoing post-treatment support and rehabilitation as 
required for dysphagia, trismus and voice disorders. However, there are currently no published 
SP specific service delivery guidelines for patients with HNC, detailing which HNC patient 
groups require support, and the nature, timing, and frequency of support required. Whilst 
guidelines such as those from the Clinical Oncology Society of Australia (Findlay et al., 2011; 
Isenring et al., 2013) recommend weekly dietetic review during RT and weekly to fortnightly 
reviews post-treatment, there are no SP recommendations. Other guidelines give only general SP 
service recommendations (National Comprehensive Cancer Network, 2016; National Institute for 
Health and Care Excellence, 2016). Similarly, Cancer Council Australia (Cancer Council 
Victoria and Department of Health and Human Services Victoria, 2015) recommends that 
patients have access to speech pathologists for supportive care before, during, and after RT for 
management of communication and swallowing impairments, but does not specify intensity or 
priority patients. Furthermore, while extensive research has been conducted exploring early and 
late treatment toxicities in mixed heterogeneous cohorts of HNC patients, there is limited 
evidence documenting the differential level of support needs of patients with HNC across 
different tumour sites, particularly those sites outside the oral cavity, oropharynx, hypopharynx, 
larynx, and nasopharynx. 
The lack of clear evidence of differential patterns of need, and lack of published 
guidelines for care, has contributed to differences in service delivery models internationally, with 
wide variations noted in the intensity and timing of SP care provided to HNC patients 
(Krisciunas et al., 2012; Roe et al., 2012). In Australia, 57% of cancer care centres reported 
seeing patients weekly during RT and providing post-treatment management, frequently in 
conjunction with a dietitian (Lawson et al., 2013; Lawson & Ward, 2014; Maclean et al., 2013; 
Wall, Cartmill, Ward, Hill, Isenring, & Porceddu, 2016). This weekly service delivery model is 
currently used at the study institution for all patients with HNC undergoing RT with or without 
chemotherapy. However, Wall and colleagues evaluated this type of weekly service delivery 
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model (Wall, Cartmill, Ward, Hill, Isenring, & Porceddu, 2016), and found 24% of appointments 
were judged unnecessary by both patient and clinician, with a further 18% proactively cancelled 
by the clinician. These results indicate a “one-size-fits-all” service delivery model may not 
adequately cater for the specific needs of all patients with HNC.  
We recently reported the outcomes of 36 patients with cutaneous HNC and 32 patients 
with parotid tumours undergoing H-IMRT and 3DCRT, where more than 75% of patients 
experienced nil or grade 1 toxicities and minimal (<10%) grade 3 dysphagia (Moroney, Helios, 
Ward, Crombie, Burns, et al., 2018 = Chapter 4). If present, dysphagia symptoms did not require 
SP support until week 5 of treatment with rapid recovery post-treatment. These results, and those 
reported by Wall and colleagues (Wall, Cartmill, Ward, Hill, Isenring, & Porceddu, 2016) 
provide evidence suggesting there are subgroups of patients with HNC who are less likely to 
develop treatment related side effects requiring SP support. Ongoing dietetic support is 
recommended due to malnutrition risk and weight loss associated with ageing and related co-
morbidities, irrespective of lower levels of treatment related toxicity (Blake et al., Unpublished 
Results). However, for SP alternative streamlined service delivery models are required to provide 
individualised care to optimise support for this subgroup of patients. 
Patient screening methods have recently been reported to provide opportunities to better 
direct supportive cares and deliver service benefits (Wall, Cartmill, Ward, Hill, Isenring, Byrnes, 
et al., 2016). Incorporating screening into SP treatment pathways may be one way to assist HNC 
centres to identify issues and appropriately prioritise services for patients at low risk of negative 
dysphagia outcomes during and post RT. Implementing clinical pathways has been associated 
with reduced in-hospital complications, improved documentation, service and resource 
efficiencies, reduced healthcare costs, and increased staff satisfaction (Kwon et al., 2018; Lawal 
et al., 2016; Rotter et al., 2012). Hence, the aim of this study was to evaluate a new clinical 
pathway, incorporating dysphagia screening via an interdisciplinary service model, to help 
ensure patients with HNC who are at low risk of dysphagia during RT, receive appropriate levels 
of SP support. The Royal Brisbane and Women’s Hospital Head and Neck Cancer Low Risk 
Speech Pathology Pathway (The Pathway) was developed as an alternative service delivery 
model for patients with HNC subtypes identified by our prior research (Moroney, Helios, Ward, 
Crombie, Burns, et al., 2018 = Chapter 4) to be at low risk of developing dysphagia. Secondary 
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aims were to determine SP service efficiencies and cost benefits as well as patient and clinician 
perceptions of need for SP review when managed within The Pathway. 
5.3 Methods 
5.3.1 Participants 
Participants were prospectively recruited over a 16-month period, between March 2017 
and June 2018 from the multidisciplinary head and neck cancer clinic of a tertiary referral 
hospital. Patients were suitable for inclusion in The Pathway if they 1) were considered at low 
risk for dysphagia (Moroney, Helios, Ward, Crombie, Burns, et al., 2018 = Chapter 4) defined as 
having tumour sites of the skin (cutaneous), thyroid, parotid, salivary gland; lymphoma; or any 
head and neck tumour site receiving <60Gy and 2) were planned for curative intent definitive RT 
or PORT. Patients were excluded from The Pathway if they were “high risk” defined as having 
tumour sites outside the “low risk” group, were planned for chemotherapy, and/or presented with 
baseline dysphagia defined as a FOIS (Crary et al., 2005) of £5 as assessed by SP at the initial 
multidisciplinary HNC clinic appointment where all new HNC patients are assessed by the MDT 
for diagnosis and treatment planning, including baseline dysphagia assessment by SP. The FOIS 
was determined through patient report and interview with SP. Any patients managed by SP as an 
inpatient or outpatient following HNC surgery who were found to have a FOIS of £5 prior to 
commencing PORT were also excluded as this was considered their new baseline dysphagia 
status. High risk patients attended the usual care joint SP and dietetics high risk clinic for weekly 
review, referred to as the joint SP and dietetics clinic. For the purposes of the service and cost 
comparison, a historical control group was used under the traditional model of weekly joint SP 
and dietetics reviews within the same clinical setting reporting the same dysphagia outcomes 
(Moroney et al., 2017 = Chapter 2). Ethical clearance provided by the Chairperson of the local 
Human Research Ethics Committee for monitoring by the local Safety and Quality Unit as a 
“Quality Assurance Activity” (HREC/17/QRBW/73). 
5.3.2 Procedure 
As per Figure 5.1, patients were identified by the radiation therapy cancer care co-
ordinator using the inclusion/exclusion criteria. Eligibility was confirmed by the study SP, using 
baseline FOIS, tumour site and treatment plan. Pathway patients attended an allied health HNC 
education lecture in week 1 along with all patients with HNC undergoing RT, where information 
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on anticipated treatment side effects, possible management options and the range of health 
professionals available for support are outlined by members of the MDT (SP, dietetics, 
physiotherapy, occupational therapy, dental, social work, psychology). Patients then attended the 
Diet Only Head and Neck Clinic in weeks 3, 5, 6 or 7 of RT. At the week 3 appointment, 
dysphagia screening was completed by the dietitian using the 1) Dysphagia Screening Tool 
(DST; containing dysphagia risk criteria and the water swallow test) (Cichero, Heaton, & 
Bassett, 2009) to screen for baseline aspiration risk and 2) the Eating Assessment Tool – 10 
(EAT-10) (Belafsky et al., 2008) which has been validated with a threshold score ³3 to trigger 
referral to SP. The EAT-10 was also completed at subsequent reviews (weeks 5,6/7) for ongoing 
monitoring and screening. If a patient was identified as at risk for dysphagia through failing the 
DST at week 3 or scoring an EAT-10 ³3 at any timepoint, a referral to SP was initiated and a 
clinical swallow examination (CSE) was conducted by the speech pathologist within 48 hours. 
Prior to implementation, the dietitian received training from the speech pathologist on the 
administration of both the DST and EAT-10. Patients received the EAT-10 upon check in to 
complete in the waiting room prior to each dietetic review. 
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Figure 5.1. The RBWH Head and Neck Cancer Low Risk Speech Pathology Pathway. SP: 
speech pathologist, HNC: head and neck cancer, Diet: Dietitian, EAT-10: Eating Assessment 
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Tool 10, RT: radiation treatment, FOIS: functional oral intake scale, CTCAE v4: common 
terminology criteria for adverse events version 4, RONC: radiation oncologist 
 
 
To evaluate the validity of The Pathway, all patients were reviewed by a speech 
pathologist at week 5, 6 or 7 (5/6/7) of RT to ensure they were not at risk of dysphagia when 
toxicity has been found to peak (Moroney, Helios, Ward, Crombie, Burns, et al., 2018 = Chapter 
4). The following data was collected at this SP review: 1) CSE outcome of ‘dysphagia risk’ or 
‘no dysphagia risk’; 2) toxicities scored by the CTCAE Version 4.0 (National Cancer Institute, 
2009) (xerostomia, dysguesia, thick saliva, oral mucositis, pharyngeal mucositis, and dysphagia); 
3) a functional measure of dysphagia using the FOIS (Crary et al., 2005) The FOIS is a 7-level 
scale where 7 represents a normal diet, 6, 5, and 4 indicate modified oral intake of varying levels, 
3 and 2 reflect consistent and inconsistent oral intake with enteral nutrition and 1 represents 
complete enteral nutrition. The FOIS was chosen as it is quick, it is used clinically across the 
study hospital and state thus allowing efficient clinical handover between clinics and sites if 
required, and is increasingly used in HNC studies investigating dysphagia, including those 
conducted by the research team allowing for comparison across studies (Moroney, Helios, Ward, 
Crombie, Burns, et al., 2018 = Chapter 4; Moroney, Helios, Ward, Crombie, Pelecanos, et al., 
2018 = Chapter 3; Moroney et al., 2017 = Chapter 2; Shukla et al., 2017); 4) diet and fluid 
texture; and 5) both the speech pathologist and patient reported whether they felt a SP review 
was required during their treatment. At this timepoint, a primary endpoint of “<10% patients 
identified by the speech pathologist to have dysphagia requiring SP management” was set by the 
authors as the study criteria to validate The Pathway’s dysphagia screening was correctly 
identifying any patients in need.  
If dysphagia risk was confirmed by the speech pathologist at an unscheduled review or 
the week 5/6/7 review, the patient returned to the joint SP and dietetic clinic for weekly review. 
Following completion of RT, any development of acute dysphagia was monitored by the speech 
pathologist via information collected during the dietitian’s phone review at 2 and 6 weeks post-
treatment, including reports of dysphagia or related symptoms, current diet and whether this was 
the patients baseline diet. Any report of dysphagia or change to eating at the radiation 
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oncologist’s review at 6 weeks post-treatment was also monitored. All clinical information was 
collected prospectively and entered into the patient’s electronic medical record.  
Number of appointments attended, cancelled and failed to attend was collected to 
examine service efficiency. All resource use was converted to costs including overheads in 
Australian dollars at a mid-level clinician weighted rate of $49.39/hour and senior clinician 
weighted rate of $63.61/hour. 
5.3.3 Statistical Methods 
Descriptive analyses were used to determine patient demographics and service outcomes, 
including the service validation primary endpoint (“<10% patients identified by the speech 
pathologist to have dysphagia requiring SP management”) and toxicity outcomes reported at the 
week 5/6/7 review. Service characteristics were described in the type, number and duration (in 
minutes) of sessions attended for both SP and dietetics and compared to unpublished service data 
from the historical control group (Moroney et al., 2017 = Chapter 2), to determine average 
numbers of appointments saved and time benefits of The Pathway. Number (%) and mean (SD) 
were reported as appropriate. Cost analysis used a decision tree with 95% confidence intervals 
comparing The Pathway dysphagia outcomes to the traditional model, and the high risk group by 
applying the high and low risk triage criteria to the published historical control group (Moroney 
et al., 2017 = Chapter 2). A FOIS £5 was determined to indicate a “swallowing problem” and a 
need for SP management. For transferability to other settings, 1-way, 2-way and multi-way 
sensitivity analysis was conducted by altering the probability at various steps of the decision tree 
to the high or low confidence interval to test the variation in proportions of people suitable for 
screening into The Pathway and other characteristics of the service. Cost sensitivity was also 
completed to determine differences associated with running The Pathway with higher level staff. 
All analyses were completed by the lead author (L.M) and study health economist (T.C). 
5.4 Results 
5.4.1 Participants 
Over the 16-month recruitment period 127 patients were triaged to The Pathway by the 
radiation therapy care co-ordinator. Figure 5.2 details the cohort inclusion and exclusion. Of 
note, 35 patients were excluded from The Pathway and returned to the joint SP and dietetic clinic 
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following triage by the study speech pathologist as they did not meet inclusion criteria. Ninety-
two patients remained suitable for The Pathway, however, a further two patients were excluded 
and returned to the joint SP and dietetic clinic after dysphagia was identified at the pre-
radiotherapy education session and 25 patients were excluded from analysis for reasons outlined 
in Figure 5.2. The total number of patients managed on The Pathway and available for analysis 
was 65. Patient demographics can be found in Table 5.1. Patients were predominantly male 
(76.9%), with an average age of 71.3 years (SD 13.4) receiving treatment for cutaneous HNC 
(70.8%) with a radiation dose of 60-65Gy. 
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Figure 5.2. Patient inclusion and exclusion results 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients triaged to pathway by 
Radiation Therapy Care Co-ordinator 
n = 127 
Inclusion criteria confirmed by 
study speech pathologist 
n = 92 
Total eligible patients for 
inclusion 
n = 65 
Excluded n = 35 
- 24 tumour site 
- 8 baseline dysphagia 
- 3 receiving chemotherapy 
 
Excluded n = 27 
- 2 dysphagia identified post inclusion 
confirmation (moved to usual care) 
- 6 palliative treatment 
- 3 administration error 
- 10 change to RT scheduling/plan 
- 2 missing week 5/6 validation data 
- 4 declined all dietetic review 
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Table 5.1.  
Patient Demographics n = 65 
Parameters No. of patients (%) 
Gender  
Male 50 (76.9%) 
Female 15 (23.1%) 
Tumour site  
Cutaneous HNC (skin) 46 (70.8%) 
Parotid 12 (18.5%) 
Salivary Gland 3 (4.6%) 
Thyroid 1 (1.5%) 
Nasal Cavity 3 (4.6%) 
Radiation Dose  
50-59Gy 11 (16.9%) 
60-65Gy 42 (64.6%) 
65-70Gy 12 (18.5%) 
 
 
5.4.2 Detection of Dysphagia Risk 
Of the 65 patients eligible for The Pathway, 58 (89.3%) were successfully managed with 
no need for dysphagia support from SP. In total 7 (10.7%) patients were found to be at risk of 
dysphagia requiring SP support at some timepoint during treatment and were returned to the joint 
SP and dietetics clinic. Five (7.7%) patients were identified through dysphagia screening at week 
3, one (1.5%) patient was identified at the week 5/6/7 SP validation review, (confirming the 
primary endpoint of <10% of patients identified by a speech pathologist requiring SP 
management was met), and one (1.5%) patient was subsequently referred to SP with new onset 
swallowing difficulties reported in week 6 during a nursing review. Detailed results at each step 
of The Pathway can be seen in Figure 5.3. 
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Figure 5.3. The RBWH Head and Neck Cancer Low Risk Speech Pathology Pathway Results. 
HNC: head and neck cancer, EAT-10: Eating Assessment Tool 10, SP: speech pathologist, RT: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Attend week 1 HNC Allied Health 
education session 
n=65 
Initial assessment Week 3 Diet Only HNC Clinic  
• Baseline EAT-10 completed by patient 
• Dietitian completes Dysphagia Screening Tool  
n=65 
 
No dysphagia risk identified 
n=47 
SP week 5/6/7 validation review  
• Weight 
• EAT 10 
• Clinical Swallow Examination 
• FOIS + Diet/Fluid texture 
• CTCAE v4 
• ? Review needed patient + SP 
• ? Return to Joint Clinic 
n=56 
No dysphagia risk identified 
n=55  
(n=5 received diet education) 
Subsequent Diet only clinic 
review if required 
• Monitor EAT 10 
n=27 
Treatment end 
• Dietitian determines 
dietetic follow up needs  
Post treatment 
• Monitor for dysphagia at 2 
and 6 week post RT dietetic 
phone review or 6 week post 
RT RONC review 
n=56 
Dysphagia risk identified 
n=18 
Dietitian refers to Speech 
Pathologist for Clinical 
Swallow Examination 
n=16 
Clinical Swallow 
Examination conducted 
by SP within 48 hours 
n=11 
 
Dysphagia risk confirmed 
n=5 
 
 
Return to joint SP & Dietetic high 
risk clinic till RT complete 
n=7 
2 patients 
declined 
referral 
3 patients 
declined 
review 
2 patients 
judged 
unnecessary 
after SP 
phone 
review 
4 patients 
cancelled 
week 5/6 
review due 
to no 
symptoms 
Dysphagia risk 
confirmed 
n=1 
Dysphagia risk 
reported to 
nursing staff 
confirmed by 
SP review 
n=1 
No dysphagia risk identified 
n=27 
No dysphagia risk 
confirmed 
n=13 
1 patient 
declined 
follow up  
1 patient 
had local 
follow up 
Summary  
n= 65 
• 58 patients successfully managed on pathway 
• 7 patients return to joint SP & Dietetic high-
risk clinic till RT complete  
o 5 via screening,  
o 1 at wk 5/6/7 review  
o 1 via nursing staff 
 140 
radiation treatment, FOIS: functional oral intake scare, CTCAE v4: common terminology criteria 
for adverse events version 4, RONC: radiation oncologist 
 
 
5.4.3 Week 5/6/7 SP Review 
Fifty-six patients attended the scheduled week 5/6/7 SP validation review with 4 patients 
proactively cancelling their scheduled review due to no symptoms. Fourteen (25%) patients 
scored an EAT-10 of 3 or greater, however, dysphagia risk was identified in only 1 (1.5%) 
patient. Most patients experienced nil or grade 1 toxicity, with no grade 3 toxicity reported. 
Grade 2 dysgeusia, xerostomia and dysphagia was reported by 44.6%, 16.1% and 3.6% of 
patients respectively. The majority of patients were consuming a regular (37, 66.1%) or soft (14, 
25%) diet with FOIS as follows, 7 (37, 66.1%), 6 (14, 25%), 5 (4, 7.1%), 4 (1, 1.8%), and 1-3 (0, 
0%). Five patients with a FOIS £5 received diet education without the need for ongoing SP 
input. No patient required fluid modification. Further dysphagia outcome and toxicity results can 
be found in supplementary materials Tables 5.2 and 5.3. Patient and speech pathologists’ 
perceptions of need for SP review, found the majority of patients (96.4%) did not feel they 
needed a SP review. Two patients wished to speak with a speech pathologist regarding dysphagia 
concerns. Only one of these was deemed necessary by the speech pathologist, with one other 
patient review felt to be necessary. Both patients were managed within a single appointment. 
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Table 5.2. 
Maximal Incidence of CTCAE Acute Toxicities at Week 5/6 Review n=56 
Toxicity Absent Grade 1 Grade 2 Grade 3 
Dysphagia 47 (83.9%) 7 (12.5%) 2 (3.6%) 0 (0%) 
Xerostomia 15 (26.8%) 32 (57.1%) 9 (16.1%) N/A 
Dysguesia 19 (33.9%) 12 (21.4%) 25 (44.6%) N/A 
Oral 
Mucositis 39 (69.6%) 15 (26.8%) 2 (3.6%) 0 (0%) 
Pharyngeal 
Mucositis 47 (83.9%) 7 (12.5%) 2 (3.6%) 0 (0%) 
Thick Saliva 39 (69.6%) 17 (30.4%) 0 (0%) 0 (0%) 
Nausea 51 (91.1%) 4 (7.1%) 1 (18%) 0 (0%) 
Note: CTCAE: Common Toxicity Criteria for Adverse Events version 4 
 
Table 5.3. 
Maximal Incidence of Diet Texture, Fluid level and FOIS at Week 5/6 Review 
Outcome Category Frequency (%)  
Diet Regular 37 (66.1%) 
 Soft 14 (25%) 
 Minced 3 (5.4%) 
 Puree 1 (1.8%) 
 Liquids only 1 (1.8%) 
 NBM 0 (0%) 
Fluids Thin 56 (100%) 
FOIS Level 7 37 (66.1%) 
 Level 6 14 (25%) 
 Level 5 4 (7.1%) 
 Level 4 1 (1.8%) 
 Level 3 0 (0%) 
  Level 2 0 (0%) 
 Level 1 0 (0%) 
Note: FOIS: Functional Oral Intake Score 
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5.4.4 Post-treatment Monitoring 
No patient reported a decline in swallowing function during the dietetic phone reviews at 
weeks 2 and 4 post-treatment or the radiation oncologist review at 6 weeks post-treatment. 
5.4.5 Service Characteristics 
There were a total of 15 SP face to face appointments and 5 phone reviews with an 
average of 0.31 appointments/patient (SD 0.52) equating to an average of 4.23 mins/patient (SD 
7.51) compared to 5.61 appointments and 112 mins/patient in the traditional model. There was a 
total of 177 dietetic face to face appointments with an average of 2.72 appointments/patient (SD 
1.07) and an average of 54.46mins/patient (SD 21.36) compared with 5.61 appointments/patients 
112 mins/patient in the traditional model. Patients failed to attend 5 appointments and cancelled 
9 appointments during The Pathway. Further details regarding service characteristics results can 
be found in supplementary materials Table 5.1 (Appendix I). 
5.4.6 Cost Analysis  
Table 5.4 presents the average staff cost per patient for the base case and sensitivity 
analyses comparing the traditional model to the new model for all patients. The base case found 
an incremental staff cost benefit of $15.02 AUD per patient for the SP service and $23.89 when 
both the SP and Dietetic staff costs were included. Figure 5.4 presents the decision tree utilising 
the base case, demonstrating the probability of each step for all possible patient outcomes on The 
Pathway and the individual cost of each step. Overall the average SP cost per patient under the 
traditional model was $92.36 versus $77.35 for the new model, and the average cost per low risk 
patient managed on The Pathway is $12.77. One-way sensitivity analyses found the most 
influential factor in affecting cost was the percentage of patients triaged to low risk, with an 
increased incremental cost benefit to $19.73 per patient if the highest proportion of patients 
triaged to low risk was used. Two- and multi-way sensitivity analyses results can be found in 
Table 5.4. Cost sensitivity analysis found the incremental cost benefit was maintained at $19.34 
per patient with higher level staff providing care. Tables detailing the probabilities (including 
confidence intervals), wage costs and service time to calculate service costs for the decision tree 
to determine incremental cost benefit can be found in supplementary materials Tables 5.2-5.6 
(Appendix I). 
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Table 5.4. 
Cost Analysis Results 
Analysis Cost traditional model Cost new model Incremental cost 
Base Case (SP and Dietetic costs) $184.73 $160.84 $23.89 
Base Case (SP costs only) $92.36 $77.34 $15.02 
One way sensitivity analyses    
Lower CI of triage to low risk $92.36 $81.35 $11.01 
Higher CI of triage to low risk $92.36 $72.63 $19.73* 
Two-way sensitivity analyses    
Higher CI of triage to low risk and 
fail week 3 screen $92.36 $73.11 $19.25 
Higher CI of triage to low risk and 
fail CSE after failing week 3 
screen $92.36 $72.97 $19.39 
Higher CI of triage to low risk and 
% swallowing problem after 
passing wk 3 screen $92.36 $72.86 $19.50 
Multi-way sensitivity analyses    
Worst case scenario: 
fewer patients triaged to low risk 
but greater probability of 
swallowing problems at all steps $92.36 $82.04 $10.32 
Best case scenario: 
more patients triaged to low risk 
and low levels of swallowing 
problems at all steps $92.36 $72.05 $20.31 
Cost Sensitivity    
HP4.2 wage rates $118.95 $99.61 $19.34 
Note: * Factor with greatest influence on incremental cost. Acronyms: SP: Speech Pathologist, CI: 
Confidence Interval, CSE: Clinical Swallow Examination, HP: Health Practitioner.
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Figure 5.4. Base case decision tree model with probability and costs at each node represented. PROB: Probability, RT: radiation 
treatment, CSE: clinical swallow examination 
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5.5 Discussion 
This study confirms the validity of a new clinical pathway for the management of patients 
at low risk for dysphagia during RT. Results showed that the primary endpoint was met and only 
a small number of patients were found to be at risk of dysphagia at some point during The 
Pathway. The efficacy of dysphagia screening was confirmed with the majority of those patients 
(5 of 7) who required ongoing SP support identified at week 3, thereby confirming patients are 
unlikely to continue on The Pathway whilst at risk of dysphagia. The patient who later developed 
dysphagia and was identified by nursing staff at week 6, had passed his CSE with the speech 
pathologist in the week prior. This demonstrates nursing staff provide another point of screening 
for change in function and timely referral. The rigorous patient selection process prior to 
commencement on The Pathway supported its successful implementation. The high number of 
patients triaged out by the study speech pathologist for not meeting inclusion criteria, confirms 
that education of the radiation therapy care co-ordinator education is vital and ongoing checking 
is recommended to ensure referral criteria is adhered to. Also, those patients excluded due to 
baseline dysphagia, confirms this is a vital step in ensuring patient safety. This point of triage 
allows for any changes in treatment plan and/or patient status to be reviewed in accordance with 
inclusion criteria. Therefore, a speech pathologist must be allocated to this role to maintain 
validity of The Pathway. Further to this, it is key that the entire HNC management team is 
involved in the implementation of The Pathway to ensure safety and efficacy, with each team 
member understanding the routine care this group of patients will receive and the role they can 
play in monitoring and timely referral to SP should the need arise. 
Results confirmed low levels of treatment related toxicity consistent with prior research 
(Al-Mamgani, van Rooij, Verduijn, et al., 2012; Chung et al., 2013; Moroney, Helios, Ward, 
Crombie, Burns, et al., 2018 = Chapter 4; Patel et al., 2014) and no deterioration of swallow 
function post-treatment in this selected low risk group. Whilst there was a relatively short period 
of follow up, patients are unlikely to experience late onset problems without the presence of 
acute toxicities given the known association between acute toxicity and late effects (Arrese & 
Hutcheson, 2018; Van Der Laan et al., 2015). Of the 7 patients who were found to be at risk of 
dysphagia and returned to the joint SP and dietetic clinic, all were receiving 60-62Gy and had ³3 
co-morbidities (i.e. diabetes, heart disease, COPD), and most were >70 years of age (57%), had 
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parotid tumours (57%), and a facial nerve sacrifice or weakness was documented post-
operatively (57%). Mucositis and xerostomia were the most commonly occurring toxicities 
amongst the 7 patients. This is consistent with toxicity outcomes reported in the literature for the 
parotid patient group (Patel et al., 2014) with factors such as advanced age (i.e. >62 years) and 
disruption of cranial nerves known to influence dysphagia risk (Denaro et al., 2013).  
One consistent issue encountered was the rate of over referral associated with the EAT-
10. At each timepoint more patients reported an EAT-10 of ³3 than were found to be at risk of 
dysphagia requiring SP management following CSE. However, this is to be expected given the 
nature of screening tools and the EAT-10 has been found to have a lower specificity and higher 
sensitivity (Cheney, Siddiqui, Litts, Kuhn, & Belafsky, 2015; Rofes, Arreola, Mukherjee, & 
Clavé, 2014). Whilst not initially developed as a screening tool, the EAT-10 has been widely 
used for this purpose due its simple quick administration and sufficient sensitivity and specificity 
(Möller, Safa, & Östberg, 2016). Whilst there are limited published studies evaluating the use of 
the EAT-10 specifically in the HNC population, a recent study (Arrese, Carrau, & Plowman, 
2017) found correlations between EAT-10 scores and swallowing pathophysiology and 
penetration aspiration scores for patients pre-treatment to 1-year post HNC treatment. 
Cost effectiveness analysis demonstrated a cost benefit per patient of $15.02 when using 
The Pathway compared to the traditional model. This is due to the large reduction in SP costs to 
manage a low risk patient ($12.77) compared with a high risk patient ($92.36). Whilst unable to 
analyse significance, the benefit is best appreciated in terms of resource recovery with an 
average of 5.3 appointments saved per patient. Thus, allowing a reallocation of appointments to 
those patients at higher risk of dysphagia who will benefit most from more intensive SP support 
(Moroney, Helios, Ward, Crombie, Pelecanos, et al., 2018 = Chapter 3). Transferability of The 
Pathway to other settings was confirmed through sensitivity analysis, with all scenarios 
indicating a similar incremental cost benefit. This is relevant for smaller regional centres that 
may see a greater proportion of patients meeting inclusion criteria for The Pathway whilst facing 
limited staff resources. Conversely, The Pathway could also be viewed as an effective service 
delivery model for metropolitan HNC centres with higher volumes of high risk patients where SP 
resources could be safely re-directed towards these patients. 
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These results are consistent with other studies reporting clinical pathways as an effective 
means of managing patients with HNC with improved resource utilisation (Gendron et al., 2002; 
Kwon et al., 2018). However, a recent systematic review of critical care pathways in HNC 
surgery whilst finding encouraging results regarding reduced length-of-stay and cost reduction, 
cautioned the evidence remains limited with few controlled studies (Gordon & Reiter, 2016). 
More studies evaluating the effectiveness of clinical pathways and service delivery models 
including cost analysis in the outpatient setting are required. 
Although this study indicated positive outcomes from implementing The Pathway, the 
authors acknowledge several limitations. Whilst representative of the patient numbers with these 
diagnoses and treatment plans at a specialist facility, a larger cohort involving more than one 
HNC centre would have strengthened the results. However, the decision tree modelling and 
sensitivity analysis aimed to alleviate these limitations. A longer follow up period would also 
have been of benefit for research purposes, however, as the patients had met discharge criteria, 
ongoing follow up was not indicated. Interviewing key stakeholders such as patients and speech 
pathologists regarding their perceptions of implementing the pathway, and particularly exploring 
with the dietitians any perceived added burden from administering dysphagia screening, will be 
important future work to inform sustainability and future implementation in other centres. The 
Pathway will undergo continual monitoring at the study institution. 
5.6 Conclusion 
This study confirms The Pathway is a safe and effective model for managing a subgroup 
of HNC patients at low risk for dysphagia during RT when implemented in its entirety with the 
support of the full HNC team. The Pathway reduces unnecessary SP appointments for patients 
and clinicians, allowing resource recovery and redirection of resources to patients requiring 
higher levels of supportive care. These results have implications for SP service planning and the 
development of evidence-based guidelines. The Pathway is simple to implement at any HNC 
facility with SP and dietetic services seeking more streamlined and cost-effective service 
delivery models. 
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CHAPTER 6: Conclusions and Future Directions 
 The following chapter content provides the reader with a summary of the major 
findings of the studies included within this thesis. Following this, there is a discussion of the 
clinical implications arising from this work to optimise HNC services and ultimately improve 
outcomes for the patient. Limitations identified within the studies are then outline, followed by 
areas of future research, completing the chapter with the main conclusions of this thesis.   
6.1 Summary 
As outlined in Chapter 1, HNC is a complex condition, largely due to the tumour 
locations and proximity to key structures of swallowing, speech, respiration, and voice. Whilst 
called “organ sparing” in comparison to surgical treatment, non-surgical treatment such as (C)RT 
is associated with significant morbidity as these key structures often fall within the treatment 
field. Common sequelae of (C)RT includes a wide range of toxicities such as dysgeusia, 
xerostomia, thick saliva, mucositis, odynophagia, nausea, and can contribute to worsening 
dysphagia. Toxicities may be acute and emerge during treatment and up to 12 weeks post-
treatment, or present as a late toxicity beyond 12 weeks post-treatment. These toxicities can have 
a negative impact on QOL. Dysphagia in particular is associated with reduced QOL and may 
have serious health implications. Dysphagia can result in aspiration in the short and long term, 
leading to aspiration pneumonia with grave consequences. Changes in the epidemiology of HNC 
due to growing rates of HPV mediated HNC and its favourable response to CRT, has resulted in 
greater numbers of younger patients receiving curative intent CRT with increased overall 
survival. This ultimately means there are a large number of HNC survivors with several decades 
of life to live with the side effects of their treatment. Now, more than ever survivorship needs are 
taking on increasing importance, with active intervention required not just once treatment is 
finished - but before treatment even starts.  
In light of this, several treatment de-escalation and detoxification  strategies have been 
proposed and are being investigated in the current literature for HNC care. One such strategy is 
the use of advanced conformal radiation techniques such as H-IMRT, which have the potential to 
reduce radiation exposure to surrounding normal tissues with reductions in treatment related 
toxicity such as dysphagia, whilst maintaining optimal dose coverage and cure rates. However, 
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the current literature reporting toxicity outcomes including dysphagia, is inconclusive as to 
whether such new treatment approaches actually result in improved functional benefits for the 
patient. Currently, evidence is largely based on retrospective studies, with inconsistent and 
limited reporting of dysphagia and related toxicity outcomes, frequently reported as a maximum 
grade 3 incidence only. There are minimal reports in the H-IMRT or traditional IMRT literature 
of the temporal patterns of presentation, peak and early recovery of acute toxicities for patients 
with HNC. Greater evidence is needed documenting the severity, peak incidence and early 
recovery of dysphagia and a wider range of related toxicity outcomes following H-IMRT to 
determine if functional benefits are realised for the patient. This information is required to inform 
supportive care needs, and enhance patient education regarding anticipated treatment side effects. 
Furthermore, evidence regarding these outcomes is rarely reported for patients with tumour sites 
outside the oral cavity, oropharynx, nasopharynx, hypopharynx, and larynx. Such information is 
required to determine the specific supportive care needs for the wide variety of patients with 
HNC, to inform patient centred care rather than one-size-fits-all service delivery models.  
Whilst speech pathologists are recognised as integral members of the HNC MDT 
providing support pre-treatment, during treatment, and weeks to years post-treatment, current 
HNC guidelines lack specific details regarding the timing and intensity of SP intervention 
broadly for HNC patients and specific patient groups. This has resulted in wide variation in the 
timing and intensity of SP services internationally and nationally. Frequently one-size-fits-all SP 
service delivery models are used, particularly in Australia, with potential over-servicing and 
under-servicing of specific patient sub-groups identified in the literature. 
The overall objective of this thesis was to evaluate the incidence and severity of 
dysphagia and related toxicities of patients undergoing H-IMRT to inform SP management 
practices. A secondary objective was to use this information to develop, and evaluate a new 
clinical pathway of care. Through a series of 4 studies this thesis has sought to fill the previously 
detailed gaps in the current literature to ultimately enhance HNC patient supportive care with 
evidence-based patient education and optimally timed SP services that meet the needs of specific 
patient groups.  
The first three studies (Chapters 2, 3, and 4) addressed the first overall aim, and 
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weeks post curative intent H-IMRT +/- chemotherapy with widely used clinician rating tools. 
The first study reported the outcomes of a large heterogeneous cohort of patients with mixed 
HNC tumour sites and stages, reflecting the true variety of patients receiving treatment at a large 
tertiary HNC centre. High proportions of patients were found to continue to experience grade 2-3 
levels of the wide range of toxicities assessed. Twenty percent or more of patients experienced 
grade 2-3 symptoms (for the majority of symptoms) by week 4 of treatment. Symptoms peaked 
in the final week of treatment and consistently improved thereafter, with the majority better than 
baseline by 12 weeks post-treatment. Concurrent chemotherapy at least doubled the odds of 
experiencing most symptoms. In comparison to the existing literature documenting outcomes for 
patients with HNC undergoing traditional IMRT, toxicity severity was comparable with some 
indication that patients undergoing H-IMRT may recover quicker or have a shorter duration of 
grade 3 toxicity, though firm conclusions were difficult due to the varied results reported. The 
findings of Chapter 2 confirmed that despite advancements in radiotherapy technique, high 
proportions of patients continue to experience dysphagia and a range of related symptoms that 
require SP supportive care, particularly in the final weeks of treatment and the acute period post-
treatment. 
Given these results, together with prior research indicating patients with oropharyngeal 
tumours are at high risk of treatment related toxicity, particularly dysphagia, Chapter 3 
comprised a subsite analysis of patients with OPSCC undergoing H-IMRT with concurrent 
chemotherapy, to better understand the needs of this high-risk patient group to inform patient 
centred care. Results found a high proportion of patients experienced grade 3 dysphagia with 
comparable or better rates of most other toxicities compared with traditional IMRT. Symptoms 
peaked in the final week of treatment and improved thereafter, however, most symptoms had not 
reached baseline by 12 weeks post-treatment. Grade 3 dysphagia was twice as common for 
patients with T3-4 tumours compared to T2. The findings of Chapter 3 confirm the OPSCC 
patient group continue to be a “high risk” patient group particularly for dysphagia despite 
advances in conformal radiotherapy, and therefore should be prioritised for intensive SP support, 
particularly from week 4 of treatment to 12 weeks post-treatment. Patients with larger T stage 
tumours should also be prioritised for supportive care. 
Whilst the needs of “high risk” patients with OPSCC were confirmed in Chapter 3, the 
specific supportive care needs of patients with HNC tumours outside the major sites remains 
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limited in the literature. From the available evidence, it was theorised that due to the location of 
the tumour and lower intensity treatment regimens (both reduced dose and infrequently requiring 
concurrent chemotherapy), patients with tumour sites of the parotid, thyroid, cutaneous HNC, 
and lymphoma in the head and neck region, should experience less treatment related side effects. 
As such this may be a proportion of the HNC population who may require less intensive 
supportive care. This patient group has particularly varied levels of SP care provided across HNC 
centres with some centres providing the same level of SP supportive care whilst others do not see 
them at all. Therefore, Chapter 4 comprised a subsite analysis of patients with parotid tumours 
and cutaneous HNC hypothesised to be “low risk” to better ascertain the needs of this select sub 
group of patients to inform SP service delivery. Results found a very low proportion of patients 
experienced dysphagia or related toxicity requiring SP support. If present, symptoms peaked in 
week 5 of treatment and resolved rapidly. Chapter 4 confirmed this patient group is indeed at 
“low risk” for dysphagia and related toxicities during RT and represent a subgroup likely 
amenable to an alternative service delivery model.  
In light of the results from Chapters 2-4, Chapter 5 prospectively evaluated the 
implementation, clinical safety, cost analysis, and service efficiency of a new interdisciplinary 
service delivery model (The Pathway) of primary dietetic management using dysphagia 
screening with rapid access to SP when required for patients at low dysphagia risk. Results 
suggest The Pathway is a safe and effective method of managing this subgroup of “low risk” 
patients during RT when implemented in its entirety and with the support of the full HNC MDT. 
Patients experienced a reduction in hospital appointments with cost benefits to the health service 
through resource recovery facilitating reallocation of SP services to the “high risk” patients 
identified in Chapter 3.  
6.2 Clinical Implications 
The research contained with this thesis provides an enhanced understanding of the 
severity and temporal pattern of dysphagia and related symptoms experienced by patients with 
HNC undergoing curative H-MRT +/-chemotherapy, which informs patient education and SP 
supportive care needs. Translating these findings into clinical practice enables health services to 
enhance patient care through more efficient service delivery models that meet the needs of 
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specific subgroups of patients with HNC. A number of key clinical implications are discussed in 
the following sections.  
6.2.1 Implications of Helical IMRT+/- Chemotherapy Dysphagia and Related Toxicity 
Outcomes 
The findings from Chapters 2-4 represent the most comprehensive report of both the 
severity of the wide range of acute treatment related toxicities including dysphagia and the 
temporal pattern of symptom presentation, peak, and early recovery for patients with HNC 
undergoing H-IMRT. This was achieved through several means: 1) seven toxicities and three 
functional measures of dysphagia were captured and reported, rather than just xerostomia and 
mucositis as is often reported in the literature; 2) each toxicity grade (i.e. CTCAE grade 0-5) and 
dysphagia score (i.e. FOIS 1-7, diet texture) was captured and reported, and; 3) data was 
collected at each treatment week (baseline, 1-7) and at regular intervals in the acute post-
treatment phase to give a more complete picture of toxicity incidence as patients progress 
through treatment and their early recovery. The current studies fill a gap in the existing H-IMRT 
literature and strengthen the evidence base regarding the range of anticipated acute treatment 
side effects and patterns of early recovery post-treatment. The body of research contained in this 
thesis has several specific clinical implications - which will be discussed in the following 
sections in more detail.  
6.2.1.1 Patient education and counselling.  Firstly, the information derived from this 
thesis can be directly applied to enhance patient education and counselling throughout the acute 
care journey. Pre-treatment, health professionals can provide information on the severity, timing 
of onset, peak and early recovery of anticipated side effects with greater confidence drawing 
from a stronger evidence base when patients attend individual or group education sessions. 
During treatment, as patients experience symptoms and require support to persevere through 
treatment, health professionals can provide more accurate and informed counselling regarding 
symptom peaks and recovery patterns to prepare, encourage, and motivate patients. For example, 
patients with OPSCC shortly finishing treatment could be counselled, that recovery will happen. 
It will be slow at first and potentially at 2 weeks post-treatment side effects may feel similar to 
how they did at week 5 of treatment, but by 12 weeks post treatment 70% of patients with a 
tumour in a similar location were eating normally or eating naturally soft foods. Post treatment, 
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particularly as patients question the speed of recovery, health professionals are now able to 
counsel with greater confidence around the extent of early recovery that may occur. Then in 
distinct contrast, patients receiving RT for parotid or cutaneous HNC can be provided with 
education regarding the anticipated lower level of treatment related toxicity, when it may occur,  
and if experienced how to access the appropriate services. 
The figures reported in Chapters 2-4 on the percentage of the cohort requiring supportive 
care for dysphagia and the 7 toxicities, can serve as a visual educational tool, and indeed has 
been used within the clinical practice in which this research was set ever since the studies have 
been published. Patients have reported that seeing the progression and recovery pattern of the 
side effects in a visual representaion reassured them their experience was “normal” for this 
treatment and encouraged and motivated them to focus on recovery and comply with strategies 
suggested by their speech pathologist and dietitian.  
6.2.2 Speech Pathology Supportive Care with Advancing Radiation Therapy Techniques 
  Chapter 1 outlined the advances in radiation techniques over the last 20-30 years and the 
potential of H-IMRT to reduce radiation doses to normal tissues to reduce treatment related 
toxicity. Reductions in treatment related toxicity has implications for supportive care needs, in 
particular if patients undergoing H-IMRT continued to require SP support. However, as discussed 
in Chapter 1, the literature documenting toxicity outcomes for patients undergoing H-IMRT for 
HNC was very limited at the time this thesis commenced, thus decisions regarding supportive 
care needs were difficult to make with such a weak evidence base to draw from.  
The findings in Chapters 2 and 3 confirmed high proportions of patients continued to 
experience a wide range of treatment related toxicity including dysphagia that required SP 
support during and in the acute phase post-treatment when receiving H-IMRT +/- chemotherapy. 
As reported in Chapter 2, although chemotherapy increased the odds of experiencing toxicity 
requiring support, 70% of the patients receiving H-IMRT alone were also found to have a FOIS 
of 1-5 in the final week of treatment, with the majority a 4-5 (single consistency or food 
requiring special preparation). In particular, the results from Chapter 3 found patients with 
OPSCC receiving H-IMRT with concurrent chemotherapy continued to be at high risk for Grade 
3 dysphagia (80% of the cohort) with 61% requiring enteral nutrition.  
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Dysphagia was not the only toxicity with high incidence. Over 50% of the patients 
receiving H-IMRT with concurrent chemotherapy in Chapter 2 and 3 experienced grade 2 or 
worse oral mucositis, pharyngeal mucositis, thick saliva, dysgeusia, and xerostomia and over 
70% of the H-IMRT patients in Chapter 2 experienced grade 2 dysguesia and xerostomia. This 
confirms high numbers of patients continue to require intensive support from SP to proactively 
manage toxicities such as xerostomia, dysgeusia, thick saliva, and mucositis to minimise the 
impact on oral intake and maintain swallowing function in the presence of these debilitating 
toxicities. Working closely with the MDT is crucial to optimise patient care in this complex 
context. Referring to the medical team if medication commencement or adjustment is required in 
between scheduled reviews, liaising with the oncology nurses if further assistance with oral cares 
or skin toxicity is required, referring to social work and psychology as required for psychosocial 
support and coping is necessary for patient support. This evidence also endorses a joint SP and 
dietetic service for “high risk” patients to ensure adequate nutrition and swallow function is 
optimised despite significant toxicities, particularly when enteral nutrition is required. 
Conversely, the findings of Chapter 4 confirmed a low incidence of toxicities and 
dysphagia requiring SP support during treatment and if present, rapid recovery post-treatment in 
patients with parotid tumours and cutaneous HNC. This evidence confirms the anecdotal view 
that these patients don’t require intensive SP support - with implications for SP HNC services. In 
light of these findings, HNC services now have prospective evidence to inform SP service 
delivery models for this subgroup of patients which will be discussed further in the next section. 
6.2.2.1 Guiding future speech pathology service delivery models.  The World Health 
Organisation advises in order to provide quality of care, health care must be safe, effective, 
timely, efficient, equitable, and people centred. Whilst we know the HNC population to be 
heterogeneous in nature with HNC patient subgroups having different supportive care needs, our 
SP services do not necessarily reflect this. As described in Chapters 1 and 5, whilst current HNC 
guidelines recommend SP involvement pre, during and post-treatment, they lack specific 
recommendations as to which patients, when, and at what intensity they require SP support, 
leading to wide variation in service provision internationally. In order to optimise SP services to 
ensure the right patients are receiving the right care at the right time we need evidence to confirm 
which patients experience treatment related toxicity including dysphagia, the severity of toxicity 
and when those symptoms present, peak, and begin to recover. The results described in Chapter 
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2-5 provide some of the required answers to inform evidence-based changes to SP service 
delivery models in order to ensure quality of SP care is provided as stated by the World Health 
Organisation. 
In order to provide timely and efficient SP care, triaging and patient prioritisation is 
required due to finite SP resources. Triaging and prioritisation should be based upon patient need 
not on availability of health care resources, and the outcomes documented in this thesis can guide 
these changes. Chapter 2 confirmed that despite receiving advanced radiation techniques, 
patients receiving concurrent chemotherapy are at least twice as likely to experience symptoms 
requiring supportive care, particularly dysphagia and should be a high priority for SP services. 
Patients receiving H-IMRT alone also continue to require support with 70% of the H-IMRT 
group consuming a modified diet (FOIS 1-5) in the final week of treatment, however, they 
present as a lower priority than their peers receiving chemotherapy. Chapter 3 confirmed despite 
receiving advanced radiation techniques with concurrent chemotherapy most patients with 
OPSCC will experience symptoms requiring support, particularly dysphagia and require enteral 
nutrition support. This sub-group of patients should be a high priority for SP services in order to 
optimise swallow function whilst receiving enteral support during the symptom peak and 
facilitate increased oral intake as soon as possible. Chapter 3 also identified patients with T3-4 
tumours are at the greatest risk and are thus the highest priority OPSCC patients.  
Chapter 4 confirmed patients with parotid tumours and cutaneous HNC present with low 
levels of treatment related toxicity that requires support from a speech pathologist, therefore are 
a low priority subgroup for SP support and may not require SP intervention. Chapter 5 further 
confirmed patients with tumours of the parotid, thyroid, salivary glands, nasal cavity, and 
cutaneous HNC who do not have baseline dysphagia (FOIS 1-5 prior to commencing RT) or are 
not planned for chemotherapy do not require regular SP support during treatment and are likely 
to be safely managed by dietetics within The RBWH Head and Neck Cancer Low Risk Speech 
Pathology Pathway. As shown in Chapter 5, the reduction in SP appointments to this low risk 
subgroup can facilitate the reallocation of SP resources to the identified higher risk groups 
Further to prioritisation, is the timing and intensity of SP support. Across Chapters 2-4, 
the symptom peak occurs in the final week of treatment, which was not unexpected, however, the 
onset of symptoms is crucial to proactive management. Most symptoms monitored in the studies 
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were observed by week 2 of treatment, particularly if receiving chemotherapy. However, a 
notable increase in symptoms is observed between weeks 3 and 4, which is likely in response to 
the second round of high dose cisplatin and presents a key week in which increased proactive 
support is required. Symptoms progressively increase in incidence from there, with more marked 
increase observed between weeks 5-6 for patients receiving H-IMRT alone. When looking 
specifically at dysphagia a peak can be observed from week 5 of treatment to 2 weeks post-
treatment and patients would benefit from increased intensity of SP support in those weeks. For 
patients receiving chemotherapy a high incidence of dysphagia (>50%) is still observed at 4 
weeks post-treatment and increased intensity of SP support should be extended for this subgroup. 
The findings from Chapter 2 state that, in comparison to traditional IMRT, patients receiving H-
IMRT may recovery more quickly post-treatment, which has implications for the timing and 
intensity of SP support. In order to better cater to patient needs, SP reviews should be more 
frequent in the first 4 weeks post-treatment and taper off as recovery occurs.  
However, it may be counter-productive to increase patient burden through travel and 
waiting for more appointments whilst they seek to be in a phase of rest and recovery. The 
potential of telepractice to conduct reviews in this setting has been examined and found to be 
effective with positive outcomes for the patient and health service (Collins et al., 2017). It is 
suggested telepractice could be used in isolation or in conjunction with face to face SP reviews 
post-treatment to increase the frequency of post-treatment support whilst symptoms are still 
significant without increasing patient travel burden. Study 4 found symptoms progressed much 
slower in this “low risk” group and if present, peaked in the final week of treatment. They were 
also observed to improve rapidly, thus these patients could either be managed through the 
implementation of The RBWH Head and Neck Cancer Low Risk Speech Pathology Pathway or 
scheduled for SP review in the final 2 weeks of treatment and at 4 weeks post-treatment.  
In order to synthesise the outcomes and implications for SP service delivery changes 
across Chapter 2-5, it is simplest to triage patients as high, medium, or low risk with 
corresponding recommendations for SP care. A table synthesizing a summary of outcomes with 
recommended SP service delivery changes is included below in Table 6.1. The increased SP 
resources required to provide the recommended intensity for the higher risk groups can be 
sourced from the reduction in SP appointment frequency required by the low risk group 
identified in Chapter 5. If due to health service constraints the SP resources are unable to 
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reallocated for such a purpose, previous research has identified telepractice programs such as 
SwallowIT as viable options for increasing service delivery to patients with HNC (Wall et al., 
2018) and should be considered.
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Table 6.1  
Recommendations for SP Service Delivery for Patients Undergoing HNC Treatment (H-IMRT+/-chemotherapy) 
Risk Group Patient Group Suggested Timing of SP support Suggested Intensity of SP support 
High • T3-4 oropharyngeal + 
chemotherapy  
• T1-T2 oropharyngeal and all other 
sites + chemotherapy 
During Treatment: Weeks 1 to 7 
Post Treatment: Up to 12 weeks unless 
symptoms have resolved; Beyond 12 
weeks as required 
Week 1 and 2 once a week 
Week 3/4 -7 twice a week  
Post-treatment once a week* for 2 to 6 
weeks increasing time between reviews 
as recovery occurs 
Medium • Oral cavity, oropharyngeal, 
hypopharyngeal, nasopharyngeal, 
laryngeal, unknown primary, 
paranasal sinus, and lip receiving 
H-IMRT alone 
• Parotid, cutaneous HNC, thyroid, 
salivary gland, nasal cavity, 
lymphoma, major sites receiving 
less than 60Gy with baseline 
dysphagia 
During Treatment: Weeks 2 to 7 
Post Treatment: Up to 12 weeks unless 
symptoms have resolved; Beyond 12 
weeks as required 
Week 2 to 7 once a week 
Post-treatment fortnightly* for 6-8 
weeks increasing time between reviews 
as recovery occurs 
Low • Parotid, cutaneous HNC, thyroid, 
salivary gland, nasal cavity, 
lymphoma, major tumour sites 
receiving less than 60Gy without 
baseline dysphagia 
For management via the Head and Neck 
Cancer Low Risk Speech Pathology 
pathway with referral to SP as required 
 
* Reviews could occur via telepractice as appropriate or in combination with Face to Face reviews as needed to minimise patient travel burden  
 
 
  159 
6.2.2.2 Informing future speech pathology guidelines in HNC.  As previously 
discussed, current HNC guidelines lack specific recommendations for SP services beyond the 
general recommendation for SP care pre, during and post-treatment for management of trismus, 
speech, swallowing, and voice disorders. The outcomes presented in this thesis provide a basis to 
begin the formulation of SP specific HNC guidelines. The above service delivery 
recommendations regarding the timing, intensity, and prioritisation of patients could be coupled 
with research into predictive factors for dysphagia pre-treatment to strengthen the evidence for 
prioritisation (Barnhart et al., 2017; Frowen et al., 2010; Langendijk et al., 2009; Van Der Laan 
et al., 2015). Research into dose constraints for SWOARs and recommendations for speech 
pathologists involvement in the treatment planning process could also be incorporated into such 
guidelines (Barnhart, Cartmill, et al., 2019; Barnhart & Hutchison, 2019; Christianen et al., 2016; 
Hutchison et al., 2019). The inclusion of survivorship priorities and rehabilitation goals post-
treatment would further compliment acute recommendations and ensure guidelines address the 
entire survivorship journey for patients (Barnhart, Ward, et al., 2019).  
6.2.3 The Multidisciplinary Team 
Whilst the studies in this thesis were conducted from the SP perspective, the 
comprehensive documentation of acute toxicity outcomes has implications for the entire HNC 
MDT. Adequate management of treatment related toxicities requires input from many members 
of the MDT to address all aspects of the toxicity. For example, managing mucositis requires 
input from the oncologist for prescription of pain relief and a management plan, including 
possible need for enteral nutrition, provision and advice regarding non-prescription medication 
and mouthwashes from nursing staff, diet texture/swallowing recommendations from SP together 
with strategies and diet adjustments/nutritional supplements/enteral nutrition recommendations 
to ensure adequate nutrition from the dietitian. Hence, the data presented in this thesis is relevant 
for all HNC MDT professionals.  
The pattern of toxicity outcomes over time also has implications for the timing of reviews 
by the MDT, both during and post-treatment. The MDT will be informed from the findings in 
Chapters 2-4 which of their patients, when, and for how long, they may require support to 
proactively manage their acute toxicities. The MDT can use this information to ensure their 
patients are closely monitored and well supported with appropriately timed reviews in order to 
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complete their treatment regime – minimising treatment breaks and disruptions which are known 
to negatively influence cure outcomes. In particular, nursing staff and radiation therapists are in 
contact with patients on a daily basis. They can use this information to proactively monitor 
patients for rapid decline at the key times identified, and refer patients for rapid medical, SP or 
dietetic review as required. Further to this, medical staff now have a stronger evidence base 
reporting toxicity outcomes for patients with HNC receiving H-IMRT +/- concurrent 
chemotherapy which may influence individual treatment decisions or health service level 
decision making regarding which radiation technique to employ.   
Post-treatment, the results from Chapter 2 and 3 confirm high proportions of patients 
continue to experience symptoms requiring support from the MDT in the first 4 weeks post-
treatment. However, traditionally the first radiation oncologist review is not until 6 weeks post-
treatment. Whilst patients are encouraged to see their primary care physician to address medical 
needs in the interim, the reality of this occurring proactively and with good effect varies for each 
patient. This is commonly due to the specialised nature of care for patients with HNC; the 
experience of the primary care physician in HNC management; timely receipt of the oncology 
treatment summary; and the patient having a dedicated primary care physician. The outcomes of 
these studies can serve as information for primary care physicians managing HNC patients, 
informing acute management post-treatment. This information can also serve as a catalyst for a 
structured medical review model in the first 6 weeks post-treatment for high risk patients, 
including the utilisation of technology enabled healthcare modalities such as telepractice to 
improve access to care and reduce patient travel burden.  
6.3 Limitations and Future Directions 
Specific limitations within the individual studies have been acknowledged within 
Chapters 2-5, however, due to word limits associated with the publication journals not all 
limitations could be discussed in detail. Therefore, this section will further discuss the 
overarching limitations common to all Chapters of the thesis, followed by more specific detail of 
limitations pertaining to Chapter 5, along with discussion of future directions for this research.  
As with all research, using the most appropriate outcome measure is crucial to ensuring 
the desired outcomes are comprehensively evaluated. Whilst significant consideration into the 
best tools to use in the studies contained within this thesis was undertaken, the decision was 
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made to use tools used in daily clinical practice that captured the range of desired outcomes and 
provided the greatest opportunity for comparison with the published literature. However, all the 
tools used were subjectively clinician rated through observation and questioning during clinical 
review (CTCAE, FOIS, Diet/Fluid texture). The inclusion of interjudge and intrajudge relability 
checks between speech pathologists for all subjective measures based on a single rater would 
have strengthened the result of all four studies and will be considered in any future research 
studies. As mentioned in the limitations of Chapters 2-5, the lack of instrumental swallowing 
assessment was a limitation of this body of work and would have greatly strengthened the 
findings of these studies. However, the feasibility of including an instrumental measure was 
beyond the funding and practical capabilities of conducting this research within the context of 
daily clinical practice.  
The addition of PROMs e.g. the CTCAE Patient Reported Outcome (CTCAE PRO) 
would have added another dimension to the studies reflecting the patients perception of treatment 
related toxicity and allowed for comparison with the clinician rated outcomes. Future research 
studies will seek to include PROMs through existing questionnaires or semi-structured 
interviews to more robustly address the research question. Further to this, prospective recording 
of the radiation oncologist scoring of the same toxicities at each medical review would provide 
an opportunity for a triad comparison of the perspectives of the radiation oncologist, speech 
pathologist, and patient on the severity of symptoms. This information could be very useful in 
understanding the perspective and priorities of each stakeholder and how strongly they align.  
Similarly, the inclusion of a QOL measure would have been ideal to not just document 
the severity of symptoms from the patients perspective but the impact on their quality of life and 
daily living from a whole patient and carer perspective. Future studies could seek to collect all 
these outcome measures to provide an extremely comprehensive evaluation of the subjective 
ratings of treatment related side effects and their effect on QOL from multiple clinician and 
patient perspectives whilst also documenting the presence of physical changes to the swallow 
mechanism through instrumental swallow assessment at set timepoints. However, this would 
require significant funding and co-ordination to ensure all data was collected accurately and on 
time. 
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Swallow sparing or swallow optimised RT was not specifically used during any of the 
studies comprising this thesis. Thus, the full potential of H-IMRT to achieve specific dose 
constraints for the DARS or SWORS to minimise radiation to these key structures and optimise 
swallow function may not be completely realised in the outcomes published within this thesis. 
Similarly, no data on dose volume histograms for the DARS were collected for any of the studies 
in this thesis. This information would have provided prospective data on actual doses received by 
the DARS and allowed for analysis in conjunction with toxicity and dysphagia profiles. There is 
little to no prospective dose volume histogram data published in the H-IMRT literature, 
particularly alongside a range of toxicity outcomes. Thus, presenting a rare opportunity to more 
comprehensively evaluate if the proposed benefit of H-IMRT is actually realised in both dose 
reduction and functional outcomes. However, whilst collecting this information was considered 
at the study conception it was deemed beyond the scope and practicalities of the research funding 
and there was no consensus of routine dose delineation of the DARS at the time of data 
collection. This is an area of future research that should be undertaken to comprehensively 
evaluate the benefits of H-IMRT. 
Further limitations of the study reported in Chapter 5 include the study design. The study 
would have been strengthened if The Pathway group and control group were randomised rather 
than using a historical control. The study design used could have introduced bias at several 
points, including investigator bias toward Pathway superiority, and the effects of testing time and 
history could have set up group differences. Whilst a superior study design, the lack of funding 
for this particular project limited its scope to be undertaken as an RCT due to the resources 
required. An evaluation of the staff perceptions of the implementation of The Pathway in Chapter 
5 was not undertaken as part of that study and represents an area of future research. A post 
service implementation evaluation using an implementation science evaluation framework such 
as the Consolidated Framework for Implementation Research (Damschroder et al., 2009) is 
proposed as a future study. This form of systematic implementation analysis will help to further 
facilitate identification of the barriers and facilitators in implementing this new service delivery 
model through the use of constructs and systematic analysis of stakeholder feedback. 
As discussed in 6.2.2.2 an area of future research is the development of consensus SP 
guidelines for HNC to improve the consistency and quality of SP care provided to patients with 
HNC. However, this type of research is a huge undertaking. It requires significant input from 
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many SP leaders in the HNC field together with other key HNC stakeholders and would require 
funding through a large grant to support such a body of work. Another area of future research 
identified through this thesis is evaluating the effectiveness of readily available existing 
xerostomia and dysgeusia strategies. These two symptoms that contribute to dysphagia had the 
highest incidence across all studies and persisted the longest. However, outside parotid sparing 
IMRT and pharmacological trials, existing management strategies such as alterations to diet 
texture, alternating food and fluids, mouthwashes, dry mouth gels, and adding/removing flavours 
are largely anecdotal with little comprehensive evaluation. The study design for such an 
investigation would require significant planning to control for the many contributing factors to 
these side effects. 
6.4 Conclusion 
The number of HNC survivors continues to grow largely in part to the changing 
epidemiology of HNC and its response to CRT. Whilst advances in radiation therapy techniques 
such as H-IMRT seek to reduce the morbidity associated with non-surgical HNC treatment, 
unfortunately reports of functional outcomes including dysphagia in the literature are limited. 
Combined with a lack of specific SP guidelines in HNC, it is difficult for health services to 
appropriately plan patient centred SP supportive care without understanding the care needs of 
patients receiving these new treatment techniques. In addressing these issues, this thesis has 
reported the incidence, severity, and temporal pattern of a wide range of treatment related side 
effects including dysphagia associated with H-IMRT. Through tumour subsite analysis, 
information is provided to assist health services and speech pathologists to better understand the 
care needs of patients with HNC undergoing H-IMRT and optimise their services.  
The outcomes of the first three studies confirmed which patients continue to require 
intensive SP support and when they need it most, with implications for intensity of support. This 
information can be used for prioritising patients, planning patient centred SP service delivery 
models, and enhancing patient management and education. Additionally, the final study 
examined the validity, efficiency, and cost benefits of an alternative service delivery model for 
patients identified as not requiring intensive SP support, with results suggesting it to be both 
valid and effective. Overall, this thesis has comprehensively documented the acute SP supportive 
care needs of patients receiving H-IMRT +/- chemotherapy with recommendations for SP service 
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delivery. Ultimately, implementing these findings can optimise SP services and subsequent QOL 
for patients in the acute phase of treatment for HNC with H-IMRT +/- chemotherapy. 
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Appendix G: Supplementary Materials pertaining to Study 1 (Chapter 2) 
Supplementary Table 2.1. GEE Results of Incidence of Xerostomia Needing Supportive Care  
Xerostomia ln Odds Std.err Odds ratio p-value 
(Intercept) -2.12 0.29 0.12 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 0.34 0.24 1.41 0.149 
Radiation  <65GY 0 
 
1 
 
Radiation  >=65GY 1.22 0.27 3.39 0.000 
5th last  
  
1.00 
 
4th last  0.51 0.16 1.66 0.002 
3rd last 0.66 0.18 1.94 0.000 
2nd last 1.13 0.18 3.11 0.000 
Final Week Treatment 1.62 0.21 5.04* 0.000 
Week 2 post 0.60 0.23 1.83 0.010 
Week 4 post 0.50 0.23 1.64 0.028 
Week 12 post 0.18 0.24 1.20 0.449† 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates when returned to baseline levels (baseline is 5th last week of treatment) 
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Supplementary Table 2.2. GEE Results of Incidence of Dysguesia Needing Supportive Care 
Dysguesia ln Odds Std.err Odds ratio p-value 
(Intercept) -1.81 0.24 0.16 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 0.48 0.25 1.61 0.062 
Radiation  <65GY 0 
 
1 
 
Radiation  >=65GY 1.35 0.29 3.84 0.000 
5th last  
  
1.00 
 
4th last  0.78 0.16 2.18 0.000 
3rd last 1.61 0.20 4.98 0.000 
2nd last 2.03 0.21 7.64 0.000 
Final Week Treatment 2.53 0.22 12.50* 0.000 
Week 2 post 1.74 0.24 5.69 0.000 
Week 4 post 0.09 0.23 1.09 0.707† 
Week 12 post -1.02 0.25 0.36 0.000‡ 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates when returned to baseline levels (baseline is 5th last week of treatment) 
‡ Indicates better than baseline levels 
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Supplementary Table 2.3. GEE Results of Incidence of Oral Mucositis Needing Supportive Care 
Oral Mucositis ln Odds Std.err Odds ratio p-value 
(Intercept) -1.91 0.28 0.15 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 0.97 0.30 2.63 0.001 
Radiation  <65GY 0 
 
1 
 
Radiation  >=65GY -0.45 0.30 0.64 0.136 
5th last  
  
1.00 
 
4th last  0.79 0.18 2.21 0.000 
3rd last 0.95 0.22 2.60 0.000 
2nd last 1.20 0.22 3.33 0.000 
Final Week Treatment 1.46 0.22 4.30* 0.000 
Week 2 post 0.64 0.27 1.89 0.017 
Week 4 post -0.11 0.28 0.90 0.703† 
Week 12 post -1.04 0.32 0.35 0.001‡ 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates when returned to baseline levels (baseline is 5th last week of treatment) 
‡ Indicates significantly better than baseline levels 
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Supplementary Table 2.4. GEE Results of Incidence of Pharyngeal Mucositis Needing 
Supportive Care 
Pharyngeal Mucositis ln Odds Std.err Odds ratio p-value 
(Intercept) -3.35 0.36 0.04 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 1.09 0.28 2.97 0.000 
Radiation  <65GY 0 
 
1 
 
Radiation  >=65GY 1.16 0.31 3.18 0.000 
5th last  
  
1.00 
 
4th last  0.40 0.21 1.49 0.060 
3rd last 0.54 0.24 1.71 0.025 
2nd last 1.34 0.24 3.83 0.000 
Final Week Treatment 1.80 0.24 6.03* 0.000 
Week 2 post 0.73 0.28 2.07 0.009 
Week 4 post -0.49 0.37 0.61 0.189† 
Week 12 post -1.45 0.45 0.23 0.001‡ 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates when returned to baseline levels (baseline is 5th last week of treatment) 
‡ Indicates significantly better than baseline levels 
 
  
 215 
Supplementary Table 2.5. GEE Results of Incidence of Thick Saliva Needing Supportive Care 
Thick Saliva ln Odds Std.err Odds ratio p-value 
(Intercept) -2.77 0.30 0.06 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 1.21 0.26 3.36 0.000 
Radiation  <65GY 0 
 
1 
 
Radiation  >=65GY 0.63 0.29 1.89 0.026 
5th last  
  
1.00 
 
4th last  0.86 0.20 2.36 0.000 
3rd last 1.23 0.22 3.43 0.000 
2nd last 1.76 0.22 5.84 0.000 
Final Week Treatment 2.07 0.23 7.94* 0.000 
Week 2 post 1.50 0.26 4.46 0.000 
Week 4 post 0.09 0.30 1.09 0.764† 
Week 12 post -1.36 0.38 0.26 0.000‡ 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates when returned to baseline levels (baseline is 5th last week of treatment) 
‡ Indicates significantly better than baseline levels 
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Supplementary Table 2.6. GEE Results of Incidence of Nausea Needing Supportive Care 
Nausea ln Odds Std.err Odds ratio p-value 
(Intercept) -4.35 0.45 0.01 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 0.91 0.33 2.49 0.006 
Radiation  <65GY 0 
 
1 
 
Radiation  >=65GY 0.85 0.36 2.33 0.017 
5th last  
  
1.00 
 
4th last  1.41 0.37 4.10 0.000 
3rd last 1.55 0.37 4.71 0.000 
2nd last 1.32 0.38 3.75 0.000 
Final Week Treatment 1.85 0.38 6.38* 0.000 
Week 2 post 0.52 0.54 1.68 0.334† 
Week 4 post 0.12 0.52 1.12 0.824† 
Week 12 post -2.05 1.14 0.13 0.072† 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates when returned to baseline levels (baseline is 5th last week of treatment) 
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Supplementary Table 2.7. GEE Results of Incidence of Dysphagia Needing Supportive Care 
Dysphagia ln Odds Std.err Odds ratio p-value 
(Intercept) -1.75 0.28 0.17 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 0.93 0.27 2.54 0.001 
Radiation  <65GY 0 
 
1 
 
Radiation  >=65GY 0.34 0.29 1.40 0.248 
5th last  
  
1.00 
 
4th last  0.74 0.15 2.10 0.000 
3rd last 1.21 0.16 3.36 0.000 
2nd last 1.48 0.19 4.40 0.000 
Final Week Treatment 1.76 0.20 5.82* 0.000 
Week 2 post 1.28 0.20 3.59 0.000 
Week 4 post 0.52 0.21 1.68 0.015 
Week 12 post -0.52 0.22 0.60 0.017† 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates significantly better than baseline levels (baseline is 5th last week of treatment) 
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Supplementary Table 2.8. GEE Results of Incidence of Food Level Needing Supportive Care 
Food Level ln Odds Std.err Odds ratio p-value 
(Intercept) -1.88 0.28 0.15 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 0.83 0.27 2.28 0.002 
Radiation  <65GY 0 
 
1 
 
Radiation  >=65GY 0.43 0.29 1.54 0.133 
5th last  
  
1.00   
4th last  0.72 0.15 2.05 0.000 
3rd last 1.16 0.17 3.20 0.000 
2nd last 1.51 0.19 4.51 0.000 
Final Week Treatment 1.84 0.20 6.31* 0.000 
Week 2 post 1.38 0.19 3.99 0.000 
Week 4 post 0.33 0.20 1.39 0.102† 
Week 12 post -0.51 0.21 0.60 0.017‡ 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates when returned to baseline levels (baseline is 5th last week of treatment) 
‡ Indicates significantly better than baseline levels 
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Supplementary Table 2.9. GEE Results of Incidence of Fluid Level Needing Supportive Care 
Fluid Level ln Odds Std.err Odds ratio p-value 
(Intercept) -3.62 0.71 0.03 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT -0.01 0.60 0.99 0.989 
Radiation  <65GY 0 
 
1 
 
Radiation  >=65GY 0.58 0.68 1.79 0.394 
5th last  
  
1.00 
 
4th last  -0.28 0.30 0.76 0.362 
3rd last 0.19 0.27 1.21 0.493 
2nd last 0.58 0.37 1.78 0.118 
Final Week Treatment 0.28 0.38 1.32 0.466 
Week 2 post -0.01 0.42 0.99 0.981 
Week 4 post -0.33 0.56 0.72 0.555 
Week 12 post -0.50 0.47 0.61 0.286 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
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Supplementary Table 2.10. GEE Results of Incidence of FOIS Needing Supportive Care 
FOIS ln Odds Std.err Odds ratio p-value 
(Intercept) -1.85 0.29 0.16 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 1.18 0.28 3.27 0.000 
Radiation  <65GY 0 
 
1 
 
Radiation  >=65GY 0.63 0.30 1.88 0.035 
5th last  
  
1.00 
 
4th last  0.68 0.14 1.98 0.000 
3rd last 1.02 0.17 2.77 0.000 
2nd last 1.41 0.18 4.09 0.000 
Final Week Treatment 1.76 0.19 5.78* 0.000 
Week 2 post 1.20 0.20 3.33 0.000 
Week 4 post 0.37 0.21 1.45 0.073† 
Week 12 post -0.71 0.23 0.49 0.002‡ 
Note: FOIS, Functional Oral Intake Score; H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, 
Chemotherapy with Helical Intensity Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates when returned to baseline levels (baseline is 5th last week of treatment) 
‡ Indicates significantly better than baseline levels 
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Supplementary Table 2.11. GEE Results of Incidence of Dysphagia Needing Supportive Care 
When Adjusted for Baseline Dysphagia 
Dysphagia ln Odds Std.err Odds ratio p-value 
(Intercept) -2.08 0.29 0.12 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 1.00 0.26 2.72 0.000 
Baseline Swallowing Problems 0 
 
1 
 
Yes 2.27 0.34 9.68 0.000 
4 week remaining 
  
1.00 
 
3 week remaining 0.90 0.18 2.45 0.000 
2 week remaining 1.44 0.20 4.22 0.000 
1 week remaining 1.74 0.22 5.70 0.000 
Final Week Treatment 2.03 0.24 7.60 0.000 
Week 2 post 1.48 0.25 4.38* 0.000 
Week 4 post 0.56 0.27 1.75 0.036† 
Week 12 post -0.62 0.26 0.54 0.019‡ 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates when returned to baseline levels (baseline is 5th last week of treatment) 
‡ Indicates significantly better than baseline levels 
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Supplementary Table 2.12. GEE Results of Incidence of Food Level Needing Supportive Care 
When Adjusted for Baseline Dysphagia 
Food Level ln Odds Std.err Odds ratio p-value 
(Intercept) -2.21 0.29 0.11 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 0.88 0.26 2.42 0.001 
Baseline Swallowing Problems 0 
 
1 
 
Yes 2.09 0.33 8.06 0.000 
4 week remaining 
  
1.00 
 
3 week remaining 0.92 0.18 2.52 0.000 
2 week remaining 1.43 0.20 4.17 0.000 
1 week remaining 1.77 0.22 5.87 0.000 
Final Week Treatment 2.13 0.23 8.39* 0.000 
Week 2 post 1.74 0.24 5.67 0.000 
Week 4 post 0.46 0.25 1.58 0.064† 
Week 12 post -0.55 0.25 0.58 0.031‡ 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates when returned to baseline levels (baseline is 5th last week of treatment) 
‡ Indicates significantly better than baseline levels  
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Supplementary Table 2.13. GEE Results of Incidence of Fluid Level Needing Supportive Care 
When Adjusted for Baseline Dysphagia 
Fluid Level ln Odds Std.err Odds ratio p-value 
(Intercept) -4.25 0.57 0.01 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT -0.14 0.66 0.87 0.832 
Baseline Swallowing Problems 0 
 
1 
 
Yes 2.10 0.60 8.13 0.000 
4 week remaining 
  
1.00 
 
3 week remaining -0.40 0.42 0.67 0.346 
2 week remaining 0.23 0.34 1.26 0.499 
1 week remaining 0.76 0.45 2.14 0.094 
Final Week Treatment 0.41 0.46 1.51 0.375 
Week 2 post 0.05 0.53 1.05 0.931 
Week 4 post -0.11 0.58 0.89 0.844 
Week 12 post -0.30 0.50 0.74 0.544 
Note: H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, Chemotherapy with Helical Intensity 
Modulated Radiation Therapy 
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Supplementary Table 2.14. GEE Results of Incidence of FOIS Needing Supportive Care When 
Adjusted for Baseline Dysphagia 
FOIS ln Odds Std.err Odds ratio p-value 
(Intercept) -2.15 0.29 0.12 0.000 
H-IMRT 0 
 
1 
 
CH-IMRT 1.33 0.27 3.79 0.000 
Baseline Swallowing Problems 0 
 
1 
 
Yes 2.47 0.32 11.77 0.000 
4 week remaining 
  
1.00 
 
3 week remaining 0.93 0.17 2.55 0.000 
2 week remaining 1.31 0.20 3.71 0.000 
1 week remaining 1.69 0.21 5.43 0.000 
Final Week Treatment 2.08 0.23 7.98* 0.000 
Week 2 post 1.52 0.24 4.58 0.000 
Week 4 post 0.51 0.27 1.66 0.059† 
Week 12 post -0.88 0.31 0.41 0.004‡ 
Note: FOIS, Functional Oral Intake Score; H-IMRT, Helical Intensity Modulated Radiation Therapy; CH-IMRT, 
Chemotherapy with Helical Intensity Modulated Radiation Therapy 
* Indicates peak incidence 
† Indicates when returned to baseline levels (baseline is 5th last week of treatment) 
‡ Indicates significantly better than baseline levels 
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Appendix H: Supplementary Materials pertaining to Study 3 (Chapter 4) 
Supplementary Table 4.1. Weekly Toxicity and Dysphagia Incidence for Patients with Parotid Tumours n=32 
Toxicity/ 
diet Level 
Week (n) 
Wk 1 
(n=5) 
Wk 2 
(n=20) 
Wk 3 
(n=24) 
Wk 4 
(n=30) 
Wk 5 
(n=30) 
Wk 6 
(n=31) 
Wk 7* 
(n=4) 
2wks post 
Tx (n=13) 
4wks post 
Tx (n=193 
12wks post 
Tx (n=18) 
Dry Mouth 
Absent 4 (80%) 7 (31.8%) 5 (20.8%) 5 (13.3%) 4 (12.9%) 74 (12.9%) 0 (0%) 3 (23.1%) 4 (30.8%) 4 (22.2%) 
Grade 1 1 (20%) 13 (59.1%) 14 (58.3%) 21 (70.0%) 17 (56.7%) 16 (51.6%) 1 (25%) 8 (61.5%) 8 (61.5%) 10 (55.6%) 
Grade 2 0 (0%) 2 (9.1%) 5 (20.8%) 4 (13.3%) 9 (30%) 11 (35.5%) 3 (75%) 2 (15.4%) 1 (7.7%) 4 (22.2%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Dysphagia 
Absent 5 (100%) 21 (95.5%) 20 (83.3%) 21 (70%) 18 (60%)  14 (45.2%) 0 (0%) 6 (46.2%) 11 (84.6%) 15 (83.3%) 
Grade 1 0 (0%) 1 (4.5%) 3 (12.5%) 6 (20%) 6 (20%) 12 (38.7%) 1 (25%) 6 (46.2%) 2 (15.4%) 2 (11.1%) 
Grade 2 0 (0%) 0 (0%) 1 (4.2%) 3 (10%) 6 (20%) 4 (12.9%) 3 (75%) 1 (7.7%) 0 (0%) 1 (5.6%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Nausea 
Absent 5 (100%) 20 (90.9%) 21 (87.5%) 23 (76.7%) 25 (83.3%) 27 (87.1%) 3 (75%) 11 (84.6%) 11 (84.6%) 17 (94.4%) 
Grade 1 0 (0%) 2 (9.1%) 1 (4.2%) 6 (20%) 5 (16.7%) 3 (9.7%) 1 (25%) 2 (15.4%) 2 (15.4%) 0 (0%) 
Grade 2 0 (0%) 0 (0%) 2 (8.3%) 1 (3.3%) 0 (0%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 1 (5.6%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 226 
Oral 
mucositis 
Absent 5 (100%) 20 (90.9%) 13 (54.2%) 20 (66.7%) 20 (66.7%) 19 (61.3%) 3 (75%) 11 (84.6%) 12 (92.3%) 18 (100%) 
Grade 1 0 (0%) 2 (9.1%) 11 (45.8%) 9 (30%) 7 (23.3%) 6 (19.4%) 0 (0%) 1 (7.7%) 1 (7.7%) 0 (0%) 
Grade 2 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 3 (10%) 6 (19.4%) 1 (25%) 1 (7.7%) 0 (0%) 0 (0%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Pharyngeal 
mucositis 
Absent 5 (100%) 20 (90.9%) 21 (87.5%) 27 (90%) 25 (83.3%) 23 (74.2%) 2 (50%) 10 (76.9%) 13 (100%) 17 (94.4%) 
Grade 1 0 (0%) 2 (9.1%) 3 (12.55) 2 (6.7%) 1 (3.3%) 2 (6.5%) 0 (0%) 3 (23.1%) 0 (0%) 1 (5.6%) 
Grade 2 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 4 (13.3%)  6 (19.4%) 2 (50%) 0 (0%) 0 (0%) 0 (0%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Taste 
Absent 4 (80%) 18 (81.8%) 12 (50%) 8 (26.7%) 7 (23.3%) 7 (22.3%) 0 (0%) 3 (23.1%) 3 (23.1%) 10 (55.6%) 
Grade 1 1 (20%) 4 (18.2%) 6 (25%) 12 (40%) 10 (33.3%) 7 (22.6%) 1 (25%) 5 (38.5%) 7 (53.8%) 7 (38.9%) 
Grade 2 0 (0%) 0 (0%) 6 (25%) 10 (33.3%)  13 (43.4%) 17 (54.8%) 3 (75%) 5 (38.5%) 3 (23.1%) 1 (5.6%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Thick 
Saliva 
Absent 5 (100%) 18 (81.8%) 18 (75%) 18 (60%) 17 (56.7%) 15 (48.4%) 3 (75%) 7 (53.8%) 9 (69.2%) 13 (72.2%) 
Grade 1 0 (0%) 4 (18.2%) 6 (255) 12 (40%) 10 (33.3%) 11 (35.5%) 1 (25%) 5 (38.5%) 4 (30.8%) 5 (27.8%) 
Grade 2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (10%) 5 (16.1%) 0 (0%) 1 (7.7%) 0 (0%) 0 (0%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
FOIS Level 7 4 (80%) 20 (90.9%) 19 (79.2%) 20 (66.7%) 16 (53.3%) 14 (45.2%) 0 (0%) 5 (38.5%) 11 (84.6%) 15 (83.3%) 
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Level 6 1 (20%) 2 (9.1%) 4 (16.7%) 7 (23.3%) 9 (30%) 13 (41.9%) 1 (25%) 7 (53.8%) 2 (15.4%) 3 (16.7%) 
Level 5 0 (0%) 0 (0%) 1 (4.2%) 3 (10%) 4 (13.3%) 3 (9.7%) 3 (75%) 1 (7.7%) 0 (0%) 0 (0%) 
Level 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
DIET  
texture 
Full 4 (80%) 20 (90.9%) 19 (79.2%) 20 (66.7%) 16 (53.3%) 14 (45.2%) 0 (0%) 5 (38.5%) 11 (84.6%) 15 (83.3%) 
Soft 1 (20%) 2 (9.1%) 4 (16.7%) 7 (23.3%) 9 (30%) 13 (41.9%) 1 (25%) 7 (53.8%) 2 (15.4%) 3 (16.7%) 
Minced 0 (0%) 0 (0%) 1 (4.2%) 2 (6.7%) 3 (10%) 2 (6.5%) 1 (25%) 1 (7.7%) 0 (0%) 0 (0%) 
Puree 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 1 (3.3%) 1 (3.2%) 2 (50%) 0 (0%) 0 (0%) 0 (0%) 
Liquids 
only 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 1 (3.2%) 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Fluids 
Thin 5 (100%) 22 (100%) 24 (100%) 30 (100%) 30 (100%) 31 (100%) 4 (100%) 13 (100%) 13 (100%) 18 (100%) 
Mildly 
Thick 0 (0%) 0 (0%) 0 (0%) 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Note: Weekly n is the number of patients available for analysis at each timepoint; *7 patients received 7 weeks of treatment 
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Supplementary Table 4.2. Weekly Toxicity and Dysphagia Incidence for Patients with Cutaneous HNC n=36 
Toxicity/ 
diet Level 
Week (n) 
Wk 1 
(n=9) 
Wk 2 
(n=26) 
Wk 3 
(n=29) 
Wk 4 
(n=31) 
Wk 5 
(n=30) 
Wk 6 
(n=31) 
Wk 7* 
(n=10) 
2wks post 
Tx (n=22) 
4wks post 
Tx (n=19) 
12wks post 
Tx (n=22) 
Dry Mouth 
Absent 5 (55.6%) 9 (34.6%) 10 (34.5%) 9 (29%) 3 (10%) 7 (22.6%) 2 (20%) 9 (40.9%) 10 (52.6%) 10 (45.5%) 
Grade 1 3 (33.3%) 15 (57.7%) 15 (51.7%) 16 (51.6%) 20 (66.7%) 12 (38.7%) 2 (20%) 6 (27.3%) 4 (21.1%) 10 (45.5%) 
Grade 2 1 (11.1%) 2 (7.7%) 4 (13.8%) 6 (19.4%) 7 (23.3%) 12 (38.7%) 6 (60%) 7 (31.8%) 5 (26.3%) 2 (9.1%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Dysphagia 
Absent 8 (88.9%) 24 (92.3%) 21 (72.4%) 20 (64.5%) 16 (53.3%) 15 (48.4%) 4 (40%) 15 (68.2%) 15 (78.9%) 18 (81.8%) 
Grade 1 1 (11.1%) 1 (3.8%) 5 (17.2%) 8 (25.8%) 9 (30%) 8 (25.8%) 2 (20%) 4 (18.2%) 2 (10.5%) 2 (9.1%) 
Grade 2 0 (0%) 1 (3.8%) 3 (10.3%) 3 (9.7%) 4 (13.3%) 7 (22.6%) 3 (30%) 3 (13.6%) 2 (10.5%) 2 (9.1%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 1 (3.2%) 1 (10%) 0 (0%) 0 (0%) 0 (0%) 
Nausea 
Absent 7 (77.8%) 25 (96.2%) 28 (96.6%) 27 (87.1%) 25 (83.3%) 28 (90.3%) 9 (90%) 21 (95.5%) 17 (89.5%) 22 (100%) 
Grade 1 2 (22.2%) 1 (3.8%) 1 (3.4%) 3 (9.7%) 5 (16.7%) 2 (6.5%) 1 (10%) 1 (4.5%) 1 (5.3%) 0 (0%) 
Grade 2 0 (0%) 0 (0%) 0 (0%) 1 (3.2%) 0 (0%) 1 (3.2%) 0 (0%) 0 (0%) 1 (5.3%) 0 (0%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Oral 
mucositis 
Absent 9 (100%) 22 (84.6%) 20 (69%) 24 (77.4%) 20 (66.7%) 20 (64.5%) 7 (70%) 19 (86.4%) 17 (89.5%) 22 (100%) 
Grade 1 0 (0%) 4 (15.4%) 7 (24.1%) 5 (16.1%) 6 (20%) 6 (19.4%) 0 (0%) 2 (9.1%) 2 (10.5%) 0 (0%) 
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Grade 2 0 (0%) 0 (0%) 2 (6.9%) 2 (6.5%) 4 (13.3%) 4 (12.9%) 3 (30%) 1 (4.5%) 0 (0%) 0 (0%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Pharyngeal 
mucositis 
Absent 9 (100%) 26 (100%) 28 (96.6%) 29 (93.5%) 26 (86.7%) 28 (90.3%) 8 (80%) 22 (100%) 19 (100%) 22 (100%) 
Grade 1 0 (0%) 0 (0%) 0 (0%) 2 (6.5%) 3 (10%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Grade 2 0 (0%) 0 (0%) 1 (3.4%) 0 (0%) 0 (0%) 1 (3.2%) 2 (20%) 0 (0%) 0 (0%) 0 (0%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Taste 
Absent 7 (77.8%) 18 (69.2%) 18 (62.1%) 13 (41.9%) 8 (26.7%) 8 (25.8%) 0 (0%) 8 (36.4%) 9 (47.4%) 11 (50%) 
Grade 1 2 (22.2%) 8 (30.8%) 8 (27.6%) 7 (22.6%) 9 (30%) 8 (25.8%) 4 (40%) 6 (27.3%) 8 (42.1%) 11 (50%) 
Grade 2 0 (0%) 0 (0%) 3 (10.3%) 11 (35.5%) 13 (43.3%) 15 (48.4%) 6 (60%) 8 (36.4%) 2 (10.5%) 0 (0%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Thick Saliva 
Absent 9 (100%) 20 (76.9%) 23 (79.3%) 23 (74.2%) 16 (53.3%) 15 (48.4%) 3 (30%) 16 (72.7%) 16 (84.2%) 20 (90.9%) 
Grade 1 0 (0%) 6 (23.1%) 4 (13.8%) 6 (19.4%) 9 (30%) 7 (22.6%) 4 (40%) 4 (18.2%) 2 (10.5%) 2 (9.1%) 
Grade 2 0 (0%) 0 (0%) 2 (6.9%) 2 (6.5%) 4 (13.3%) 8 (25.8%) 3 (30%) 2 (9.1%) 1 (5.3%) 0 (0%) 
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
FOIS 
Level 7 7 (77.8%) 24 (92.3%) 21 (72.4%) 21 (67.7%) 15 (50%) 15 (48.4%) 4 (40%) 15 (68.2%) 15 (78.9%) 18 (81.8%) 
Level 6 2 (22.2%) 2 (7.7%) 6 (20.7%) 7 (22.6%) 11 (36.7%) 10 (32.3%) 0 (0%) 4 (18.2%) 2 (10.5%) 2 (9.1%) 
Level 5 0 (0%) 0 (0%) 2 (6.9%) 3 (9.7%) 3 (10%) 5 (16.1%) 5 (50%) 1 (4.5%) 2 (10.5%) 2 (9.1%) 
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Level 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 1 (3.2%) 1 (10%) 2 (9.1%) 0 (0%) 0 (0%) 
DIET  
texture 
Full 7 (77.8%) 24 (92.3%) 21 (72.4%) 21 (67.7%) 15 (50%) 15 (48.4%) 4 (40%) 15 (68.2%) 15 (78.9%) 18 (81.8%) 
Soft 2 (22.2%) 2 (7.7%) 6 (20.7%) 7 (22.6%) 11 (36.7%) 9 (29%) 0 (0%) 4 (18.2%) 2 (10.5%) 2 (9.1%) 
Minced 0 (0%) 0 (0%) 1 (3.4%) 2 (6.5%) 2 (6.7%) 3 (9.7%) 3 (30%) 0 (0%) 1 (5.3%) 1 (4.5%) 
Puree 0 (0%) 0 (0%) 1 (3.4%) 1 (3.2%) 1 (3.3%) 3 (9.7%) 2 (20%) 1 (4.5%) 1 (5.3%) 1 (4.5%) 
Liquids only 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 1 (3.2%) 1 (10%) 2 (9.1%) 0 (0%) 0 (0%) 
Fluids 
Thin 9 (100%) 26 (100%) 29 (100%) 30 (96.8%) 29 (96.7%) 30 (96.8%) 10 (100%) 22 (100%) 19 (100%) 22 (100%) 
Mildly 
Thick 0 (0%) 0 (0%) 0 (0%) 1 (3.2%) 1 (3.3%) 1 (3.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Note: Weekly n is the number of patients available for analysis at each timepoint; 12 patients received 7 weeks of treatment 
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Appendix I: Supplementary Materials pertaining to Study 4 (Chapter 5) 
Supplementary Table 5.1. Service Characteristics Results  
Appointment Type Total Average SD 
Standard Care 
Weighted Average 
Speech Pathologist Telephone appointments 5 0.08 0.27   
Speech Pathologist Face to Face appointments 15 0.23 0.49 
 
Total Speech Pathologist appointments 20 0.31 0.53 5.61 
Total Speech Pathologist Time (mins) 275 4.23 7.51 112 
Total Dietitian Face to Face appointments 177 2.72 1.07 5.61 
Total Dietitian Time (mins) 3540 54.46 21.36 112 
Fail to Attends 5 0.08 0.27   
Cancellations 9 0.14 0.39   
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Supplementary Table 5.2. Probabilities Table for Decision Tree 
Probabilities Base Model Low CI High CI 
% triage to low risk 0.188679245 0.1384 0.2479 
% fail week 3 swallow screen 0.276923077 0.1731 0.4019 
% fail CSE after failing week 3 screen 0.076923077 0.0255 0.1705 
% swallowing problem after passing CSE 0.015384615 0.0004 0.0828 
% swallowing problem after passing week 
3 screen 0.017857143 0.0004 0.0955 
% triage to high risk 0.811320755 0.7521 0.8616 
% high risk with swallowing problem 
(FOIS) 0.88372093 0.8261 0.9275 
% traditional model with swallowing 
problem (FOIS) 0.768867925 0.7062 0.8238 
Note: CSE, Clinical swallow Examination; FOIS, Functional Oral Intake Score 
 
Supplementary Table 5.3. Costing Table for Decision Tree 
Costs Time (minutes) Health professional 
Cost per 
minute 
Total 
cost 
Triage 5 SP HP3 $0.82 4.116053 
Week 3 screen 5 Dietician HP3 $0.82 4.116053 
Failed swallow screen (including 
documentation)* 13.75 SP HP3 $0.82 11.31914 
Swallow Problem week 3* 64 SP HP3 $0.82 52.68547 
Swallow Problem week 5 or later 20 SP HP3 $0.82 16.46421 
Standard care* 112.2 SP HP3 $0.82 92.36422 
Note:* Weighted cost, minimal consumables were not costed 
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Supplementary Table 5.4. Codebook for Weighted Costs for Costing table (Supplementary Table 
5.1) 
Item Description % weighting Weighted Mins 
Failed swallow screen phone r/v 10mins 25 2.5 
  F2F r/v 15mins 75 11.25 
  Total weighted time 
 
13.75 
Swallow Problem week 3 return to high risk clinic  
 
  
  80mins - 4 x 20min SP reviews 20 16 
  
60mins - 3 x 20 mins SP 
reviews 80 48 
  Total weighted time 
 
64 
Swallow Problem week 5 
or later return to high risk clinic  
 
  
  1 x 20min SP reviews 100 20 
  Total weighted time 
 
20 
Standard Care  Joint SP and ND HNC clinic 
 
  
 (High risk and traditional 
model groups) 
 120mins - 6 x 20min SP 
reviews 66 79.2 
  100mins - 5 x 20min SP reviews 33 33 
  Total weighted time   112.2 
Note: F2F, Face to face; SP, Speech Pathologist; ND, Nutrition and Dietetics; HNC, Head and neck 
cancer  
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Supplementary Table 5.5. Wage Rates for Costing Table (Supplementary Table 5.1) 
Wage rates Wage Rate HP 3.4 Wage Rate HP 4.2 Unit 
March 1/17 - Oct 17/17 $3,089.60  $3,978.80  fortnight 
Oct 18/17 - June 30/18 $3,166.80  $4,078.30  Fortnight 
weighted average $3,128.20  $4,028.55  fortnight 
20% on costs $625.64  $805.71  fortnight 
hourly rate (38 hr week - 76 hr fortnight) $49.39  $63.61  hour 
Minute rate $0.82  $1.06  minute 
 
Supplementary Table 5.6. Functional Oral Intake Score Results for High Risk and Traditional 
Model Groups 
Outcome FOIS 1-5 Frequency (%)  
High Risk Group 
n=172 
152* 88.3* 
Traditional 
Model Group 
n=212 
163† 76.8† 
Note: * Calculated by applying new high and low risk criteria to existing published dataset 
(Moroney et al., 2017 = Chapter 2) 
† previously published results for mixed head and neck cancer cohort by study team (Moroney et 
al., 2017 = Chapter 2) 
 
